
<html lang="en"     class="pb-page"  data-request-id="b8582af3-8612-4ae1-a89f-fb86c2c37e1c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.9b01293;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer" /></meta><meta name="dc.Creator" content="Youssef  El-Ahmad" /></meta><meta name="dc.Creator" content="Michel  Tabart" /></meta><meta name="dc.Creator" content="Frank  Halley" /></meta><meta name="dc.Creator" content="Victor  Certal" /></meta><meta name="dc.Creator" content="Fabienne  Thompson" /></meta><meta name="dc.Creator" content="Bruno  Filoche-Rommé" /></meta><meta name="dc.Creator" content="Florence  Gruss-Leleu" /></meta><meta name="dc.Creator" content="Claire  Muller" /></meta><meta name="dc.Creator" content="Maurice  Brollo" /></meta><meta name="dc.Creator" content="Laurence  Fabien" /></meta><meta name="dc.Creator" content="Véronique  Loyau" /></meta><meta name="dc.Creator" content="Luc  Bertin" /></meta><meta name="dc.Creator" content="Patrick  Richepin" /></meta><meta name="dc.Creator" content="Fabienne  Pilorge" /></meta><meta name="dc.Creator" content="Pascal  Desmazeau" /></meta><meta name="dc.Creator" content="Chrystelle  Girardet" /></meta><meta name="dc.Creator" content="Sylvie  Beccari" /></meta><meta name="dc.Creator" content="Audrey  Louboutin" /></meta><meta name="dc.Creator" content="Gilles  Lebourg" /></meta><meta name="dc.Creator" content="Jacques  Le-Roux" /></meta><meta name="dc.Creator" content="Corinne  Terrier" /></meta><meta name="dc.Creator" content="François  Vallée" /></meta><meta name="dc.Creator" content="Valérie  Steier" /></meta><meta name="dc.Creator" content="Magali  Mathieu" /></meta><meta name="dc.Creator" content="Alexey  Rak" /></meta><meta name="dc.Creator" content="Pierre-Yves  Abecassis" /></meta><meta name="dc.Creator" content="Pascale  Vicat" /></meta><meta name="dc.Creator" content="Tsiala  Benard" /></meta><meta name="dc.Creator" content="Monsif  Bouaboula" /></meta><meta name="dc.Creator" content="Fangxian  Sun" /></meta><meta name="dc.Creator" content="Maysoun  Shomali" /></meta><meta name="dc.Creator" content="Andrew  Hebert" /></meta><meta name="dc.Creator" content="Mikhail  Levit" /></meta><meta name="dc.Creator" content="Hong  Cheng" /></meta><meta name="dc.Creator" content="Albane  Courjaud" /></meta><meta name="dc.Creator" content="Celine  Ginesty" /></meta><meta name="dc.Creator" content="Christelle  Perrault" /></meta><meta name="dc.Creator" content="Carlos  Garcia-Echeverria" /></meta><meta name="dc.Creator" content="Gary  McCort" /></meta><meta name="dc.Creator" content="Laurent  Schio" /></meta><meta name="dc.Description" content="More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-depe..." /></meta><meta name="Description" content="More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-depe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 13, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01293" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01293" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01293" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01293" /></link>
        
    
    

<title>Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01293" /></meta><meta property="og:title" content="Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0019.jpeg" /></meta><meta property="og:description" content="More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective. Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy. However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections. This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (43d), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01293"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01293">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01293&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01293&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01293&amp;href=/doi/10.1021/acs.jmedchem.9b01293" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 512-528</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00863" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.9b00927" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Youssef El-Ahmad</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Youssef El-Ahmad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +33 1 58933606. E-mail: <a href="/cdn-cgi/l/email-protection#f68f998385859390d8939adb979e9b9792b685979899909fd895999b"><span class="__cf_email__" data-cfemail="90e9ffe5e3e3f5f6bef5fcbdf1f8fdf1f4d0e3f1fefff6f9bef3fffd">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Youssef++El-Ahmad">Youssef El-Ahmad</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3038-0986" title="Orcid link">http://orcid.org/0000-0002-3038-0986</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michel Tabart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michel Tabart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michel++Tabart">Michel Tabart</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frank Halley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frank Halley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Halley">Frank Halley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victor Certal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victor Certal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victor++Certal">Victor Certal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fabienne Thompson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabienne Thompson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabienne++Thompson">Fabienne Thompson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bruno Filoche-Rommé</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bruno Filoche-Rommé</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bruno++Filoche-Romm%C3%A9">Bruno Filoche-Rommé</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Florence Gruss-Leleu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Florence Gruss-Leleu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Florence++Gruss-Leleu">Florence Gruss-Leleu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claire Muller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claire Muller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claire++Muller">Claire Muller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maurice Brollo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maurice Brollo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maurice++Brollo">Maurice Brollo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laurence Fabien</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laurence Fabien</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laurence++Fabien">Laurence Fabien</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Véronique Loyau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Véronique Loyau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=V%C3%A9ronique++Loyau">Véronique Loyau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luc Bertin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luc Bertin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luc++Bertin">Luc Bertin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick Richepin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick Richepin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Richepin">Patrick Richepin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fabienne Pilorge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabienne Pilorge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabienne++Pilorge">Fabienne Pilorge</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pascal Desmazeau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pascal Desmazeau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pascal++Desmazeau">Pascal Desmazeau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chrystelle Girardet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chrystelle Girardet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chrystelle++Girardet">Chrystelle Girardet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sylvie Beccari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sylvie Beccari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sylvie++Beccari">Sylvie Beccari</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Audrey Louboutin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Audrey Louboutin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Audrey++Louboutin">Audrey Louboutin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gilles Lebourg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gilles Lebourg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gilles++Lebourg">Gilles Lebourg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacques Le-Roux</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacques Le-Roux</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacques++Le-Roux">Jacques Le-Roux</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Corinne Terrier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Corinne Terrier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Corinne++Terrier">Corinne Terrier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">François Vallée</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">François Vallée</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fran%C3%A7ois++Vall%C3%A9e">François Vallée</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Valérie Steier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Valérie Steier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Val%C3%A9rie++Steier">Valérie Steier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Magali Mathieu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Magali Mathieu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Magali++Mathieu">Magali Mathieu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexey Rak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexey Rak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexey++Rak">Alexey Rak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pierre-Yves Abecassis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pierre-Yves Abecassis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics (DMPK), Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pierre-Yves++Abecassis">Pierre-Yves Abecassis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pascale Vicat</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pascale Vicat</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics (DMPK), Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pascale++Vicat">Pascale Vicat</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsiala Benard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsiala Benard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pre-Development Sciences-Formulation, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsiala++Benard">Tsiala Benard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Monsif Bouaboula</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Monsif Bouaboula</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Monsif++Bouaboula">Monsif Bouaboula</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fangxian Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fangxian Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fangxian++Sun">Fangxian Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maysoun Shomali</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maysoun Shomali</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maysoun++Shomali">Maysoun Shomali</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew Hebert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew Hebert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Hebert">Andrew Hebert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mikhail Levit</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mikhail Levit</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mikhail++Levit">Mikhail Levit</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Cheng">Hong Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Albane Courjaud</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Albane Courjaud</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Albane++Courjaud">Albane Courjaud</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Celine Ginesty</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Celine Ginesty</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Celine++Ginesty">Celine Ginesty</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christelle Perrault</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christelle Perrault</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christelle++Perrault">Christelle Perrault</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlos Garcia-Echeverria</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlos Garcia-Echeverria</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlos++Garcia-Echeverria">Carlos Garcia-Echeverria</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary McCort</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary McCort</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary++McCort">Gary McCort</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Laurent Schio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laurent Schio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Integrated Drug Discovery, Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laurent++Schio">Laurent Schio</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01293&amp;href=/doi/10.1021%2Facs.jmedchem.9b01293" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 512–528</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 13, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 August 2019</li><li><span class="item_label"><b>Published</b> online</span>13 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 January 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01293" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01293</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D512%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYoussef%2BEl-Ahmad%252C%2BMichel%2BTabart%252C%2BFrank%2BHalley%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D2%26contentID%3Dacs.jmedchem.9b01293%26title%3DDiscovery%2Bof%2B6-%25282%252C4-Dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2Bacid%2B%2528SAR439859%2529%252C%2Ba%2BPotent%2Band%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2B%2528SERD%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BEstrogen-Receptor-Positive%2BBreast%2BCancer%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D528%26publicationDate%3DJanuary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01293"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7450</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01293" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Youssef&quot;,&quot;last_name&quot;:&quot;El-Ahmad&quot;},{&quot;first_name&quot;:&quot;Michel&quot;,&quot;last_name&quot;:&quot;Tabart&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Halley&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;Certal&quot;},{&quot;first_name&quot;:&quot;Fabienne&quot;,&quot;last_name&quot;:&quot;Thompson&quot;},{&quot;first_name&quot;:&quot;Bruno&quot;,&quot;last_name&quot;:&quot;Filoche-Rommé&quot;},{&quot;first_name&quot;:&quot;Florence&quot;,&quot;last_name&quot;:&quot;Gruss-Leleu&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;Muller&quot;},{&quot;first_name&quot;:&quot;Maurice&quot;,&quot;last_name&quot;:&quot;Brollo&quot;},{&quot;first_name&quot;:&quot;Laurence&quot;,&quot;last_name&quot;:&quot;Fabien&quot;},{&quot;first_name&quot;:&quot;Véronique&quot;,&quot;last_name&quot;:&quot;Loyau&quot;},{&quot;first_name&quot;:&quot;Luc&quot;,&quot;last_name&quot;:&quot;Bertin&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Richepin&quot;},{&quot;first_name&quot;:&quot;Fabienne&quot;,&quot;last_name&quot;:&quot;Pilorge&quot;},{&quot;first_name&quot;:&quot;Pascal&quot;,&quot;last_name&quot;:&quot;Desmazeau&quot;},{&quot;first_name&quot;:&quot;Chrystelle&quot;,&quot;last_name&quot;:&quot;Girardet&quot;},{&quot;first_name&quot;:&quot;Sylvie&quot;,&quot;last_name&quot;:&quot;Beccari&quot;},{&quot;first_name&quot;:&quot;Audrey&quot;,&quot;last_name&quot;:&quot;Louboutin&quot;},{&quot;first_name&quot;:&quot;Gilles&quot;,&quot;last_name&quot;:&quot;Lebourg&quot;},{&quot;first_name&quot;:&quot;Jacques&quot;,&quot;last_name&quot;:&quot;Le-Roux&quot;},{&quot;first_name&quot;:&quot;Corinne&quot;,&quot;last_name&quot;:&quot;Terrier&quot;},{&quot;first_name&quot;:&quot;François&quot;,&quot;last_name&quot;:&quot;Vallée&quot;},{&quot;first_name&quot;:&quot;Valérie&quot;,&quot;last_name&quot;:&quot;Steier&quot;},{&quot;first_name&quot;:&quot;Magali&quot;,&quot;last_name&quot;:&quot;Mathieu&quot;},{&quot;first_name&quot;:&quot;Alexey&quot;,&quot;last_name&quot;:&quot;Rak&quot;},{&quot;first_name&quot;:&quot;Pierre-Yves&quot;,&quot;last_name&quot;:&quot;Abecassis&quot;},{&quot;first_name&quot;:&quot;Pascale&quot;,&quot;last_name&quot;:&quot;Vicat&quot;},{&quot;first_name&quot;:&quot;Tsiala&quot;,&quot;last_name&quot;:&quot;Benard&quot;},{&quot;first_name&quot;:&quot;Monsif&quot;,&quot;last_name&quot;:&quot;Bouaboula&quot;},{&quot;first_name&quot;:&quot;Fangxian&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Maysoun&quot;,&quot;last_name&quot;:&quot;Shomali&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Hebert&quot;},{&quot;first_name&quot;:&quot;Mikhail&quot;,&quot;last_name&quot;:&quot;Levit&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Albane&quot;,&quot;last_name&quot;:&quot;Courjaud&quot;},{&quot;first_name&quot;:&quot;Celine&quot;,&quot;last_name&quot;:&quot;Ginesty&quot;},{&quot;first_name&quot;:&quot;Christelle&quot;,&quot;last_name&quot;:&quot;Perrault&quot;},{&quot;first_name&quot;:&quot;Carlos&quot;,&quot;last_name&quot;:&quot;Garcia-Echeverria&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;McCort&quot;},{&quot;first_name&quot;:&quot;Laurent&quot;,&quot;last_name&quot;:&quot;Schio&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;512-528&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01293&quot;},&quot;abstract&quot;:&quot;More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective. Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy. However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections. This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01293&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01293" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01293&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01293" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01293&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01293" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01293&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01293&amp;href=/doi/10.1021/acs.jmedchem.9b01293" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01293" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01293" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26pmid%3D31721572%26genre%3Darticle%26aulast%3DEl-Ahmad%26date%3D2020%26atitle%3DDiscovery%2Bof%2B6-%25282%252C4-Dichlorophenyl%2529-5-%255B4-%255B%25283S%2529-1-%25283-fluoropropyl%2529pyrrolidin-3-yl%255Doxyphenyl%255D-8%252C9-dihydro-7H-benzo%255B7%255Dannulene-2-carboxylic%2Bacid%2B%2528SAR439859%2529%252C%2Ba%2BPotent%2Band%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2B%2528SERD%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BEstrogen-Receptor-Positive%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D2%26spage%3D512%26epage%3D528%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/jmcmar.2020.63.issue-2/20200123/jmcmar.2020.63.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0019.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-dependent, but mutations usually confer constitutive activation to the hormone receptor, rendering ERα modulator drugs such as tamoxifen and aromatase inhibitors ineffective. Fulvestrant is a potent selective estrogen receptor degrader (SERD), which degrades the ERα receptor in drug-resistant tumors and has been approved for the treatment of hormone-receptor-positive metastatic breast cancer following antiestrogen therapy. However, fulvestrant shows poor pharmacokinetic properties in human, low solubility, weak permeation, and high metabolism, limiting its administration to inconvenient intramuscular injections. This Drug Annotation describes the identification and optimization of a new series of potent orally available SERDs, which led to the discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic acid (<b>43d</b>), showing promising antitumor activity in breast cancer mice xenograft models and whose properties warranted clinical evaluation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span></span> Note</h4><p class="last">This article published November 27, 2019 with errors in Figure 1. The figure was replaced and the article reposted December 5, 2019.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer (BC) is the most common cancer in women today. It is estimated that worldwide, 627 000<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> women died in 2018 due to BC, which makes it the deadliest cancer in women. BCs can be classified into three groups according to their phenotype.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The first group of breast tumors is estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+), which represents ∼75% of all BCs. The second group is Her2/neu-positive, representing 15% of all BCs. The last group is called triple negative, in which the BC cells do not express estrogen, progesterone, or HER2 receptors, representing ∼10% of all BCs. ERs exist in two isoforms, alpha (ERα) and beta (ERβ), encoded by distinct genes and belong to the nuclear receptor group implicated in gene expression regulation, cellular proliferation, and differentiation in different tissues.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> ERα and ERβ are activated by the estrogen hormone 17β-estradiol, which induces ER dimerization and DNA binding, initiating the expression of genes leading to cancer cell proliferation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> ERα is expressed in reproductive tissues, and abnormal ERα signaling leads to the development of a variety of diseases, especially cancers. Unlike normal breast epithelium in which ER detection is <10% positive, breast tumors present substantially higher levels of ER, reaching 50–80% positivity. Presently, there are three standard of care treatments for ER-positive BC (often combined with other anticancer agents with a non-ER-related mechanism of action):</div><div class="NLM_p">(1) Natural ER ligand biosynthesis in the cell is blocked by using aromatase inhibitors, a key enzyme implicated in the conversion of testosterone (<b>1</b>) to estradiol (<b>2</b>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These inhibitors are either steroidal, such as exemestane (Aromasin) (<b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), or nonsteroidal, such as anastrozole (Arimidex) (<b>4</b>) and letrozole (Femara) (<b>5</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, the acceleration of the loss of bone density is the major side effect of aromatase inhibitors. Unfortunately, resistance is common and essentially inevitable in advanced disease.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Role of aromatase and approved inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">(2) Estrogen ligand binding is antagonized to ERα by a selective estrogen receptor modulator (SERM),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> tamoxifen (<b>6a</b>), a prodrug that is metabolized into 4-hydroxy-tamoxifen (<b>6b</b>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Tamoxifen (<b>6a</b>) has been shown to display agonist activity, and treatment with tamoxifen increases the risk of endometrial cancer in some patients.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Moreover, cancer cells may circumvent reliance on estrogen-stimulated growth and become hormone-independent and tamoxifen-resistant.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, it has been shown that ER continues to be active in these resistant cancer types.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. SERM and SERD inhibitors on the market and in development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">(3) ER is degraded by a selective estrogen receptor degrader (SERD), Fulvestrant<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> (<b>7</b>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), whose binding to the ERα triggers its degradation by ubiquitinylation. This has shown clinical benefit in the treatment of BC patients who have progressed under endocrine therapies such as tamoxifen (<b>6a</b>) or aromatase inhibitors, and it received marketing approval in 2002. Nevertheless, fulvestrant (<b>7</b>) is highly insoluble and has a very low bioavailability and a high metabolic lability, limiting its in vivo efficacy.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Fulvestrant must be administered as a monthly intramuscular injection of a 500 mg dose to each gluteus maximus.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p last">Several companies are actively engaged in the search for orally available SERDs, and a number of new compounds have progressed into the clinical trials over the past few years. For some of them, structures have been disclosed, such as GDC-810<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (<b>8</b>) from Seragon/Genentech, AZD9496<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (<b>9a</b>) from AstraZeneca, LSZ102<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (<b>9b</b>) from Novartis, and GDC-0927<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (<b>9c</b>) from Genentech.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The identification of the hit compounds was achieved by performing a medium-throughput screening (MTS) on a collection of preselected compounds previously designed to bind ERα. This strategy allowed us to identify compound <b>10a</b> with attractive in vitro biological properties (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) as a starting point (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hit compound <b>10a</b> and optimization strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Degradation Activity of the Different O–R Side Chains Investigated</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ERα degradation measured in MCF-7 (Michigan Cancer Foundation-7) BC cells in phenol-red-free MEM medium containing 5% charcoal-dextran-treated FBS. Readings taken after 4 h of incubation using an anti-ER rabbit monoclonal antibody.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Efficacy recorded as the percent of efficacy of the fulvestrant control.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Not determined due to low potency of compound.</p></div></div><div></div></div><div class="NLM_p">Hit compound <b>10a</b> showed an estrogen receptor degradation activity of 42% in the ERα downregulation assay. (See <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.) The most important optimization effort was directed toward the side chain (O–CH<sub>2</sub>–CH<sub>2</sub>–pyrrolidine) via modulations of the nature and the position of the basic residue, aiming at identifying a new drug-like degrader side chain with improved ERα degradation activity while maintaining acceptable physicochemical properties for an oral drug. In this respect, a variety of side-chain lengths together with structurally different opened and cyclized amines were investigated. (See <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>.) Opening the pyrrolidine ring of compound <b>10a</b> as in <b>10b</b> and <b>10c</b> or increasing the length of the alkyl chain such as in <b>10d</b> leads to a loss of degradation activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The replacement of the pyrrolidine ring of compound <b>10a</b> by heterocycles such as imidazole (<b>10e</b>), azetidine (<b>10f</b>), piperidine (<b>10g</b>), and morpholine (<b>10h</b>) was also detrimental to the degradation activity. However, when cyclization was performed on the carbon atom alpha to the oxygen, the degradation activity was improved. Thus the <i>O</i>-azetidine (<b>10i</b>) side chain cited in a Merck patent<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and introduced on our chemical scaffold displayed a 75% degradation activity with good potency (EC<sub>50</sub> = 0.2 nM). In the case of <i>O</i>-pyrrolidine, only the S isomer <b>10j</b> was active, with a degradation of 70%; the R isomer <b>10k</b> was inactive. These results seemed to suggest a dramatic influence of the side-chain geometry on the degradation activity, with efficacy obtained only when the oxygen atom and the basic nitrogen are separated by two carbon atoms. From these series of chemical modifications, <i>O</i>-azetidine (<b>10i</b>) and (<i>S</i>)-<i>O</i>-pyrrolidine (<b>10j</b>) turned out to be the most potent and most active compounds. The undescribed pyrrolidine side chain in compound <b>10j</b> was chosen for further optimization of the degradation activity. On the basis of the aforementioned results, only the S isomers were thus synthesized. It is worth noting that the N-substitution of the pyrrolidine ring with shorter alkyl groups such as methyl (<b>10l</b>), ethyl (<b>10m</b>), or fluoroethyl (<b>10n</b>) or longer alkyl groups such as butyl (<b>10o</b>) led to a decrease in or a loss of degradation activity. Only fluoropropyl substitution (<b>10p</b>) resulted in enhanced degradation activity (84%) together with high potency (0.3 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">This potent fluoropropyl–pyrrolidine degrader side chain was then chosen for further exploration of the different scaffolds (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The replacement of the cyclohexene ring (fused to the phenol) in <b>10p</b> (84% degradation) with a cycloheptene ring (<b>33a</b>) led to a slight increase in degradation activity (88% degradation) and similar potency (0.4 nM). The modification of the proximal hydroxyl group position on the phenol ring led to compound <b>33c</b> with similar degradation activity (89%).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Bicycle Size and Hydroxyl Position Effect on Degradation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0014.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">ERα degradation<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">efficacy (%)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10p</b></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">89</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">ERα degradation measured in MCF-7 BC cells in phenol-red-free MEM medium containing 5% charcoal-dextran-treated FBS. Readings taken after 4 h of incubation using an anti-ER rabbit monoclonal antibody.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Efficacy recorded as the percent of efficacy of the fulvestrant control.</p></div></div></div><div class="NLM_p">To differentiate between compounds <b>33a</b> and <b>33c</b> and to circumvent the high clearance issues generally associated with the phenol moiety,<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> distal phenol replacement with halogenated aryl moieties, such as 2-chloro-4-fluoro-phenyl, was introduced. This chemical modification resulted in a retention of degradation efficacy and potency compared with compounds <b>33b</b> and <b>33d</b> together with a significant improvement in the metabolic stability measured on microsomes for the three species tested (human, mouse, and rat), especially for compound <b>33d</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Degradation and Metabolic Lability Results for Phenol- and Distal-Substituted Aryls</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0015.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">ERα degradation<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">efficacy (%)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">metabolic lability (%) total metab H/M/R<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="left">49/55/58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33b</b></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="left">57/30/80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">89</td><td class="colsep0 rowsep0" align="left">55/25/48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33d</b></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="left">31/20/44</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">ERα degradation measured in MCF-7 BC cells in phenol-red-free MEM medium containing 5% charcoal-dextran-treated FBS. Readings taken after 4 h of incubation using an anti-ER rabbit monoclonal antibody.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Efficacy recorded as the percent of efficacy of the fulvestrant control.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">H: human; M: mouse; R: rat.</p></div></div></div><div class="NLM_p">This positive impact on metabolic stability observed with compound <b>33d</b> prompted us to explore other aryl substituents. The compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> showed that the unsubstituted phenyl derivative <b>33e</b> and halogenated phenyl compounds (<b>33d</b>, <b>33f–j</b>) produced ER-potent degraders. Substitution on the para position with OCF<sub>3</sub> (<b>33k</b>) or SCF<sub>3</sub> (<b>33l</b>) also maintained a high degradation potency. These compounds exhibited acceptable metabolic stability but also high LogD.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR in the Distal Aryl-1</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0016.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">ERα degradation<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" rowspan="2" align="center" char=".">LogD pH 7.4<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">efficacy (%)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">metabolic lability (%) total metab H/M/R<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33d</b></td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="left">31/20/44</td><td class="colsep0 rowsep0" align="char" char=".">4.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="left">34/44/53</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33f</b></td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">96</td><td class="colsep0 rowsep0" align="left">45/38/71</td><td class="colsep0 rowsep0" align="char" char=".">4.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33g</b></td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="left">37/41/45</td><td class="colsep0 rowsep0" align="char" char=".">4.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33h</b></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="left">25/17/16</td><td class="colsep0 rowsep0" align="char" char=".">4.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33i</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="left">41/31/53</td><td class="colsep0 rowsep0" align="char" char=".">4.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33j</b></td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="left">30/18/17</td><td class="colsep0 rowsep0" align="char" char=".">5.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33k</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="left">38/3/3</td><td class="colsep0 rowsep0" align="char" char=".">4.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33l</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="left">2/25/2</td><td class="colsep0 rowsep0" align="char" char=".">5.12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">ERα degradation measured in MCF-7 BC cells in phenol-red-free MEM medium containing 5% charcoal-dextran-treated FBS. Readings taken after 4 h of incubation using an anti-ER rabbit monoclonal antibody.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Efficacy recorded as the percent of efficacy of the fulvestrant control.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">H: human; M: mouse; R: rat.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">LogD measured at pH 7.4, 50 mM phosphate buffer.</p></div></div></div><div class="NLM_p">The LogD decrease was achieved by the replacement of the distal phenol moiety by heterocyclic bioisosteres (indole <b>33m</b> and indazole <b>33n</b>) or pyridine rings (<b>33o</b>, <b>33p</b>). This substitution afforded active compounds in degradation (82–91%). However, the metabolic stability was not improved (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR in the Distal Aryl-2</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0017.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">ERα degradation<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">efficacy (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">metabolic lability (%) total metab H/M/R<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">LogD pH 7.4<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33m</b></td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="left">39/61/75</td><td class="colsep0 rowsep0" align="char" char=".">3.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33n</b></td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">80</td><td class="colsep0 rowsep0" align="left">72/65/74</td><td class="colsep0 rowsep0" align="char" char=".">2.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33o</b></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="left">70/39/60</td><td class="colsep0 rowsep0" align="char" char=".">2.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33p</b></td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="left">70/31/80</td><td class="colsep0 rowsep0" align="char" char=".">2.11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">ERα degradation measured in MCF-7 BC cells in phenol-red-free MEM medium containing 5% charcoal-dextran-treated FBS. Readings taken after 4 h of incubation using an anti-ER rabbit monoclonal antibody.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Efficacy recorded as the percent of efficacy of the fulvestrant control.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">H: human; M: mouse; R: rat.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">LogD measured at pH 7.4, 50 mM phosphate buffer.</p></div></div></div><div class="NLM_p">To lower LogD while maintaining an acceptable metabolic stability, the proximal hydroxyl moiety was replaced by a carboxylic acid.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Combined with the distal aryls of compounds in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, this chemical modification produced stable compounds (<b>43a</b>–<b>f</b>) together with high degradation activity (84–98%) and potency (0.2–8 nM), as illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR in the Carboxylic Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0018.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">ERα degradation<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">efficacy (%)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">metabolic lability (%) total metab H/M/R<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">LogD pH 7.4<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43a</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="left">0/5/4</td><td class="colsep0 rowsep0" align="char" char=".">2.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43b</b></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="left">2/15/1</td><td class="colsep0 rowsep0" align="char" char=".">2.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43c</b></td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="left">28/0/2</td><td class="colsep0 rowsep0" align="char" char=".">2.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i><b>43d</b></i></td><td class="colsep0 rowsep0" align="char" char="."><i>0.2</i></td><td class="colsep0 rowsep0" align="char" char="."><i>98</i></td><td class="colsep0 rowsep0" align="left"><i>12/13/4</i></td><td class="colsep0 rowsep0" align="char" char="."><i>3.25</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43e</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="left">20/10/2</td><td class="colsep0 rowsep0" align="char" char=".">3.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43f</b></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="left">10/12/4</td><td class="colsep0 rowsep0" align="char" char=".">3.46</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">ERα degradation measured in MCF-7 BC cells in phenol-red-free MEM medium containing 5% charcoal-dextran-treated FBS. Readings taken after 4 h of incubation using an anti-ER rabbit monoclonal antibody.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Efficacy recorded as the percent of efficacy of the fulvestrant control.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">H: human; M: mouse; R: rat.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">LogD measured at pH 7.4, 50 mM phosphate buffer.</p></div></div></div><div class="NLM_p">Among these carboxylic acid molecules, compound <b>43d</b> showed an outstanding overall profile with high degradation efficacy (98%) and good potency (0.2 nM) comparable to the in vitro activity of fulvestrant combined with a remarkable metabolic stability. An in-house X-ray crystal structure of the ERα ligand binding domain [298–554]-L536S in complex with compound <b>43d</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) solved at 1.48 Å resolution showed that <b>43d</b> lies in the estradiol binding cavity. In this orientation, the carboxylic group interacts with Glu353 (<i>d</i> = 2.5 Å) and Arg394 (<i>d</i> = 3.0 Å), whereas the dichloro-phenyl moiety faces His524, whose side-chain is oriented toward the outside of the protein, and the nitrogen atom of the <i>N</i>-propylpyrrolidine moiety interacts with Asp351 (<i>d</i> = 3.0 Å), as the fluoropropyl chain of the molecule points toward the solvent.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystallography of (<b>43d</b>) bounds to the ERα ligand binding domain construct [298–554]-L536S (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SBO">6SBO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>43d</b> was evaluated in a large Cerep panel for in vitro selectivity, and no off-target activity (IC<sub>50</sub> ≤ 1 μM) was detected.</div><div class="NLM_p">The in vivo pharmacokinetic profile of <b>43d</b> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) showed a-low to-moderate clearance in the three animal species tested (0.03 to 1.92 L h<sup>–1</sup> kg<sup>–1</sup>), a low-to-moderate volume of distribution (<i>V</i><sub>dss</sub> = 0.5–6.1 L/kg), and good bioavailability (54–76%) across species. It was noticed that <i>T</i><sub>1/2</sub> was variable across species (1.98 h in mouse, 4.13 h in rat, and 9.80 h in dog).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Cross-Species Pharmacokinetics of <b>43d</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>dss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">clearance (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">bioavailability (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">0.83</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">4.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="center">6.10</td><td class="colsep0 rowsep0" align="char" char=".">1.92</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">1.98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">0.50</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">9.80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Dosed iv at 3 mg/kg and po at 10 mg/kg in solution (0.6 mg/mL) in glycofurol/PS80/G5 (10/5/85%) and in solution (1 mg/mL) in labrasol/solutol/G5 (20/5/75%), respectively.</p></div></div></div><div class="NLM_p">Compound <b>43d</b> was then evaluated in xenograft murine models of ER+ BC. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> points out the robust activity of <b>43d</b> in a tamoxifen-sensitive MCF-7 xenograft tumor model. At 2.5, 5, and 12.5 mg/kg/BID dosed orally, compound <b>43d</b> exhibited substantial tumor-growth inhibition, whereas at a dose of 25 mg/kg/BID, compound <b>43d</b> displayed tumor regression of Δ<i>T</i>/Δ<i>C</i>% = −28. Compound <b>43d</b> was well tolerated, and no weight loss was observed.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo efficacy of compound <b>43d</b> in MCF-7 tamoxifen-sensitive xenograft at indicated doses po BID (MCF-7 tamoxifen-sensitive xenograft in mice supplemented subcutaneously with 0.72 mg estradiol pellets). MCF-7 cells were subcutaneously inoculated 2 to 3 days post-estradiol-pellet-implantation. <i>n</i> = 9 to 10 animals per group. Tumor volume (length × width<sup>2</sup>/2) was monitored weekly. Animals were treated with the vehicle or with compound <b>43d</b> twice daily.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last"><b>43d</b> was also evaluated in mutant and patient-derived xenograft (PDX) models.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Following these encouraging preclinical pharmacological in vivo results and based on the favorable pharmacokinetic properties observed, compound <b>43d</b> was selected for development and is being evaluated in phase-I clinical trials in patients with metastatic ER-positive BC.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>10a</b> and analogs were prepared according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10a</b>–<b>h</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KHMDS, PhN(SO<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>, THF, −50 °C to rt, 96%. (b) (4-Hydroxyphenyl)boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, rt, 70%. (c) Pyridinium tribromide, THF, rt, 79%. (d) (4-Methoxyphenyl)boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 70 °C, 55%. (e) For <b>16a</b>: 1,2-dibromoethane, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 73%. For <b>16b</b>: 1,3-dibromopropane, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 71%. (f) For <b>17a</b>: BF<sub>3</sub>, Me<sub>2</sub>S, DCM, rt, 86%. For <b>10d</b>: BF<sub>3</sub>·Me<sub>2</sub>S, DCM, rt, 28%. (g) For <b>10a</b>–<b>c</b> and <b>10e</b>–<b>h</b>: K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 15–73%. For <b>18d</b>: K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 93%.</p></p></figure><div class="NLM_p">The carbonyl group of the substituted tetralone <b>11</b> was transformed into the enol triflate <b>12</b> by reacting the enolate (formed under basic conditions) with phenyltriflimide.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The triflate derivative <b>12</b> was sequentially engaged in a Suzuki coupling reaction with <i>p</i>-phenol boronic acid to afford compound <b>13</b>. The double bond was then brominated with pyridinium tribromide<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> to give bromo derivative <b>14</b>, which was immediately submitted to a second Suzuki coupling reaction with <i>p</i>-methoxyphenyl boronic acid, thus introducing the second substituted distal aryl group to give <b>15</b>. The phenol group was transformed into an ether by condensation on 1,2-dibromoethane or 1,3-dibromopropane to give bromo derivatives <b>16a</b><b>,b</b>. Compounds <b>10a</b>–<b>h</b> were prepared either by cleaving both methoxy groups of compounds <b>16a,b</b> with boron trifluoride to give compounds <b>17a</b><b>,b</b>, followed by nucleophilic substitution with secondary amines HNR′R″ under basic conditions or by reacting compounds <b>16a,b</b> with secondary amines HNR′R″, followed by cleaving both methoxy groups with boron trifluoride.</div><div class="NLM_p">The introduction of an azetidine moiety was performed as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>10i</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 80%. (b) 4 N HCl, dioxane, MeOH, rt, 81%. (c) BF<sub>3</sub>, Me<sub>2</sub>S, DCM, rt, 64%. (d) Propanal, NaBH<sub>3</sub>CN, AcOH, MeOH, 0 °C to rt, 50%. (e) (4-Hydroxyphenyl)boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, rt, 57%.</p></p></figure><div class="NLM_p">Thus phenol intermediate <b>14</b> was alkylated in the presence of cesium carbonate with 3-iodo-<i>N</i>-Boc azetidine to provide ether <b>19</b>. The Boc protective group was then removed using hydrochloric acid in dioxane, leading to compound <b>20</b>; then, the methoxy group was cleaved with boron trifluoride, giving the amino phenol <b>21</b>. The secondary amine was engaged in a reductive amination reaction in the presence of propanal to afford compound <b>22</b>. Finally, the distal <i>p</i>-phenol was introduced via a Suzuki coupling reaction, giving compound <b>10i</b>.</div><div class="NLM_p">The introduction of the pyrrolidine ring was performed as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>10j</b>–<b>p</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<b>24a</b><b>,b</b>): Mitsunobu: (<i>E</i>)-<i>N</i>1,<i>N</i>1,<i>N</i>2,<i>N</i>2-tetramethyldiazene-1,2-dicarboxamide, PPh<sub>3</sub>, THF, rt, 37–75%. (b) (<b>25a</b><b>,b</b>): 4 N HCl, dioxane, MeOH, rt, 33–93%. (c) (<b>26a</b><b>,b</b>): BF<sub>3</sub>,Me<sub>2</sub>S, DCM, rt, 51–95%. (d) (<b>10j</b>–<b>l</b>): aldehyde, NaBH<sub>3</sub>CN, AcOH, MeOH, 0 °C to rt, 40–64%. (e) (<b>10m</b>–<b>p</b>): iodoalkyl, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 40–64%.</p></p></figure><div class="NLM_p">The key step in this process is a Mitsunobu reaction<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> of phenol <b>15</b> with (<i>R</i>)- or (<i>S</i>)-<i>N</i>-Boc-3-hydroxy-pyrrolidine <b>23a,b</b>. This reaction proceeded with an inversion of configuration and was followed by the deprotection in acidic medium of the secondary amine to give compounds <b>25a,b</b>. Compounds <b>10j</b>–<b>p</b> were then prepared by the cleavage of both methoxy groups of <b>25a,b</b> with boron trifluoride to give phenol derivatives <b>26a,b</b>, followed by alkylation with iodoalkyl derivatives or by the reductive amination reaction with the corresponding aldehydes.</div><div class="NLM_p">The benzocycloheptene derivatives <b>33a</b>–<b>p</b> were synthesized according to <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. This route is a variation of the previous ones in which the whole side chain was prepared as a boronic ester building block and introduced directly on the scaffold using a Suzuki coupling reaction.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>33a</b>–<b>p</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pivaloyl chloride, K<sub>2</sub>CO<sub>3</sub>, acetone, rt, 69–73%. (b) Trifluoromethanesulfonic anhydride, pyridine, DCM, rt, 93–97%. (c) PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, rt, 98–100%. (d) Pyridinium tribromide, THF, rt, 75–82%. (e) 5 N NaOH, MeOH, rt, 72–78%. (f) Ar-boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 70 °C, 8–92%.</p></p></figure><div class="NLM_p">The commercially available phenol derivatives <b>27a</b><b>,b</b> were first protected with a pivaloyl group to give the intermediates <b>28a,b</b>, which were converted into the corresponding enol triflate intermediates <b>29a,b</b> with triflic anhydride in the presence of pyridine at room temperature. The side chain was then added in one step via a Suzuki coupling reaction on these triflates with boronate <b>37</b> prepared according to <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Compounds <b>30a</b><b>,b</b> were then brominated with pyridinium tribromide to give bromo derivatives <b>31a,</b><b>b</b>. The pivaloyl esters (R<sub>1</sub> or R<sub>2</sub>) were saponified to obtain the phenol derivatives <b>32a,b</b>, which were subjected to Suzuki coupling reaction with different boronic acids to afford compounds <b>33a</b>–<b>p</b>.</div><figure id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>37</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Mitsunobu: (<i>E</i>)-<i>N</i>1<i>,N</i>1,<i>N</i>2,<i>N</i>2-tetramethyldiazene-1,2-dicarboxamide, PPh<sub>3</sub>, THF, rt, 100%. (b) 4 N HCl, dioxane, MeOH, rt, 95%. (c) K<sub>2</sub>CO<sub>3</sub>, MeCN, 40 °C, 100%.</p></p></figure><div class="NLM_p">The commercially available boronic ester <b>34</b> was alkylated with (<i>R</i>)-1-<i>N</i>-Boc-3-hydroxypyrrolidine (<b>23a</b>) via a Mitsunobu reaction to give compound <b>35</b>. The Boc protective group was then removed using a mixture of methanol and 4 N HCl in dioxane to yield compound <b>36</b>, which was alkylated with 1-iodo-3-fluoropropane in acetonitrile in the presence of potassium carbonate to afford compound <b>37</b>.</div><div class="NLM_p">The carboxylic acid derivatives <b>43a</b>–<b>f</b> were prepared according to <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>.</div><figure id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds (<b>43a–f</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5 N NaOH, MeOH, rt, 93%. (b) Trifluoromethanesulfonic anhydride, pyridine, DCM, 5 °C to rt, 89%. (c) PdCl<sub>2</sub>dppf, MeOH, DMF, CO (5 bar), 70 °C, 86%. (d) Pyridinium tribromide, THF, rt, 85%. (e) Ar-boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 70 °C, 45–75%. (f) 2 N NaOH, MeOH, rt, 28–96%.</p></p></figure><div class="NLM_p last">The carboxylic ester derivative <b>40</b> was obtained by the carbonylation<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> in methanol of the corresponding triflate <b>39</b>, which was prepared by treating the phenol <b>38</b> with triflic anhydride. <b>38</b> was issued from the deprotection of pivaloyl intermediate <b>30b</b> under basic conditions. The ester derivative <b>40</b> was brominated with pyridinium tribromide, and the bromo compound <b>41</b> obtained was used in the Suzuki coupling reaction to afford compounds <b>42a</b>–<b>f</b>, which were finally saponified to give carboxylic acid compounds <b>43a</b>–<b>f</b>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">After a MTS screening, structure activity relationship studies focused on the side chain of the hit compound <b>10a</b> allowed us to identify the fluoro-propyl-pyrrolidine degrader side chain as a key pharmacophore of a new chemical series of ERα degraders (SERD). Distal phenol replacement with halogenated phenyl moieties permitted us to retain degradation potency while improving the metabolic stability of the compounds. Proximal hydroxy replacement with a carboxylic acid was beneficial for potency as a result of a productive interaction with Ar394 and for physicochemical properties with respect to oral absorption and formulation. Overall, the medicinal chemistry optimization of the molecules led to compound <b>43d</b>, identified as a potent SERD of the ERα and reducing the levels of ERα to a similar extent as fulvestrant in vitro. Compound <b>43d</b> exhibited good oral bioavailability across different species and displayed robust activity in BC mice xenograft models with remarkable tumor regression. Compound <b>43d</b> is currently being evaluated orally in phase I/II clinical trials in patients with advanced estrogen-receptor (ERα)-positive BC patients.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p">The nomenclature of the compounds was obtained using ACDLABS software, version 11.01. All solvents and reagents obtained from commercial sources were used without further purification. Thin layer chromatography was carried out on Merck silica gel 60 F254 glass plates. Flash chromatography was performed using prepacked Merck silica gel cartridges (15–40 μm). The microwave oven used was a Biotage, Initiator 2.0, 400 W max, 2450 MHz instrument. <sup>1</sup>H NMR spectra at 400 MHz and <sup>1</sup>H NMR spectra at 500 MHz were performed on a Bruker Avance DRX-400 or Bruker Avance DPX-500 spectrometer with the chemical shifts (δ) in the solvent dimethyl sulfoxide-<i>d</i><sub>6</sub> (<i>d</i><sub>6</sub>-DMSO) referenced at 2.5 ppm at a temperature of 303 K. Coupling constants (J) are given in hertz.</div><div class="NLM_p">Mass spectra (MS) were obtained on a Waters UPLC-SQD instrument scanned over an appropriate mass range.</div><div class="NLM_p">Purities for final compounds were measured using UV detection at 220 nm and are ≥95.0%.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 7-(4-Hydroxyphenyl)-8-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6-dihydronaphthalen-2-ol (<b>10a</b>)</h4><div class="NLM_p last">A mixture of 8-[4-(2-bromoethoxy)phenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>17a</b>) (80 mg, 182.93 μmol), potassium carbonate (77 mg, 551.57 μmol), and pyrrolidine (46 μL, 39.4 mg, 548.43 μmol) in acetonitrile (1 mL) was sealed in a microwave tube. The solution was heated to 110 °C for 6 h in a microwave oven, then evaporated to dryness. After cooling to room temperature, water (5 mL) and ethyl acetate (20 mL) were added. After decantation, the organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of dichloromethane/methanol from 100/0 to 95/5 to give 39 mg (50%) of 7-(4-hydroxyphenyl)-8-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6-dihydronaphthalen-2-ol (<b>10a</b>) as a beige meringue. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.68 (m, 4 H), 2.51 (m, 4 H), 2.62 (m, 2 H), 2.77 (m, 4 H), 4.03 (t, J = 6.0 Hz, 2 H), 6.09 (d, J = 2.5 Hz, 1 H), 6.49 (m, 3 H), 6.82 (m, 7.2 Hz, 4 H), 6.89 (m, 2 H), 6.98 (d, J = 8.0 Hz, 1 H), 8.90 (s, 1 H), 9.23 (s, 1 H). LCMS: 428 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 7-(4-Hydroxyphenyl)-8-[4-[2-[methyl(propyl)amino]ethoxy]phenyl]-5,6-dihydronaphthalen-2-ol (<b>10b</b>)</h4><div class="NLM_p last">Obtained from <b>17a</b> and <i>N</i>-methylpropan-1-amine in 73% yield by an analogous method to <b>10a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 0.85 (t, J = 7.3 Hz, 3 H), 1.42 (m, 2 H), 2.23 (s, 3 H), 2.34 (m, 2 H), 2.60 to 2.80 (m, 6 H), 4.01 (t, J = 5.9 Hz, 2 H), 6.09 (d, J = 2.4 Hz, 1 H), 6.49 (m, 3 H), 6.80 to 6.95 (m, 6 H), 6.98 (d, J = 7.9 Hz, 1 H), 8.89 (s, 1 H), 9.23 (s, 1 H). LCMS: 430 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 8-[4-[2-(Diethylamino)ethoxy]phenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>10c</b>)</h4><div class="NLM_p last">Obtained from <b>17a</b> and diethylamine in 73% yield by an analogous method to <b>10a</b>.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 0.97 (t, J = 7.1 Hz, 6 H), 2.54 (m, 4 H), 2.61 (m, 2 H), 2.76 (m, 4 H), 3.98 (m, 2 H), 6.09 (d, J = 2.4 Hz, 1 H), 6.49 (m, 3 H), 6.84 (m, 6 H), 6.99 (d, J = 7.9 Hz, 1 H), 8.92 (s, 1 H), 9.26 (s, 1 H). LCMS: 430 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 7-(4-Hydroxyphenyl)-8-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-5,6-dihydronaphthalen-2-ol (<b>10d</b>)</h4><div class="NLM_p last">Obtained from <b>18d</b> in 28% yield by an analogous method to <b>17a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.88 (m, 4 H), 2.04 (m, 2 H), 2.63 (t, J = 8.3 Hz, 2 H), 2.77 (t, J = 7.0 Hz, 2 H), 3.10 (m, 6 H), 4.01 (br t, J = 5.9 Hz, 2 H), 6.07 (d, J = 2.2 Hz, 1 H), 6.50 (m, 3 H), 6.83 (m, 4 H), 6.91 (m, 2 H), 6.99 (d, J = 7.5 Hz, 1 H), 8.90 (s, 1 H), 9.24 (s, 1 H). LCMS: 442 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 7-(4-Hydroxyphenyl)-8-[4-(2-imidazol-1-ylethoxy)phenyl]-5,6-dihydronaphthalen-2-ol (<b>10e</b>)</h4><div class="NLM_p last">Obtained from <b>17a</b> and imidazole in 15% yield by an analogous method to <b>10a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.61 (m, 2 H), 2.76 (m, 2 H), 4.21 (t, J = 5.0 Hz, 2 H), 4.35 (t, J = 5.0 Hz, 2 H), 6.06 (d, J = 2.32 Hz, 1 H), 6.49 (br d, J = 8.6 Hz, 3 H), 6.78 to 6.92 (m, 7 H), 6.98 (m, 1 H), 7.24 (s, 1 H), 7.67 (s, 1 H), 8.93 (br s, 1 H), 9.28 (br s, 1 H). LCMS: 425 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 8-[4-[2-(Azetidin-1-yl)ethoxy]phenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>10f</b>)</h4><div class="NLM_p last">Obtained from <b>17a</b> and azetidine in 69% yield by an analogous method to <b>10a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.09 (m, 2 H), 2.62 (m, 2 H), 2.77 (m, 2 H), 2.97 (br s, 2 H), 3.49 (m, 4 H), 3.96 (br t, J = 5.1 Hz, 2 H), 6.08 (m, 1 H), 6.49 (br d, J = 8.2 Hz, 3 H), 6.82 (br d, J = 8.6 Hz, 4 H), 6.90 (d, J = 7.5 Hz, 2H), 6.98 (d, J = 8.0 Hz, 1H), 8.88 (s, 1 H), 9.21 (s, 1 H). LCMS: 414 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 7-(4-Hydroxyphenyl)-8-[4-[2-(1-piperidyl)ethoxy]phenyl]-5,6-dihydronaphthalen-2-ol (<b>10g</b>)</h4><div class="NLM_p last">Obtained from <b>17a</b> and piperidine in 69% yield by an analogous method to <b>10a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.38 (m, 2 H), 1.50 (m, 4 H), 2.43 (m, 4 H), 2.63 (m, 4 H), 2.76 (m, 2 H), 4.02 (t, J = 5.9 Hz, 2 H), 6.09 (d, J = 2.2 Hz, 1 H), 6.49 (d, J = 8.7 Hz, 3 H), 6.80 to 7.00 (m, 7 H), 8.87 (s, 1 H), 9.20 (s, 1 H). LCMS: 442 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 7-(4-Hydroxyphenyl)-8-[4-(2-morpholinoethoxy)phenyl]-5,6-dihydronaphthalen-2-ol (<b>10h</b>)</h4><div class="NLM_p last">Obtained from <b>17a</b> and morpholine in 62% yield by an analogous method to <b>10a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.47 (m, 4 H), 2.55 to 2.80 (m, 6 H), 3.58 (m, 4 H), 4.05 (t, J = 5.7 Hz, 2 H), 6.08 (d, J = 2.4 Hz, 1 H), 6.49 (m, 3 H), 6.80 to 6.90 (m, 6 H), 6.99 (d, J = 8,0 Hz, 1 H), 8.92 (s, 1 H), 9.26 (s, 1 H). LCMS: 444 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 7-(4-Hydroxyphenyl)-8-[4-(1-propylazetidin-3-yl)oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>10i</b>)</h4><div class="NLM_p last">Obtained from <b>22</b> and <i>p</i>-hydroxyphenyl boronic acid in 57% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 0.85 (t, J = 7.3 Hz, 3 H), 1.31 (m, 2 H), 2.40 (t, J = 7.1 Hz, 2 H), 2.61 (m, 2 H), 2.76 (m, 2 H), 2.93 (br t, J = 6.3 Hz, 2 H), 3.72 (br t, J = 6.9 Hz, 2 H), 4.73 (quin, J = 5.6 Hz, 1 H), 6.07 (d, J = 2.4 Hz, 1 H), 6.49 (m, 3 H), 6.72 (d, J = 8.6 Hz, 2 H), 6.80 (d, J = 8.6 Hz, 2 H), 6.88 (d, J = 8.6 Hz, 2 H), 6.98 (d, J = 8.1 Hz, 1 H), 8.91 (s, 1 H), 9.24 (s, 1 H). LCMS: 428 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 7-(4-Hydroxyphenyl)-8-[4-[(3<i>S</i>)-1-propylpyrrolidin-3-yl]oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>10j</b>)</h4><div class="NLM_p last">Obtained from <b>26a</b> and propionaldehyde in 40% yield by an analogous method to <b>22</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 0.87 (t, J = 7.3 Hz, 3 H), 1.45 (m, 2 H), 1.75 (m, 1 H), 2.24 (m, 1 H), 2.36 (m, 3 H), 2.62 (m, 4 H), 2.78 (m, 3 H), 4.81 (m, 1 H), 6.10 (m, 1 H), 6.49 (br d, J = 8.4 Hz, 3 H), 6.79 (m, 4 H), 6.87 (br d, J = 8.4 Hz, 2 H), 6.98 (br d, J = 8.1 Hz, 1 H), 8.91 (s, 1 H), 9.24 (s, 1 H). LCMS: 442 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 7-(4-Hydroxyphenyl)-8-[4-[(3<i>R</i>)-1-propylpyrrolidin-3-yl]oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>10k</b>)</h4><div class="NLM_p last">Obtained from <b>26b</b> and propionaldehyde in 45% yield by an analogous method to <b>22</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 0.87 (t, J = 7.3 Hz, 3 H), 1.45 (m, 2 H), 1.74 (m, 1 H), 2.33 (m, 4 H), 2.62 (m, 4 H), 2.79 (m, 3 H), 4.81 (m, 1 H), 6.10 (d, J = 2.2 Hz, 1 H), 6.49 (m, 3 H), 6.75 to 6.90 (m, 6 H), 6.98 (d, J = 8.1 Hz, 1 H), 8.91 (s, 1 H), 9.24 (s, 1 H). LCMS: 442 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 7-(4-Hydroxyphenyl)-8-[4-[(3<i>S</i>)-1-methylpyrrolidin-3-yl]oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>10l</b>)</h4><div class="NLM_p last">Obtained from <b>26a</b> and formaldehyde in 64% yield by an analogous method to <b>22</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.75 (m, 1 H), 2.20 to 2.40 (m, 6 H), 2.61 (m, 4 H), 2.76 (m, 2 H), 4.81 (m, 1 H), 6.10 (d, J = 2.4 Hz, 1 H), 6.49 (m, 3 H), 6.82 (m, 6 H), 6.98 (d, J = 8.1 Hz, 1 H), 8.91 (s, 1 H), 9.24 (s, 1 H). LCMS: 414 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 8-[4-[(3<i>S</i>)-1-Ethylpyrrolidin-3-yl]oxyphenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>10m</b>)</h4><div class="NLM_p last">Obtained from <b>26a</b> and iodoethane in 64% yield by an analogous method to <b>10p</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.03 (t, J = 7.2 Hz, 3 H), 1.75 (m, 1 H), 2.24 (m, 1 H), 2.41 (m, 3 H), 2.63 (m, 4 H), 2.78 (m, 3 H), 4.81 (m, 1 H), 6.10 (d, J = 2.3 Hz, 1 H), 6.49 (m, 3 H), 6.79 (dd, J = 14.6, 8.6 Hz, 4 H), 6.87 (m, 2 H), 6.98 (d, J = 8.1 Hz, 1 H), 8.92 (s, 1 H), 9.24 (br s, 1 H). LCMS: 428 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 8-[4-[(3<i>S</i>)-1-(2-Fluoroethyl)pyrrolidin-3-yl]oxyphenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>10n</b>)</h4><div class="NLM_p last">Obtained from <b>26a</b> and 1-fluoro-2-iodoethane in 40% yield by an analogous method to <b>10p</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.76 (m, 1 H), 2.25 (m, 1 H), 2.62 (m, 2 H), 2.69 (m, 3 H), 2.76 (m, 4 H), 2.90 (m, 1 H), 4.53 (dt, J = 47.7, 5.0 Hz, 2 H), 4.83 (m, 1 H), 6.10 (d, J = 2.3 Hz, 1 H), 6.49 (m, 3 H), 6.79 (m, 4 H), 6.87 (m, 2 H), 6.98 (d, J = 7.9 Hz, 1 H), 8.91 (s, 1 H), 9.24 (s, 1 H). LCMS: 446 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 8-[4-[(3<i>S</i>)-1-Butylpyrrolidin-3-yl]oxyphenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>10o</b>)</h4><div class="NLM_p last">Obtained from <b>26a</b> and 1-iodobutane in 40% yield by an analogous method to <b>10p</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 0.88 (t, J = 7.3 Hz, 3 H), 1.31 (m, 2 H), 1.41 (m, 2 H), 1.74 (m, 1 H), 2.23 (m, 1 H), 2.38 (m, 3 H), 2.61 (m, 4 H), 2.79 (m, 3 H), 4.80 (br t, J = 6.8 Hz, 1 H), 6.10 (d, J = 2.4 Hz, 1 H), 6.49 (m, 3 H), 6.79 (dd, J = 15.1, 8.6 Hz, 4 H), 6.87 (m, 2 H), 6.98 (d, J = 8.1 Hz, 1 H), 8.91 (s, 1 H), 9.24 (s, 1 H). LCMS: 456 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 8-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>10p</b>)</h4><div class="NLM_p last">To a solution of 7-(4-hydroxyphenyl)-8-[4-[(3<i>S</i>)-pyrrolidin-3-yl]oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>26a</b>) (50 mg, 125.16 μmol) in dimethylformamide (0.5 mL) was added potassium carbonate (26 mg, 188 μmol) and 1-iodo-3-fluoropropane (15 μL, 139 μmol). The reaction mixture was stirred for 2 h at 70 °C. After cooling to room temperature, ethyl acetate and water were added. After decantation, the organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with isopropyl ether/methanol (95/5 v/v) to give 23 mg (40%) of 8-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>10p</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.80 (m, 3 H), 2.26 (m, 1 H), 2.41 (m, 1 H), 2.48 (m, 2 H), 2.54 à 2.72 (m, 5 H), 2.77 (m, 2 H), 2.85 (dd, J = 10.2 et 6.2 Hz, 1 H), 4.49 (dt, J = 47.4 et 6.0 Hz, 2 H), 4.82 (d, J = 6.7 Hz, 1 H), 6.10 (d, J = 2.3 Hz, 1 H), 6.49 (m, 2 H), 6.80 (m, 4 H), 6.89 (m, 2 H), 6.98 (d, J = 8.1 Hz, 1 H), 8.91 (s, 1 H), 9.23 (s, 1 H). LCMS: 460 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (7-Methoxy-3,4-dihydronaphthalen-1-yl) Trifluoromethanesulfonate (<b>12</b>)</h4><div class="NLM_p last">To a mixture of 7-methoxytetralin-1-one (<b>11</b>) (32.5 g, 184.44 mmol), tetrahydrofuran (500 mL), and 1,1,1-trifluoro-<i>N</i>-phenyl-<i>N</i>-((trifluoromethyl)sulfonyl)methanesulfonamide (79.07 g, 221.32 mmol) cooled to −50 °C was added dropwise potassium bis(trimethylsilyl)amide (246 mL, 221.32 mmol) in 0.9 M solution in THF. The reaction mixture was stirred for 1 h at −50 °C, then 20 h at room temperature. The reaction mixture was cooled to 0 °C, and water (500 mL) and ethyl acetate (200 mL) were added. The organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with dichloromethane/<i>n</i>-heptane 10/90 to give 55 g (96%) of (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (<b>12</b>) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.47 (m, 2 H), 2.75 (m, 2 H), 3.75 (s, 3 H), 6.25 (t, J = 4.8 Hz, 1 H), 6.75 (d, J = 2.4 Hz, 1 H), 6.91 (dd, J = 8.2, 2.6 Hz, 1 H), 7.22 (d, J = 8.3 Hz, 1 H). LCMS: 309 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-(7-Methoxy-3,4-dihydronaphthalen-1-yl)phenol (<b>13</b>)</h4><div class="NLM_p last">To a mixture of (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (<b>12</b>) (96 g, 311.41 mmol), (4-hydroxyphenyl)boronic acid (42.95 g, 311.41 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (11.39 g, 15.57 mmol) in dioxane (1000 mL) was added dropwise an aqueous solution of 1.5 M cesium carbonate (384 mL, 576 mmol). The reaction mixture was stirred for 30 min at room temperature. Water (150 mL) and ethyl acetate (500 mL) were added. The organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with ethyl acetate/<i>n</i>-heptane 10/90 to give 55 g (70%) of 4-(7-methoxy-3,4-dihydronaphthalen-1-yl)phenol (<b>13</b>) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.28 (m, 2 H), 2.69 (t, J = 7.8 Hz, 2 H), 3.62 (s, 3 H), 6.01 (t, J = 4.6 Hz, 1 H), 6.45 (d, J = 2.4 Hz, 1 H), 6.74 (dd, J = 8.2, 2.7 Hz, 1 H), 6.78 (d, J = 8.4 Hz, 2 H), 7.11 (m, 3 H), 9.43 (s, 1 H). LCMS: 253 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-(2-Bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenol (<b>14</b>)</h4><div class="NLM_p last">To a solution of 4-(7-methoxy-3,4-dihydronaphthalen-1-yl)phenol (<b>13</b>) (55 g, 217.99 mmol) in tetrahydrofuran (1000 mL) was added pyridinium tribromide (69.72 g, 217.99 mmol). The reaction mixture was stirred for 24 h at room temperature. Water (500 mL) was added, then pH was adjusted to 8 with an aqueous solution of sodium bicarbonate. Ethyl acetate was added (500 mL). After decantation, the organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was triturated with a mixture of isopropyl ether/heptane 50/50. The solid formed and was filtered and dried to give 57 g (79%) of 4-(2-bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenol (<b>14</b>) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.89 (m, 4 H), 3.57 (s, 3 H), 6.08 (d, J = 2.6 Hz, 1 H), 6.75 (m, 1 H), 6.83 (d, J = 8.6 Hz, 2 H), 6.97 (d, J = 8.6 Hz, 2 H), 7.11 (d, J = 8.5 Hz, 1 H), 9.52 (s, 1 H). LCMS: 331 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-[7-Methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenol (<b>15</b>)</h4><div class="NLM_p last">A mixture of 4-(2-bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenol (6.09 g, 18.39 mmol), (4-methoxyphenyl)boronic acid (<b>14</b>) (3.46 g, 22.06 mmol), tetrakis(triphenylphosphine)palladium (2.15 g, 1.84 mmol), cesium carbonate (3.90 g, 36.77 mmol) in dioxane (150 mL), and water (15 mL) was heated to 100 °C for 2.5 h. After cooling to room temperature, water (300 mL) and ethyl acetate (300 mL) were added. The organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of ethyl acetate/<i>n</i>-heptane from 5/95 to 30/70 to give 3.6 g (55%) of 4-[7-methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenol (<b>15</b>) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.65 (m, 2 H), 2.82 (m, 2 H), 3.57 (s, 3 H), 3.67 (s, 3 H), 6.18 (d, J = 2.6 Hz, 1 H), 6.71 (m, 7 H), 6.95 (m, 2 H), 7.13 (d, J = 8.2 Hz, 1 H), 9.30 (s, 1 H). LCMS: 359 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-[4-(2-Bromoethoxy)phenyl]-6-methoxy-3-(4-methoxyphenyl)-1,2-dihydronaphthalene (<b>16a</b>)</h4><div class="NLM_p last">A mixture of 4-[7-methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenol (<b>15</b>) (400 mg, 1.12 mmol), 1,2-dibromoethane (293 μL, 3.36 mmol), and potassium carbonate (779 mg, 5.60 mmol) in acetonitrile (10 mL) was heated to 70 °C for 48 h. After cooling to room temperature, the reaction mixture was filtered and concentrated under reduced pressure. To the residue obtained, water (30 mL) and ethyl acetate (60 mL) were added. The organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of ethyl acetate/<i>n</i>-heptane from 5/95 to 30/70 to give 380 mg (73%) of 4-[4-(2-bromoethoxy)phenyl]-6-methoxy-3-(4-methoxyphenyl)-1,2-dihydronaphthalene (<b>16a</b>) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.67 (m, 2 H), 2.83 (m, 2 H), 3.57 (s, 3 H), 3.67 (s, 3 H), 3.80 (t, J = 6.11 Hz, 2 H), 4.29 (t, J = 7 Hz, 2 H), 6.13 (d, J = 2.7 Hz, 1 H), 6.71 (m, 3 H), 6.85 to 7.00 (m, 6 H), 7.15 (d, J = 8.2 Hz, 1 H). LCMS: 465 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-[4-(3-Bromopropoxy)phenyl]-6-methoxy-3-(4-methoxyphenyl)-1,2-dihydronaphthalene (<b>16b</b>)</h4><div class="NLM_p last">Obtained from <b>15</b> and 1,3-diromopropane in 71% yield by an analogous method to <b>16a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.24 (t, J = 6.3 Hz, 2 H), 2.67 (m, 2 H), 2.83 (m, 2 H), 3.57 (s, 3 H), 3.67 (m, 5 H), 4.05 (t, J = 6.0 Hz, 2 H), 6.13 (d, J = 2.4 Hz, 1 H), 6.71 (m, 3 H), 6.81 to 7.00 (m, 6 H), 7.14 (d, J = 8.2 Hz, 1 H). LCMS: 479 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 8-[4-(2-Bromoethoxy)phenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>17a</b>)</h4><div class="NLM_p last">To a solution of 4-[4-(2-bromoethoxy)phenyl]-6-methoxy-3-(4-methoxyphenyl)-1,2-dihydronaphthalene (<b>16a</b>) (800 mg, 1.72 mmol) in dichloromethane (80 mL) was added dropwise a boron trifluoride–dimethyl sulfide complex (3.62 mL, 34.38 mmol). The reaction mixture was stirred for 24 h at room temperature. The reaction mixture was cooled to 0 °C, and water (10 mL) was added. The pH was adjusted to 8 by adding an aqueous solution of 2 N NaOH. After decantation, the organic phase was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by flash chromatography eluting with a gradient of dichloromethane/methanol from 100/0 to 95/5 to give 650 mg (86%) of 8-[4-(2-bromoethoxy)phenyl]-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol (<b>17a</b>) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.62 (m, 2 H), 2.77 (m, 2 H), 3.80 (m, 2 H), 4.29 (t, J = 5.4 Hz, 2 H), 6.09 (d, J = 2.4 Hz, 1 H), 6.50 (m, 3 H), 6.80 to 7.00 (m, 7 H), 8.91 (br s, 1 H), 9.24 (br s, 1 H). LCMS: 437 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-[3-[4-[7-Methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenoxy]propyl]pyrrolidine (<b>18d</b>)</h4><div class="NLM_p last">Obtained from <b>16b</b> and pyrrolidine in 93% yield by an analogous method to <b>10a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.67 (m, 4 H), 1.87 (m, 2 H), 2.42 (m, 4 H), 2.53 (m, 1 H), 2.67 (m, 3 H), 2.83 (m, 2 H), 3.57 (s, 3 H), 3.67 (s, 3 H), 3.98 (t, J = 6.4 Hz, 2 H), 6.13 (d, J = 2.6 Hz, 1 H), 6.71 (m, 3 H), 6.82 (d, J = 7.5 Hz, 2 H), 6.90 (d, J = 7.5 Hz, 2 H), 6.95 (d, J = 7.5 Hz, 2 H), 7.14 (d, J = 8.2 Hz, 1 H). LCMS: 470 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 3-[4-(2-Bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]azetidine-1-carboxylate (<b>19</b>)</h4><div class="NLM_p last">A mixture of 4-(2-bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenol (<b>14</b>) (6.02 g, 18.18 mmol), 1-Boc-3-iodoazetidine (8 g, 27.13 mmol), and cesium carbonate (11.82 g, 36.24 mmol) in dimethylformamide (45 mL) was stirred at room temperature for 24 h. To the reaction mixture, water (200 mL) and ethyl acetate (200 mL) were added. The organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was triturated with isopropyl ether, and the solid obtained was filtered and washed with isopropyl ether to give 7.1 g (80%) of <i>tert</i>-butyl 3-[4-(2-bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]azetidine-1-carboxylate (<b>19</b>) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.40 (s, 9 H), 2.91 (s, 4 H), 3.57 (s, 3 H), 3.84 (br dd, J = 9.3, 3.3 Hz, 2 H), 4.32 (br t, J = 7.4 Hz, 2 H), 5.04 (m, 1 H), 6.02 (d, J = 2.6 Hz, 1 H), 6.77 (dd, J = 8.2, 2.6 Hz, 1 H), 6.91 (d, J = 8.6 Hz, 2 H), 7.12 (m, 3 H). LCMS: 486 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-[4-(2-Bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]azetidine hydrochloride (<b>20</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-[4-(2-bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]azetidine-1-carboxylate (<b>19</b>) (7.1 g, 14.60 mmol) in methanol (40 mL) was added hydrochloric acid in 4 N dioxane (29 mL, 116 mmol). The reaction mixture was stirred for 1 h at room temperature, then concentrated under reduced pressure, and the residue obtained was triturated with dichloromethane and filtered to give 5.10 g (81%) of 3-[4-(2-bromo-7-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]azetidine hydrochloride (<b>20</b>) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.91 (s, 4 H), 3.57 (s, 3 H), 4.04 (br dd, J = 12.0, 4.8 Hz, 2 H), 4.45 (br dd, J = 11.9, 6.6 Hz, 2 H), 5.14 (quin, J = 5.3 Hz, 1 H), 6.01 (d, J = 2.7 Hz, 1 H), 6.77 (dd, J = 8.2, 2.6 Hz, 1 H), 6.95 (d, J = 8.6 Hz, 2 H), 7.14 (m, 3 H), 9.20 (br s, 2 H). LCMS: 386 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 8-[4-(Azetidin-3-yloxy)phenyl]-7-bromo-5,6-dihydronaphthalen-2-ol (<b>21</b>)</h4><div class="NLM_p last">Obtained from <b>20</b> in 64% yield by an analogous method to <b>17a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.86 (s, 4 H), 3.59 (m, 2 H), 3.85 (br t, J = 7.5 Hz, 2 H), 5.01 (m, 1 H), 6.00 (m, 1 H), 6.54 (m, 1 H), 6.88 (m, 2 H), 6.98 (d, J = 8.1 Hz, 1 H), 7.08 (m, J = 8.3 Hz, 2 H), 9.08 (s, 1 H). LCMS: 372 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 7-Bromo-8-[4-(1-propylazetidin-3-yl)oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>22</b>)</h4><div class="NLM_p last">To a suspension of 8-[4-(azetidin-3-yloxy)phenyl]-7-bromo-5,6-dihydronaphthalen-2-ol (<b>21</b>) (1.36 g, 3.65 mmol), methanol (10 mL), propionaldehyde (437 mg, 7.31 mmol), and sodium cyanoborohydride (725 mg, 11 mmol) was added acetic acid (10 mL). After stirring for 2 h at room temperature, water (100 mL) and ethyl acetate (100 mL) were added. After decantation, the organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was treated on SCX columns (Isolute Flash SCX-2; 20 g): The SCX columns were equilibrated with methanol, and the compound was introduced in solution in methanol. Elution with methanol then with a 2 M solution of ammonia in methanol gave 760 mg (50%) of 7-bromo-8-[4-(1-propylazetidin-3-yl)oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>22</b>) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 0.86 (t, J = 8.8 Hz, 3 H), 1.32 (m, 2 H), 2.40 (t, J = 7.2 Hz, 2 H), 2.87 (m, 4 H), 2.96 (m, 2 H), 3.76 (m, 2 H), 4.81 (m, 1 H), 6.00 (d, J = 2.4 Hz, 1 H), 6.54 (dd, J = 8.1, 2.4 Hz, 1 H), 6.93 (m, 3 H), 7.07 (d, J = 8.7 Hz, 2 H), 9.07 (s, 1 H). LCMS: 414 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl (3<i>S</i>)-3-[4-[7-Methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenoxy]pyrrolidine-1-carboxylate (<b>24a</b>)</h4><div class="NLM_p last">To a solution of 4-[7-methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenol (<b>15</b>) (1.11 g, 3.10 mmol) in tetrahydrofuran (20 mL) was added (<i>R</i>)-<i>tert</i>-butyl 3-hydroxypyrrolidine-1-carboxylate (<b>23a</b>) (732 mg, 3.71 mmol), (<i>E</i>)-<i>N</i>1,<i>N</i>1,<i>N</i>2,<i>N</i>2-tetramethyldiazene-1,2-dicarboxamide (1.06 g, 6.16 mmol), and triphenylphosphine (1.66 g, 6.27 mmol). The reaction mixture was stirred for 24 h at room temperature. Water (50 mL) and ethyl acetate (100 mL) were added. After decantation, the organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of heptane in ethyl acetate (100/0 to 70/30 v/v) to give 1.22 g (75%) of <i>tert</i>-butyl (3<i>S</i>)-3-[4-[7-methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenoxy]pyrrolidine-1-carboxylate (<b>24a</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.40 (m, 9 H), 2.08 (m, 2 H), 2.67 (t, J = 7.6 Hz, 2 H), 2.83 (d, J = 7.6 Hz, 2 H), 3.35 to 3.45 (m, 3 H), 3.52 (m, 1 H), 3.57 (s, 3 H), 3.67 (s, 3 H), 4.97 (br s, 1 H), 6.14 (m, 1 H), 6.71 (m, 3 H), 6.85 (d, J = 8.4 Hz, 2 H), 6.92 (d, J = 8.2 Hz, 2 H), 6.95 (d, J = 8.4 Hz, 2 H), 7.15 (d, J = 8.2 Hz, 1 H). LCMS: 528 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>tert</i>-Butyl (3<i>R</i>)-3-[4-[7-Methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenoxy]pyrrolidine-1-carboxylate (<b>24b</b>)</h4><div class="NLM_p last">Obtained from <b>15</b> and (<i>S</i>)-<i>tert</i>-butyl 3-hydroxypyrrolidine-1-carboxylate (<b>23b</b>) in 37% yield by an analogous method to <b>24a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.40 (m, 9 H), 2.08 (m, 2 H), 2.67 (t, J = 7.6 Hz, 2 H), 2.83 (t, J = 7.6 Hz, 2 H), 3.35 to 3.45 (m, 3 H), 3.52 (m, 1 H), 3.57 (s, 3 H), 3.67 (s, 3 H), 4.97 (br s, 1 H), 6.14 (m, 1 H), 6.71 (m, 3 H), 6.85 (d, J = 8.4 Hz, 2 H), 6.92 (d, J = 8.2 Hz, 2 H), 6.95 (d, J = 8.4 Hz, 2 H), 7.15 (d, J = 8.2 Hz, 1 H). LCMS: 528 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (3<i>S</i>)-3-[4-[7-Methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenoxy]pyrrolidine (<b>25a</b>)</h4><div class="NLM_p last">Obtained from <b>24a</b> in 93% yield by an analogous method to <b>20</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.16 (m, 2 H), 2.67 (m, 2 H), 2.84 (m, 2 H), 3.27 (m, 2 H), 3.44 (m, 2 H), 3.58 (s, 3 H), 3.68 (s, 3 H), 5.11 (m, 1 H), 6.13 (d, J = 2.6 Hz, 1 H), 6.71 (m, 3 H), 6.88 (m, 2 H), 6.95 (d, J = 8.7 Hz, 4 H), 7.16 (d, J = 8.2 Hz, 1 H), 9.24 (br s, 1 H). LCMS: 428 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (3<i>R</i>)-3-[4-[7-Methoxy-2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]phenoxy]pyrrolidine hydrochloride (<b>25b</b>)</h4><div class="NLM_p last">Obtained from <b>24b</b> in 88% yield by an analogous method to <b>20</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.16 (m, 2 H), 2.67 (m, 2 H), 2.84 (m, 2 H), 3.27 (m, 2 H), 3.44 (m, 2 H), 3.58 (s, 3 H), 3.68 (s, 3 H), 5.11 (m, 1 H), 6.13 (d, J = 2.6 Hz, 1 H), 6.71 (m, 3 H), 6.88 (m, 2 H), 6.95 (d, J = 8.7 Hz, 4 H), 7.16 (d, J = 8.2 Hz, 1 H), 9.24 (br s, 2 H). LCMS: 428 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 7-(4-Hydroxyphenyl)-8-[4-[(3<i>S</i>)-pyrrolidin-3-yl]oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>26a</b>)</h4><div class="NLM_p last">Obtained from <b>25a</b> in 71% yield by an analogous method to <b>17a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.74 (m, 1 H), 1.98 (m, 1 H), 2.62 (m, 2 H), 2.81 (m, 5 H), 3.02 (dd, J = 12.1, 5.3 Hz, 1 H), 4.80 (m, 1 H), 6.10 (d, J = 2.3 Hz, 1 H), 6.50 (m, 3 H), 6.80 (m, 4 H), 6.87 (d, J = 8.6 Hz, 2 H), 6.99 (d, J = 8.1 Hz, 1 H), 8.95 (br s, 1 H), 9.28 (br s, 1 H). LCMS: 400 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 7-(4-Hydroxyphenyl)-8-[4-[(3<i>R</i>)-pyrrolidin-3-yl]oxyphenyl]-5,6-dihydronaphthalen-2-ol (<b>26b</b>)</h4><div class="NLM_p last">Obtained from <b>25b</b> in 65% yield by an analogous method to <b>17a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.74 (m, 1 H), 1.98 (m, 1 H), 2.62 (m, 2 H), 2.81 (m, 5 H), 3.02 (dd, J = 12.1, 5.3 Hz, 1 H), 4.80 (m, 1 H), 6.10 (d, J = 2.3 Hz, 1 H), 6.50 (m, 3 H), 6.80 (m, 4 H), 6.87 (d, J = 8.6 Hz, 2 H), 6.99 (d, J = 8.1 Hz, 1 H), 8.95 (br s, 1 H), 9.28 (br s, 1 H). LCMS: 400 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 9-Oxo-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl 2,2-Dimethylpropanoate (<b>28a</b>)</h4><div class="NLM_p last">To a solution of 3-hydroxy-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-5-one (<b>27a</b>) (2.42 g, 13.73 mmol) in acetone (100 mL) was added potassium carbonate (1.90 g, 13.73 mmol) and pivaloyl chloride (1.69 mL, 13.73 mmol). The reaction mixture was stirred at room temperature for 18 h, then was filtered and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of heptane in ethyl acetate (100/0 to 85/15 v/v) to give 2.62 g (73%) of 9-oxo-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl 2,2-dimethylpropanoate (<b>28a</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.30 (s, 9H), 1.65 to 1.85 (m, 4H), 2.70 (t, J = 6.3 Hz, 2H), 2.95 (t, J = 6.3 Hz, 2H), 7.20 to 7.28 (m, 2H), 7.37 (d, J = 8.2 Hz, 1H). LCMS: 261 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 5-Oxo-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl 2,2-Dimethylpropanoate (<b>28b</b>)</h4><div class="NLM_p last">Obtained from <b>27b</b> in 69% yield by an analogous method to <b>28a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.30 (s, 9H), 1.65 to 1.85 (m, 4H), 2.68 (t, J = 6.3 Hz, 2H), 2.95 (t, J = 6.3 Hz, 2H), 7.04 to 7.10 (m, 2H), 7.65 (d, J = 8.8 Hz, 1H). LCMS: 261 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> [5-(Trifluoromethylsulfonyloxy)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-yl] 2,2-Dimethylpropanoate (<b>29a</b>)</h4><div class="NLM_p last">To a solution of 9-oxo-6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-2-yl 2,2-dimethylpropanoate (<b>28a</b>) (2.6 g, 10 mmol) in dichloromethane (100 mL) was added pyridine (1.26 mL, 14.98 mmol) and trifluoromethanesulfonic anhydride (3.39 mL, 19.97 mmol) dropwise under argon. The reaction mixture was stirred at room temperature for 16 h, and ice (200 g) and dichloromethane (200 mL) were added. The phases were separated, the aqueous phase was washed with dichloromethane, and the gathered organic phases were dried over magnesium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of heptane in ethyl acetate (100/0 to 90/10 v/v) to give 3.65 g (93%) of [5-(trifluoromethylsulfonyloxy)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-yl] 2,2-dimethylpropanoate (<b>29a</b>) as an orange oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.30 (s, 9H), 1.98 (m, 2H), 2.26 (m, 2H), 2.72 (m, 2H), 6.46 (t, J = 6.2 Hz, 1H), 7.10 to 7.14 (m, 2H) ; 7.38 (m, 1H). LCMS: 393 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 9-(Trifluoromethanesulfonyloxy)-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-yl-2,2-dimethylpropanoate (<b>29b</b>)</h4><div class="NLM_p last">Obtained from <b>28b</b> in 97% yield by an analogous method to <b>29a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.30 (s, 9H), 1.98 (m, 2H), 2.26 (m, 2H), 2.72 (m, 2H), 6.38 (t, J = 6.2 Hz, 1H), 7.10 to 7.15 (m, 2H) ; 7.48 (m, 1H). LCMS: 393 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> [5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-yl] 2,2-dimethylpropanoate (<b>30a</b>)</h4><div class="NLM_p last">Obtained from <b>29a</b> and (3<i>S</i>)-1-(3-fluoropropyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (<b>37</b>) in 98% yield by an analogous method to <b>13</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.24 (s, 9H), 1.70 to 1.92 (m, 5H), 2.11 (m, 2H), 2.26 (m, 1H), 2.42 (m, 1H), 2.48 (t, J = 7.2 Hz, 2H), 2.52 to 2.74 (m, 4H), 2.85 (dd, J = 6.2 and 10.4 Hz, 1H), 4.49 (td, J = 6.1 and 47.5 Hz, 2H), 4.85 (m, 1H), 6.39 (t, J = 7.4 Hz, 1H), 6.59 (d, J = 2.6 Hz, 1H) ; 6.84 (d, J = 8.8 Hz, 2H), 6.97 (dd, J = 2.6 and 8.2 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 7.35 (d, J = 8.2 Hz, 1H). LCMS: 466 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 9-(4-[[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxy]phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-yl-2,2-dimethylpropanoate (<b>30b</b>)</h4><div class="NLM_p last">Obtained from <b>29b</b> and (3<i>S</i>)-1-(3-fluoropropyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (<b>37</b>) in 100% yield by an analogous method to <b>13</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.31 (s, 9H), 1.70 to 1.90 (m, 6H), 2.10 (m, 2H), 2.25 (m, 1H), 2.43 (m, 1H), 2.55 to 2.71 (m, 4H), 2.85 (m, 2H), 4.48 (td, J = 6.1 and 47.5 Hz, 2H), 4.85 (m, 1H), 6.38 (t, J = 7.4 Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 6.93 (s, 1H), 7.06 to 7.15 (m, 4H). LCMS: 466 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> [6-Bromo-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-yl] 2,2-Dimethylpropanoate (<b>31a</b>)</h4><div class="NLM_p last">Obtained from <b>30a</b> in 82% yield by an analogous method to <b>14</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.21 (s, 9H), 1.71 to 1.91 (m, 3H) ; 2.18 to 2.33 (m, 3H), 2.42 (m, 1H), 2.48 (t, J = 7.2 Hz, 2H), 2.50 (m, 2 H), 2.62 (dd, J = 3.0 and 10.4 Hz, 1H), 2.65 to 2.77 (m, 3 H), 2.86 (dd, J = 6.2 and 10.4 Hz, 1H), 4.49 (td, J = 6.1 and 47.5 Hz, 2H), 4.87 (m, 1 H), 6.44 (d, J = 2.6 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 6.97 (dd, J = 2.6 and 8.2 Hz, 1H), 7.10 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 8.2 Hz, 1H). LCMS: 544 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 8-Bromo-9-(4-[[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy]phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-yl-2,2-dimethylpropanoate (<b>31b</b>)</h4><div class="NLM_p last">Obtained from <b>30b</b> in 75% yield by an analogous method to <b>14</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.29 (s, 9 H), 2.05 to 2.30 (m, 6 H), 2.48 (m, 2 H), 2.60 (m, 1 H), 2.74 (t, J = 6.8 Hz, 2 H), 3.26 to 3.50 (m, 3 H), 3.73 to 4.05 (m, 2 H), 4.55 (dq, J = 47.1, 3.9 Hz, 2H), 5.16 (m, 1 H), 6.77 (d, J = 8.4 Hz, 1 H), 6.90 (dd, J = 8.4, 2.4 Hz, 1 H), 6.97 (d, J = 8.4 Hz, 2 H), 7.08 (d, J = 2.4 Hz, 1 H), 7.15 (d, J = 8.7 Hz, 2 H), 10.81 (br s, 0.5H), 11.37 (br s, 0.5 H). LCMS: 544 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 6-Bromo-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-ol (<b>32a</b>)</h4><div class="NLM_p last">To a solution of [6-bromo-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-yl] 2,2-dimethylpropanoate (<b>31a</b>) (665 mg, 1.22 mmol) in methanol (30 mL) was added NaOH (5 N, 2 mL, 10.00 mmol). The reaction mixture was stirred for 15 min at room temperature, and 2 mL of an aqueous solution of 5 N HCl was added. The solvent was removed under reduced pressure. The residue was taken up in ethyl acetate. The phases were separated, and the aqueous phase was washed with ethyl acetate. The organic phases were combined and dried over magnesium sulfate, then were filtered and concentrated under reduced pressure, and the residue was purified by column chromatography eluting with a gradient of methanol in dichloromethane (100/0 to 97/3 v/v) to give 0.4 g (72%) of 6-bromo-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-ol (<b>32a</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.71 to 1.89 (m, 3H), 2.14 (m, 2H), 2.28 (m, 1H), 2.38 to 2.55 (m, 5H), 2.58 to 2.72 (m, 4H), 2.87 (dd, J = 6.4 and 10.4 Hz, 1H), 4.49 (td, J = 6.1 and 47.5 Hz, 2H); 4.85 (m, 1H), 6.20 (d, J = 2.7 Hz, 1H), 6.60 (dd, J = 2.7 and 8.2 Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 7.18 (d, J = 8.8 Hz, 3H), 9.11 (s, 1H). LCMS: 460 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 8-Bromo-9-(4-[[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy]phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-ol (<b>32b</b>)</h4><div class="NLM_p last">Obtained from <b>31b</b> in 78% yield by an analogous method to <b>32a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>):1.71 to 1.89 (m, 3H), 2.19 (m, 2H), 2.28 (m, 1H), 2.39 to 2.52 (m, 5H), 2.59 to 2.72 (m, 4H), 2.87 (dd, J = 6.4 and 10.4 Hz, 1H), 4.49 (td, J = 6.1 and 47.5 Hz, 2H), 4.83 (m, 1H), 6.52 (m, 2H), 6.68 (s, 1H), 6.83 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 9.50 (s, 1H). LCMS: 460 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(4-hydroxyphenyl)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-ol (<b>33a</b>)</h4><div class="NLM_p last">Obtained from <b>32a</b> and <i>p</i>-hydroxyphenyl boronic acid in 71% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1,69 (m, 1 H), 1,80 (dm, J = 25.3 Hz, 2 H), 1,98 (m, 2 H), 2,20 (m, 3 H), 2,39 (m, 1 H), 2,48 (m, 2 H), 2,54 (m, 1 H), 2,63 (m, 3 H), 2,80 (dd, J = 6,4 and10,4 Hz, 1 H), 4,48 (td, J = 6,1 and 47,5 Hz, 2 H), 4,75 (m, 1 H), 6,19 (d, J = 2,6 Hz, 1 H), 6,55 (m, 3 H), 6,62 (d, J = 8,8 Hz, 2 H), 6,72 (d, J = 8,8 Hz, 2 H), 6,92 (d, J = 8,6 Hz, 2 H), 7,04 (d, J = 8,6 Hz, 1 H), 8,98 (s, 1 H), 9,28 (s, 1 H). LCMS: 474 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 6-(2-Chloro-4-fluoro-phenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-3-ol (<b>33b</b>)</h4><div class="NLM_p last">Obtained from <b>32a</b> and 2-chloro-4-fluorophenyl boronic acid in 74% yield by an analogous method to <b>15</b>.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1,67 (m, 1 H), 1,79 (dm, J = 25.3 Hz, 2 H), 2,03 (m, 2 H), 2,15 (t, J = 7,0 Hz, 2 H), 2,20 (m, 1 H), 2,38 (m, 1 H), 2,46 (t, J = 7,2 Hz, 2 H), 2,52 (dd, J= 3,2 and 10,4 H z, 1 H), 2,62 (m, 1 H), 2,69 to 2,82 (m, 3 H), 4,47 (td, J = 6,1 and 47,5 Hz, 2 H), 4,72 (m, 1 H), 6,20 (d, J = 2,7 Hz, 1 H), 6,62 (dd, J = 2,7 and 8,3 Hz, 1 H), 6,64 (d, J = 8,8 Hz, 2 H), 6,72 (d, J= 8,8 H z, 2 H), 7,04 (dt, J = 2,7 and 9,0 Hz, 1 H), 7,10 (d, J = 8,3 Hz, 1 H), 7,17 (dd, J = 6,4 and 8,9 Hz, 1 H), 7,40 (dd J = 2,7 and 8,9 Hz, 1 H), 9,07 (s, 1 H). LCMS: 510 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(4-hydroxyphenyl)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33c</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and <i>p</i>-hydroxyphenylboronic acid in 41% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.69 (m, 1H), 1.80 (dm, J = 25.3 Hz, 2 H), 2.02 (m, 2H), 2.20 (m, 3H), 2.39 (m, 1H), 2.48 (t, J = 7.2 Hz, 2H), 2.54 (dd, J = 3.2 and 10.4 Hz, 1H), 2.63 (m, 3H), 2.80 (dd, J = 6.4 and 10.4 Hz, 1H), 4.48 (td, J = 6.1 and 47.5 Hz, 2H), 4.73 (m, 1H), 6.52 (m, 4H), 6.60 (d, J = 8.8 Hz, 2H), 6.68 (s, 1H), 6.71 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 9.23 (s, 1H), 9.32 (s, 1H). LCMS: 474 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 6-(2-Chloro-4-fluoro-phenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33d</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and 2-chloro-4-fluorophenylboronic acid in 78% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.67 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.08 (m, 2H), 2.19 (m, 3H), 2.37 (m, 1H), 2.46 (t, J = 7.2 Hz, 2H), 2.53 (m, 1H), 2.61 to 2.83 (m, 4H), 4.47 (td, J = 6.2 and 47.6 Hz, 2H), 4.72 (m, 1H), 6.57 (m, 2H), 6.60 (d, J = 8.8 Hz, 2H), 6.71 (m, 3H), 7.02 (dt, J = 2.6 and 9.0 Hz, 1H), 7.17 (dd, J = 6.4 and 9.0 Hz, 1H), 7.39 (dd, J = 2.6 and 9.0 Hz, 1H), 9.43 (s, 1H). LCMS: 510 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 9-(4-[[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxy]phenyl)-8-phenyl-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-ol (<b>33e</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and phenylboronic acid in 72% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.70 (m, 1H), 1.80 (dm, J = 25.3 Hz, 2 H), 2.04 (m, 2H), 2.19 (m, 1H), 2.27 (t, J = 7.0 Hz, 2H), 2.40 (m, 1H), 2.48 (m, 2H), 2.55 (m, 1H), 2.60 to 2.71 (m, 3H), 2.80 (m, 1H), 4.48 (td, J = 6.1 and 47.5 Hz, 2H), 4.73 (m, 1H), 6.56 (m, 2H), 6.59 (d, J = 8.8 Hz, 2H), 6.69 (s, 1H), 6.71 (d, J = 8.8 Hz, 2H), 7.05 to 7.19 (m, 5H), 9.37 (s, 1H). LCMS: 458(M + H)<sup>+</sup>.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 6-(2-Chloro-3-fluoro-phenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33f</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and 2-chloro-3-fluorophenylboronic acid in 78% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.66 (m, 1H), 1,79 (dm, J = 25.3 Hz, 2 H), 2,08 (m, 2 H), 2,18 (m, 3 H), 2,37 (m, 1 H), 2,43 (t, J = 7,2 Hz, 2 H), 2,52 (m, 1 H), 2,62 (m, 1 H), 2,78 (m, 3 H), 4,47 (td, J = 6,1 and 47,5 Hz, 2 H), 4,71 (m, 1 H), 6,58 (s, 2 H), 6,60 (d, J = 8,9 Hz, 2 H), 6,70 (s, 1 H), 6,72 (d, J = 8,9 Hz, 2 H), 6,99 (m, 1 H), 7.20 (m, 2H), 9.46 (s, 1H). LCMS: 510 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 6-(3-Chloro-2-fluoro-phenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33g</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and 2-fluoro-3-chlorophenylboronic acid in 18% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.68 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.07 (m, 2H), 2.19 (m, 3H), 2.38 to 2.58 (m, 4H), 2.60 to 2.81 (m, 4H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.75 (m, 1H), 6.56 (s, 2H), 6.61 (d, J = 8.8 Hz, 2H), 6.71 (m, 3H), 7.05 (t, J = 8.2 Hz, 1H), 7.13 (m, 1H), 7.36 (m, 1H), 9.48 (s, 1H). LCMS: 510 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 6-(4-Chloro-2-fluoro-phenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33h</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and 2-fluoro-4-chlorophenylboronic acid in 92% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.70 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.06 (m, 2H), 2.13 to 2.24 (m, 3H), 2.39 (m, 1H), 2.47 (t, J = 7.2 Hz, 2H), 2.53 (m, 1H), 2.73 (m, 1H), 2.70 (t, J = 7.2 Hz, 2H), 2.80 (dd, J = 6.3 and 10.4 Hz, 1H), 4.47 (td, J = 6.3 and 47.5 Hz, 2H), 4.73 (m, 1H), 6.58 (m, 2H), 6.62 (d, J = 8.8 Hz, 2H), 6.70 (s, 1H), 6.72 (d, J = 8.8 Hz, 2H), 7.11 (dd, J = 2.2 and 8.2 Hz, 1H), 7.18 (t, J = 8.2 Hz, 1H), 7.27 (dd, J = 2.2 and 9.9 Hz, 1H), 9.41 (s, 1H). LCMS: 510 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 6-(2-Chlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33i</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and 2-chlorophenylboronic acid in 74% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.66 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.06 (m, 2H), 2.18 (m, 3H), 2.37 (m, 1H), 2.44 (t, J = 7.2 Hz, 2H), 2.52 (m, 1H), 2.61 (m, 1H), 2.69 to 2.85 (m, 3H), 4.46 (td, J = 6.1 and 47.5 Hz, 2H), 4.71 (m, 1 H), 6.57 (m, 4H), 6.71 (m, 3H), 7.08 to 7.20 (m, 3H), 7.39 (d, J = 8.2 Hz, 1H), 9.40 (s, 1H). LCMS: 492 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33j</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and 2,4-dichlorophenylboronic acid in 35% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.68 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.06 (m, 2H), 2.18 (m, 3H), 2.38 (m, 1H), 2.48 (t, J = 7.2 Hz, 2H), 2.53 (m, 1H), 2.62 (m, 1H), 2.69 to 2.82 (m, 3H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.72 (m, 1H), 6.57 (m, 2H), 6.61 (d, J = 8.8 Hz, 2H), 6.70 (s, 1H), 6.72 (d, J = 8.8 Hz, 2H), 7.14 (d, J = 8.8 Hz, 1H), 7.23 (dd, J = 2.5 and 8.8 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 9.42 (s, 1H). LCMS: 526 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethoxy)phenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33k</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and <i>p</i>-trifluoromethoxyphenylboronic acid in 61% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.70 (m, 1H), 1.80 (dm, J = 25.3 Hz, 2 H), 2.10 (m, 2H), 2.20 (m, 1H), 2.27 (t, J = 7.0 Hz, 2H), 2.41 (m, 1H), 2.48 (m, 2H), 2.57 (m, 1H), 2.68 (m, 1H), 2.78 (t, J = 7.0 Hz, 2H), 2.82 (m, 1H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.76 (m, 1H), 6.64 (d, J = 8.8 Hz, 2H), 6.73 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.6 Hz, 1H), 7.03 (ddd, J = 1.3 and 2.8 and 8.6 Hz, 1H), 7.16 (d, J = 2.8 Hz, 1H), 7.18 (d, J = 8.9 Hz, 2H), 7.28 (d, J = 8.9 Hz, 2H), 9.44 (s, 1H). LCMS: 542 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethylsulfanyl)phenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33l</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and <i>p</i>-trifluoromethylthiophenylboronic acid in 70% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.69 (m, 1H), 1.80 (dm, J = 25.3 Hz, 2 H), 2.05 (m, 2H), 2.19 (m, 1H), 2.29 (t, J = 7.0 Hz, 2H), 2.38 (m, 1H), 2.45 (t, J = 7.2 Hz, 2H), 2.54 (dd, J = 3.2 and 10.4 Hz, 1H), 2.60 to 2.71 (m, 3H), 2.78 (dd, J = 6.4 and 10.4 Hz, 1H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.72 (m, 1H), 6.57 (s, 2H), 6.60 (d, J = 8.8 Hz, 2H), 6.70 (s, 1H), 6.71 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 9.46 (s, 1H). LCMS: 558 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(1<i>H</i>-indol-5-yl)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33m</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and (1H-indol-5-yl)boronic acid in 46% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.67 (m, 1H), 1.78 (dm, J = 25.3 Hz, 2 H), 2.03 (m, 2H), 2.15 (m, 1H), 2.30 (t, J = 7.0 Hz, 2H), 2.37 (m, 1H), 2.45 (t, J = 7.2 Hz, 2H), 2.51 (m, 1H), 2.61 (m, 1H), 2.70 (t, J = 7.0 Hz, 2H), 2.77 (dd, J = 6.4 and 10.4 Hz, 1H), 4.46 (td, J = 6.1 and 47.5 Hz, 2H), 4.69 (m, 1H), 6.28 (t, J = 2.8 Hz, 1H), 6.53 (d, J = 8.8 Hz, 2H), 6.55 (m, 2H) ; 6.68 (d, J = 1.5 Hz, 1H), 6.73 (d, J = 8.8 Hz, 2H), 6.84 (dd, J = 1.8 and 8.5 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 7.23 (t, J = 2.8 Hz, 1H), 7.32 (d, J = 1.8 Hz, 1H), 9.38 (s, 1H), 11.90 (t, J = 2.8 Hz, 1H). LCMS: 497 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(1<i>H</i>-indazol-5-yl)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33n</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-indazole in 8% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.66 (m, 1H), 1.78 (dm, J = 25.3 Hz, 2 H), 2.06 (m, 2H), 2.17 (m, 1H), 2.29 to 2.40 (m, 3H), 2.43 (t, J = 7.2 Hz, 2H), 2.53 (m, 1H), 2.61 (m, 1H), 2.70 (t, J = 7.0 Hz, 2H), 2.77 (dd, J = 6.4 and 10.4 Hz, 1H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.70 (m, 1H), 6.54 (d, J = 8.8 Hz, 2H), 6.56 (m, 2H), 6.70 (s, 1H), 6.72 (d, J = 8.8 Hz, 2H), 7.09 (d, J = 8.7 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 7.52 (s, 1H), 7.91 (s, 1H), 9.35 (s, 1H), 12.90 (s, 1H). LCMS: 498 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(4-pyridyl)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33o</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and pyridin-4-boronic acid in 66% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.70 (m, 1H), 1.80 (dm, J = 25.3 Hz, 2 H), 2.03 (m, 2H), 2.20 (m, 1H), 2.28 (t, J = 7.0 Hz, 2H), 2.38 (m, 1H), 2.47 (t, J = 7.2 Hz, 2H), 2.55 (dd, J = 3.0 and 10.4 Hz, 1H), 2.63 (m, 3H), 2.80 (dd, J = 6.3 and 10.4 Hz, 1H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.76 (m, 1H), 6.55 (m, 2H), 6.62 (d, J = 8.8 Hz, 2H), 6.70 (s, 1H), 6.73 (d, J = 8.8 Hz, 2H), 7.08 (d, J = 6.3 Hz, 2H), 8.03 (d, J = 6.3 Hz, 2H), 9.48 (s, 1H). LCMS: 459 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(3-pyridyl)-8,9-dihydro-7<i>H</i>-benzo[7]annulen-2-ol (<b>33p</b>)</h4><div class="NLM_p last">Obtained from <b>32b</b> and pyridin-3-boronic acid in 63% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.69 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.05 (m, 2H), 2.20 (m, 1H), 2.29 (t, J = 7.0 Hz, 2H), 2.38 (m, 1H), 2.47 (t, J = 7.2 Hz, 2H), 2.54 (dd, J = 3.0 and 10.4 Hz, 1H), 2.60 to 2.72 (m, 3H), 2.80 (dd, J = 6.4 and 10.4 Hz, 1H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.74 (m, 1H), 6.57 (s, 2H), 6.62 (d, J = 8.8 Hz, 2H), 6.71 (s, 1H), 6.74 (d, J = 8.8 Hz, 2H), 7.22 (dd, J = 5.0 and 8.3 Hz, 1H), 7.57 (td, J = 2.3 and 8.3 Hz, 1H), 8.23 (d, J = 2.3 Hz, 1H), 8.27 (dd, J = 2.3 and 5.0 Hz, 1H), 9.44 (s, 1H). LCMS: 459 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>tert</i>-Butyl(3<i>S</i>)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy]pyrrolidine-1-carboxylate (<b>35</b>)</h4><div class="NLM_p last">Obtained from <b>34</b> and (<i>R</i>)-<i>tert</i>-butyl 3-hydroxypyrrolidine-1-carboxylate in 100% yield by an analogous method to <b>24a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.27 (s, 12H), 1.39 (s, 9H), 2.05 (m, 1H), 2.14 (m, 1H), 3.37 (m, 3H), 3.55 (m, 1H), 5.05 (m, 1H), 6.94 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H). LCMS: 390 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (3<i>S</i>)-3-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2yl)phenoxy]pyrrolidine Hydrochloride (<b>36</b>)</h4><div class="NLM_p last">Obtained from <b>35</b> in 95% yield by an analogous method to <b>20</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.28 (s, 12H), 2.10 (m, 1H), 2.21 (m, 1H), 3.31 (m, 3H), 3.48 (m, 1H), 5.19 (m, 1H), 6.97 (d, J = 8,4 Hz, 2H), 7.63 (d, J = 8,4 Hz, 2H), 9.71 (s, 1H). LCMS: 290 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (3<i>S</i>)-1-(3-Fluoropropyl)-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (<b>37</b>)</h4><div class="NLM_p last">Obtained from <b>36</b> and 1-fluoro-3-iodopropane in 100% yield by an analogous method to <b>10p</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.27 (s, 12H), 1.77 (m, 2H), 1.84 (m, 1H), 2.27 (m, 1H), 2.41 (m, 1H), 2.49 (m, 2H), 2.62 (dd, J = 2.6 and 10.4 Hz, 1H), 2.69 (m, 1H), 2.83 (dd, J = 6.2 and 10.4 Hz, 1H), 4.47 (td, J = 6.2 and 47 Hz, 2H), 4.99 (m, 1H), 6.77 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H). LCMS: 350 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 9-(4-{[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-ol (<b>38</b>)</h4><div class="NLM_p last">Obtained from <b>30b</b> in 93% yield by an analogous method to <b>32a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.82 (m, 5 H), 2.07 (q, J = 6.9 Hz, 2 H), 2.25 (m, 1 H), 2.42 (m, 1 H), 2.47 (m, 4 H), 2.61 (dd, J = 10.3, 2.7 Hz, 1 H), 2.68 (m, 1 H), 2.84 (dd, J = 10.3, 6.2 Hz, 1 H), 4.48 (dt, J = 47.5, 6.0 Hz, 2 H), 4.84 (m, 1 H), 6.22 (t, J = 7.2 Hz, 1 H), 6.60 (dd, J = 8.4, 2.4 Hz, 1 H), 6.70 (m, 2 H), 6.81 (d, J = 8.7 Hz, 2 H), 7.10 (d, J = 8.7 Hz, 2 H), 9.36 (s, 1 H). LCMS: 382 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 9-(4-{[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-yl Trifluoromethanesulfonate (<b>39</b>)</h4><div class="NLM_p last">Obtained from <b>38</b> in 89% yield by an analogous method to <b>29a</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.87 (q, J = 7.1 Hz, 2 H), 2.10 (m, 6 H), 2.65 (t, J = 7.1 Hz, 2 H), 3.21 (m, 1 H), 3.43 (m, 2 H), 3.76 (m, 3 H), 4.54 (dt, J = 47.1, 5.6 Hz, 2 H), 5.16 (br s, 1 H), 6.49 (t, J = 7.3 Hz, 1 H), 6.95 (d, J = 8.7 Hz, 2 H), 7.06 (d, J = 8.7 Hz, 1 H), 7.17 (d, J = 8.7 Hz, 2 H), 7.34 (m, 1 H), 7.51 (d, J = 2.6 Hz, 1 H). LCMS: 514 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Methyl 9-(4-[[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxy]phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulene-3-carboxylate (<b>40</b>)</h4><div class="NLM_p last">To a solution of 9-(4-{[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulen-3-yl trifluoromethanesulfonate (<b>39</b>) (10.1 g, 19.67 mmol) in dimethylformamide (66 mL) and methanol (33 mL) was added [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride complex (909 mg, 1.18 mmol) and diisopropylethylamine (7.21 mL). The black suspension was carbonylated in an autoclave at 70 °C under 5 bar of CO for 5 h. The reaction mixture was filtered; then, the filtrate was partially concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic phase was washed with water (2 × 100 mL), dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with a gradient of dichloromethane/methanol (100/0 to 95/5 v/v) to give 7.13 g (86%) of methyl 9-(4-[[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy]phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulene-3-carboxylate (<b>40</b>) as a brown gum. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.87 (q, J = 7.1 Hz, 2 H), 1.98 (m, 3 H), 2.15 (m, 2 H), 2.42 (br m, 3 H), 2.66 (br t, J = 6.8 Hz, 2 H), 2.79 (m, 2 H), 3.05 (m, 2 H), 3.86 (s, 3 H), 4.52 (dt, J = 47.2, 5.7 Hz, 2 H), 5.06 (br s, 1 H), 6.49 (t, J = 7.3 Hz, 1 H), 6.91 (d, J = 8.6 Hz, 2 H), 7.03 (d, J = 7.9 Hz, 1 H), 7.15 (d, J = 8.6 Hz, 2 H), 7.81 (dd, J = 8.0, 1.8 Hz, 1 H), 7.93 (d, J = 1.8 Hz, 1 H). LCMS: 424 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Methyl 8-Bromo-9-(4-[[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxy]phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulene-3-carboxylate Hydrobromide (<b>41</b>)</h4><div class="NLM_p last">Obtained from <b>40</b> in 85% yield by an analogous method to <b>14</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 2.07 (m, 4 H), 2.28 (m, 2 H), 2.48 (m, 6 H), 2.81 (br t, J = 6.9 Hz, 2 H), 3.43 (m, 2 H), 3.84 (s, 3 H), 4.54 (dt, J = 47.1, 5.6 Hz, 2 H), 5.16 (m, 1 H), 6.87 (d, J = 8.1 Hz, 1 H), 6.97 (d, J = 8.7 Hz, 2 H), 7.16 (d, J = 8.7 Hz, 2 H), 7.75 (dd, J = 8.1, 1.7 Hz, 1 H), 7.92 (d, J = 1.7 Hz, 1 H), 10.04 (br s, 1 H). LCMS: 502 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Methyl (<i>S</i>)-8-(2-Chlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5<i>H</i>-benzo[7]annulene-3-carboxylate (<b>42a</b>)</h4><div class="NLM_p last">Obtained from <b>41</b> and 2-chlorophenylboronic acid in 75% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.75 (m, 3 H), 2.17 (m, 5 H), 2.35 (m, 1 H), 2.44 (m, 2 H), 2.58 (m, 2 H), 2.78 (m, 1 H), 2.94 (m, 2 H), 3.86 (s, 3 H), 4.46 (dt, J = 47.4, 6.0 Hz, 2 H), 4.72 (m, J = 6.8 Hz, 1 H), 6.68 (m, 4 H), 6.92 (d, J = 8.1 Hz, 1 H), 7.19 (m, 3 H), 7.42 (d, J = 7.6 Hz, 1 H), 7.78 (dd, J = 8.1, 1.5 Hz, 1 H), 7.94 (d, J = 1.5 Hz, 1 H). LCMS: 534 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Methyl 6-(4-Chlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylate (<b>42b</b>)</h4><div class="NLM_p last">Obtained from <b>41</b> and <i>p</i>-chlorophenylboronic acid in 75% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.77 (m, 3 H), 2.18 (m, 5 H), 2.38 (m, 1 H), 2.44 (m, 2 H), 2.56 (m, 1 H), 2.67 (m, 1 H), 2.82 (m, 3 H), 3.85 (s, 3 H), 4.47 (dt, J = 47.5, 6.0 Hz, 2 H), 4.77 (m, 1 H), 6.70 (m, 4 H), 6.90 (d, J = 8.1 Hz, 1 H), 7.22 (m, 4 H), 7.77 (d, J = 8.1 Hz, 1 H), 7.92 (s, 1 H). LCMS: 534 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Methyl 6-(2-Chloro-3-fluoro-phenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylate (<b>42c</b>)</h4><div class="NLM_p last">Obtained from <b>41</b> and 2-chloro-3-fluorophenylboronic acid in 65% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.76 (m, 3 H), 2.17 (m, 4 H), 2.37 (m, 1 H), 2.45 (m, 3 H), 2.54 (m, 1 H), 2.62 (m, 1 H), 2.78 (m, 1 H), 2.95 (m, 2 H), 3.86 (s, 3 H), 4.46 (dt, J = 47.5, 6.0 Hz, 2 H), 4.73 (m, 1 H), 6.69 (m, 4 H), 6.92 (d, J = 8.1 Hz, 1 H), 7.05 (m, 1 H), 7.24 (m, 2 H), 7.78 (d, J = 7.7 Hz, 1 H), 7.94 (s, 1 H). LCMS: 552 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 6-(2,4-Dichloro-phenyl)-5-[4-[1-(3-fluoro-propyl)-pyrrolidin-3-yloxy]-phenyl]-8,9-dihydro-7<i>H</i>-benzocycloheptene-2-carboxylic Acid Methyl Ester (<b>42d</b>)</h4><div class="NLM_p last">Obtained from <b>41</b> and 2,4-dichlorophenylboronic acid in 47% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.78 (m, 3 H), 2.16 (m, 5 H), 2.37 (m, 1 H), 2.46 (t, J = 7.1 Hz, 2 H), 2.54 (m, 1 H), 2.63 (m, 1 H), 2.79 (m, 1 H), 2.93 (m, 2 H), 3.86 (s, 3 H), 4.46 (dt, J = 47.4, 6.0 Hz, 2 H), 4.74 (m, 1 H), 6.70 (m, 4 H), 6.91 (d, J = 8.1 Hz, 1 H), 7.20 (d, J = 7.5 Hz, 1 H), 7.28 (dd, J = 7.5, 2.0 Hz, 1 H), 7.59 (d, J = 2.0 Hz, 1 H), 7.78 (dd, J = 8.1, 1.7 Hz, 1 H), 7.94 (d, J = 1.7 Hz, 1 H). LCMS: 568 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Methyl 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethoxy)phenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylate (<b>42e</b>)</h4><div class="NLM_p last">Obtained from <b>41</b> and <i>p</i>-trifluoromethoxyphenylboronic acid in 45% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.76 (m, 3 H), 2.20 (m, 5 H), 2.38 (m, 1 H), 2.46 (t, J = 7.3 Hz, 2 H), 2.54 (dd, J = 10.6, 2.9 Hz, 1 H), 2.65 (m, 1 H), 2.79 (dd, J = 10.6, 6.2 Hz, 1 H), 2.86 (br t, J = 6.7 Hz, 2 H), 3.86 (s, 3 H), 4.46 (dt, J = 47.4, 6.0 Hz, 2 H), 4.75 (m, 1 H), 6.64 (d, J = 8.0 Hz, 2 H), 6.73 (d, J = 8.0 Hz, 2 H), 6.91 (d, J = 8.1 Hz, 1 H), 7.19 (d, J = 8.0 Hz, 2 H), 7.28 (d, J = 8.0 Hz, 2 H), 7.77 (dd, J = 7.6, 1.0 Hz, 1 H), 7.92 (d, J = 1.0 Hz, 1 H). LCMS: 584 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Methyl 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethylsulfanyl)phenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylate (<b>42f</b>)</h4><div class="NLM_p last">Obtained from <b>41</b> and 4-trifluoromethylthiophenylboronic acid in 56% yield by an analogous method to <b>15</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.76 (m, 3 H), 2.16 (m, 3 H), 2.27 (m, 2 H), 2.38 (m, 1 H), 2.46 (t, J = 7.4 Hz, 2 H), 2.55 (m, 1 H), 2.64 (m, 1 H), 2.79 (m, 1 H), 2.87 (t, J = 6.7 Hz, 2 H), 3.86 (s, 3 H), 4.46 (dt, J = 47.4, 6.0 Hz, 2 H), 4.75 (m, 1 H), 6.68 (m, 4 H), 6.91 (d, J = 8.1 Hz, 1 H), 7.31 (d, J = 8.3 Hz, 2 H), 7.54 (d, J = 8.1 Hz, 2 H), 7.78 (d, J = 8.1 Hz, 1 H), 7.93 (s, 1 H). LCMS: 600 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 6-(2-Chlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic Acid (<b>43a</b>)</h4><div class="NLM_p last">Obtained from <b>42a</b> in 53% yield by an analogous method to <b>43d</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.66 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.08 to 2.24 (m, 5H), 2.38 (m, 1H), 2.45 (t, J = 7.2 Hz, 2H), 2.52 (dd, J = 3.0 and 10.4 Hz, 1H), 2.62 (m, 1H), 2.79 (m, 1H), 2.93 (m, 2H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.71 (m, 1H), 6.60 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.5 Hz, 1H), 7.13 to 7.25 (m, 3H), 7.41 (d, J = 8.3 Hz, 1H), 7.75 (dd, J = 2.0 and 8.5 Hz, 1H), 7.90 (d, J = 2.0 Hz, 1H), 12.67 (m, 1H). LCMS: 520 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 6-(4-Chlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic Acid (<b>43b</b>)</h4><div class="NLM_p last">Obtained from <b>42b</b> in 96% yield by an analogous method to <b>43d</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.70 (m, 1H), 1.80 (dm, J = 25.3 Hz, 2 H), 2.10 (m, 2H), 2.15 to 2.28 (m, 3H), 2.38 (m, 1H), 2.48 (t, J = 7.2 Hz, 2H), 2.55 (dd, J = 3.2 and 10.4 Hz, 1H), 2.65 (m, 1H), 2.81 (m, 3H), 4.48 (td, J = 6.1 and 47.5 Hz, 2H), 4.77 (m, 1H), 6.65 (d, J = 8.8 Hz, 2H), 6.73 (d, J = 8.8 Hz, 2H), 6.81 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H), 7.71 (dd, J = 1.9 and 8.1 Hz, 1H), 7.87 (d, J = 1.9 Hz, 1H), 12.05 (m, 1H). LCMS: 520 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 6-(2-Chloro-3-fluoro-phenyl)-5-{4-[(<i>S</i>)-1-(3-fluoro-propyl)-pyrrolidin-3-yloxy]-phenyl}-8,9-dihydro-7<i>H</i>-benzocycloheptene-2-carboxylic Acid (<b>43c</b>)</h4><div class="NLM_p last">Obtained from <b>42c</b> in 36% yield by an analogous method to <b>43d</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.68 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.10 to 2.25 (m, 5H), 2.18 (m, 1H), 2.46 (t, J = 7.2 Hz, 2H), 2.53 (dd, J = 3.0 and 10.4 Hz, 1H), 2.63 (m, 1H), 2.79 (m, 1H), 2.93 (t, J = 7.0 Hz, 2H), 4.46 (td, J = 6.1 and 47.5 Hz, 2H), 4.73 (m, 1H), 6.63 (d, J = 8.8 Hz, 2H), 6.73 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.1 Hz, 1H), 7.05 (m, 1H), 7.24 (m, 2H), 7.77 (dd, J = 2.0 and 8.1 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 12.60 (m, 1H). LCMS: 538 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 6-(2,4-Dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic Acid (<b>43d</b>)</h4><div class="NLM_p last">To a solution of 6-(2,4-dichloro-phenyl)-5-[4-[1-(3-fluoro-propyl)-pyrrolidin-3-yloxy]-phenyl]-8,9-dihydro-7<i>H</i>-benzocycloheptene-2-carboxylic acid methyl ester (<b>42d</b>) (80 mg, 140.72 μmol) in methanol (5 mL) was added 5 N NaOH (562.88 μL), the reaction mixture was heated to 60 °C for 5 h, and the solvent was removed under reduced pressure. The residue was taken up in water (10 mL), and aqueous HCl (5 M) was added to pH 7. The slurry was extracted with dichloromethane, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The solid was purified by column chromatography eluting with a mixture of dichloromethane, acetonitrile, and methanol (90/5/5 v/v/v) to give 60 mg (77%) of 6-(2,4-dichlorophenyl)-5-[4-[(3<i>S</i>)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic acid (<b>43d</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.68 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.07 to 2.23 (m, 5H), 2.38 (m, 1H), 2.46 (t, J = 7.2 Hz, 2H), 2.52 (m, 1H), 2.62 (m, 1H), 2.55 to 2.89 (m, 3H), 4.47 (td, J = 6.2 and 47.6 Hz, 2H), 4.72 (m, 1H), 6.63 (d, J = 8.9 Hz, 2H), 6.71 (m, 3H), 7.18 (d, J = 8.4 Hz, 1H), 8.26 (dd, J = 2.0 and 8.4 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.79 (s, 1H), 12.3 (m, 1H). LCMS: 554 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethoxy)phenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic Acid (<b>43e</b>)</h4><div class="NLM_p last">Obtained from <b>42e</b> in 28% yield by an analogous method to <b>43d</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.69 (m, 1H), 1.79 (dm, J = 25.3 Hz, 2 H), 2.12 (t, J = 7.0 Hz, 2H), 2.20 (m, 1H), 2.27 (t, J = 7.0 Hz, 2H), 2.39 (m, 1H), 2.48 (t, J = 7.2 Hz, 2H), 2.55 (dd, J = 3.0 and 10.5 Hz, 1H), 2.65 (m, 1H), 2.79 (dd, J = 6.4 and 10.4 Hz, 1H), 2.84 (t, J = 7.0 Hz, 2H), 4.47 (td, J = 6.1 and 47.5 Hz, 2H), 4.75 (m, 1H), 6.65 (d, J = 8.8 Hz, 2H), 6.73 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 7.74 (dd, J = 1.9 and 8.4 Hz, 1H), 7.90 (d, J = 1.9 Hz, 1H), 12.84 (m, 1H). LCMS: 570 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 5-[4-[(3<i>S</i>)-1-(3-Fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethylsulfanyl)phenyl]-8,9-dihydro-7<i>H</i>-benzo[7]annulene-2-carboxylic Acid (<b>43f</b>)</h4><div class="NLM_p last">Obtained from <b>42f</b> in 74% yield by an analogous method to <b>43d</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.70 (m, 1H), 1.80 (dm, J = 25.3 Hz, 2 H), 2.11 (m, 2H), 2.20 (m, 1H), 2.29 (t, J = 7.0 Hz, 2H), 2.38 (m, 1H), 2.46 (t, J = 7.2 Hz, 2H), 2.54 (m, 1H), 2.65 (m, 1H), 2.79 (dd, J = 6.3 and 10.4 Hz, 1H), 2.83 (t, J = 7.0 Hz, 2H), 4.48 (td, J = 6.1 and 47.5 Hz, 2H), 4.74 (m, 1H), 6.62 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.1 Hz, 1H), 7.31 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H), 7.72 (dd, J = 1.9 and 8.3 Hz, 1H), 7.88 (d, J = 1.9 Hz, 1H), 12.90 (m, 1H). LCMS: 586 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Estrogen Receptor Degradation Activity</h3><div class="NLM_p">The measurements on the protein abundance of ER were made by fluorescence detection in the MCF7 BC cell line.</div><div class="NLM_p">MCF7 cells (ATCC) were seeded in a 384-well microplate (Greiner) at a concentration of 10 000 cells/30 μL per well in red-phenol-free MEM alpha medium (Gibco) containing 5% charcoal-dextran-stripped fetal bovine serum (FBS). The following day, compounds were added to the cells in a 10-point dose response with a 1:3 fold serial dilution in 2.5 μL at final concentrations ranging from 300 to 0.15 nM or 0.1 μM for fulvestrant (used as a positive control). At 4 h post-compound-addition, the cells were fixed by adding 25 μL of formalin (final concentration 5% formalin containing 0.05% triton) for 15 min at room temperature and then washed twice with PBS-1×. Then, cells were incubated overnight in a cold room with 25 μL of anti-ER rabbit monoclonal antibody (Thermo Scientific MA1-39540) diluted at 1:500 in Power Block buffer. Wells were washed three times with PBS-1× and incubated at 37 °C for 60 min in Power Block buffer containing goat antirabbit antibody Alexa 488 (1:1000) and Syto-64 a DNA dye (1.5 μM final concentration). Cells were then washed three times in PBS-1× and scanned in an ACUMEN explorer apparatus (TTP-Labtech). Integrated intensities in the green fluorescence and red fluorescence were measured to determine the levels of ERα and DNA, respectively.</div><div class="NLM_p">The degradation potency is determined as the concentration of compound that achieves 50% degradation of the estrogen receptor (or IC<sub>50</sub>) in nanomoles.</div><div class="NLM_p last">The percent ERα level decrease was calculated as follows: % inhibition = 100*(1 – (sample – fulvestrant)/(DMSO – fulvestrant)).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> MCF-7 Xenograft Studies</h3><div class="NLM_p last">0.72 mg of 17-β estradiol pellets (90 days release) was subcutaneously implanted into nu/nu mice 2 days prior to MCF7 cell implantation. MCF7 cells were grown in Eagle’s minimum essential medium supplemented with 10% FBS and 0.01 mg/mL human insulin in 5% CO<sub>2</sub> at 37 °C. The cells were harvested and resuspended in DPBS with 50% matrigel and subcutaneously implanted into the right flank of female nude mice. The tumor volume (length × width<sup>2</sup>/2) was monitored biweekly. When tumors reached an average volume of 200 mm<sup>3</sup>, animals were randomized and treatment was started. Animals were treated with the vehicle or the <b>43d</b> compound twice daily. The tumor volume and body weight were monitored biweekly throughout the study.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Determination of ERα Crystal Structure</h3><div class="NLM_p">The ERα ligand-binding-domain (LBD)-mutated (amino acids 298–554) Tyr-536-Ser was induced in BL21 (DE3) cells and purified. The purified protein was then concentrated to ∼12 mg/mL in 50 mM Tris, pH 8, 150 mM NaCl, 50 mM β-mercapto-ethanol, 10% glycerol. The protein was incubated with the compound at 1 mM overnight at 4 °C. The protein with compound was crystallized by the hanging drop vapor diffusion method at 20 °C with a 1:1 ratio of protein solution to reservoir solution of 22.5% PEG-4000, 100 mM Cacodylate Na pH 6.5, and 0.2 M MgCl<sub>2</sub> with 0.2 μL of the diluted seeding solution. The crystals were cryoprotected in glycerol to the mother liquor. Crystals were flash-frozen in liquid nitrogen prior to data collection. Diffraction data were collected at the SOLEIL synchrotron facility, Beamline Proxima 1, Saclay, France and were processed with programs AutoPROC and STARANISO (Global Phasing).<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> The structure was solved using molecular replacement technique with coordinates of ER-LBD available internally and the program PHASER.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The structure was refined using REFINE (Global Phasing) (X), the ligand was placed manually, and the manual rebuilds were made in COOT.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The final validation checks were performed using MOLPROBITY<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> prior to the deposition of coordinates and structure factors into the Protein Data Bank.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The data set statistics of crystal structure are given in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. X-ray Data Collection, Statistics, and PDB Code for the Structure of ER-LBD Bound to <b>43d</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">Data Collection</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left">C2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell (Å; α = γ = 90°)</td><td class="colsep0 rowsep0" align="left">101.4, 57.7, 87.8, β = 103.1°</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution</td><td class="colsep0 rowsep0" align="left">1.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. unique reflections</td><td class="colsep0 rowsep0" align="left">57280</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">88.5 (51.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average multiplicity</td><td class="colsep0 rowsep0" align="left">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>merge</sub> (<i>R</i><sub>merge</sub> last resolution shell) (%)</td><td class="colsep0 rowsep0" align="left">4.1 (48.2)</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">Refinement</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>cryst</sub></td><td class="colsep0 rowsep0" align="left">19.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>free</sub></td><td class="colsep0 rowsep0" align="left">21.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rmsd bond lengths (Å)</td><td class="colsep0 rowsep0" align="left">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rmsd bond angles (deg)</td><td class="colsep0 rowsep0" align="left">1.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average B-factor protein (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">26.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average B-factor ligand (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">22.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average B-factor solvent (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">37.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDB code</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SBO">6SBO</a></td></tr></tbody></table></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i106"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01293" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01293?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01293</a>. <ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings as well as IC<sub>50</sub> and percent ER degradation (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01293/suppl_file/jm9b01293_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01293/suppl_file/jm9b01293_si_001.csv">jm9b01293_si_001.csv (3.11 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01293" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youssef El-Ahmad</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3038-0986" title="Orcid link">http://orcid.org/0000-0002-3038-0986</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b4cddbc1c7c7d1d29ad1d899d5dcd9d5d0f4c7d5dadbd2dd9ad7dbd9"><span class="__cf_email__" data-cfemail="31485e44424254571f545d1c50595c50557142505f5e57581f525e5c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michel Tabart</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Halley</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor Certal</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabienne Thompson</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruno Filoche-Rommé</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florence Gruss-Leleu</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire Muller</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maurice Brollo</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurence Fabien</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Véronique Loyau</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luc Bertin</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Richepin</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabienne Pilorge</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascal Desmazeau</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chrystelle Girardet</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sylvie Beccari</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Audrey Louboutin</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gilles Lebourg</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacques Le-Roux</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Corinne Terrier</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">François Vallée</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valérie Steier</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Magali Mathieu</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexey Rak</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre-Yves Abecassis</span> - <span class="hlFld-Affiliation affiliation">Drug Metabolism and Pharmacokinetics
(DMPK), , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascale Vicat</span> - <span class="hlFld-Affiliation affiliation">Drug Metabolism and Pharmacokinetics
(DMPK), , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsiala Benard</span> - <span class="hlFld-Affiliation affiliation">Pre-Development
Sciences-Formulation, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monsif Bouaboula</span> - <span class="hlFld-Affiliation affiliation">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fangxian Sun</span> - <span class="hlFld-Affiliation affiliation">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maysoun Shomali</span> - <span class="hlFld-Affiliation affiliation">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Hebert</span> - <span class="hlFld-Affiliation affiliation">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mikhail Levit</span> - <span class="hlFld-Affiliation affiliation">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Cheng</span> - <span class="hlFld-Affiliation affiliation">Oncology, Sanofi, 640 Memorial Drive, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albane Courjaud</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celine Ginesty</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christelle Perrault</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlos Garcia-Echeverria</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary McCort</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurent Schio</span> - <span class="hlFld-Affiliation affiliation">Integrated Drug Discovery, , and , Sanofi, 13, quai Jules Guesde, 94403 Vitry-sur-Seine, France</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5154-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i107">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Serge Sablé, Frédéric Herman, Bertrand Monegier, Fabrice Debu, and their respective teams for structural analyses. We thank Jean-Pascal Ridoux for physicochemical studies, Olivier Courtin for Caliper binding assay studies, and Odile Angouillant, Pierre-Eric Bardouillet, Eric Brohan, Pascal Collemine, and Celine Prévost for chiral separations.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">adsorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">bis in diem (twice a day)</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EC</td><td class="NLM_def"><p class="first last">effective concentration</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">inhibitory concentration at half maximal effect</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">per os</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>New Global Cancer Data: GLOBOCAN 2018</i>; <span class="NLM_publisher-name">World
Health Organization</span>, 2018. <a href="https://www.uicc.org/new-global-cancer-data-globocan-2018" class="extLink">https://www.uicc.org/new-global-cancer-data-globocan-2018</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Global+Cancer+Data%3A+GLOBOCAN+2018%3B+World%0AHealth+Organization%2C+2018.+https%3A%2F%2Fwww.uicc.org%2Fnew-global-cancer-data-globocan-2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Global%2520Cancer%2520Data%253A%2520GLOBOCAN%25202018%26pub%3DWorld%250AHealth%2520Organization" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yersal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barutca, S.</span></span> <span> </span><span class="NLM_article-title">Biological subtypes of breast cancer: prognostic and therapeutic implications</span>. <i>World J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.5306/wjco.v5.i3.412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.5306%2Fwjco.v5.i3.412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=25114856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhtVGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=412-424&author=O.+Yersalauthor=S.+Barutca&title=Biological+subtypes+of+breast+cancer%3A+prognostic+and+therapeutic+implications&doi=10.5306%2Fwjco.v5.i3.412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biological subtypes of breast cancer: Prognostic and therapeutic implications</span></div><div class="casAuthors">Yersal Ozlem; Barutca Sabri</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-24</span>
        ISSN:<span class="NLM_cas:issn">2218-4333</span>.
    </div><div class="casAbstract">Breast cancer is a heterogeneous complex of diseases, a spectrum of many subtypes with distinct biological features that lead to differences in response patterns to various treatment modalities and clinical outcomes.  Traditional classification systems regarding biological characteristics may have limitations for patient-tailored treatment strategies.  Tumors with similar clinical and pathological presentations may have different behaviors.  Analyses of breast cancer with new molecular techniques now hold promise for the development of more accurate tests for the prediction of recurrence.  Gene signatures have been developed as predictors of response to therapy and protein gene products that have direct roles in driving the biology and clinical behavior of cancer cells are potential targets for the development of novel therapeutics.  The present review summarizes current knowledge in breast cancer molecular biology, focusing on novel prognostic and predictive factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjCFvwnmL6j5NiNltV31zlfW6udTcc2eYwUbixI1PJl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhtVGmtg%253D%253D&md5=2c6cc4bc4f0926c142f7e2e6af3c6e71</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v5.i3.412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v5.i3.412%26sid%3Dliteratum%253Aachs%26aulast%3DYersal%26aufirst%3DO.%26aulast%3DBarutca%26aufirst%3DS.%26atitle%3DBiological%2520subtypes%2520of%2520breast%2520cancer%253A%2520prognostic%2520and%2520therapeutic%2520implications%26jtitle%3DWorld%2520J.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D5%26spage%3D412%26epage%3D424%26doi%3D10.5306%2Fwjco.v5.i3.412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minutolo, F.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptors alpha (ERalpha) and beta (ERbeta): subtype-selective ligands and clinical potential</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.steroids.2014.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.steroids.2014.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=24971815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFenu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2014&pages=13-29&author=I.+Paterniauthor=C.+Granchiauthor=J.+A.+Katzenellenbogenauthor=F.+Minutolo&title=Estrogen+receptors+alpha+%28ERalpha%29+and+beta+%28ERbeta%29%3A+subtype-selective+ligands+and+clinical+potential&doi=10.1016%2Fj.steroids.2014.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential</span></div><div class="casAuthors">Paterni, Ilaria; Granchi, Carlotta; Katzenellenbogen, John A.; Minutolo, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-29</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Estrogen receptors alpha (ERα) and beta (ERβ) are nuclear transcription factors that are involved in the regulation of many complex physiol. processes in humans.  Modulation of these receptors by prospective therapeutic agents is currently being considered for prevention and treatment of a wide variety of pathol. conditions, such as, cancer, metabolic and cardiovascular diseases, neurodegeneration, inflammation, and osteoporosis.  This review provides an overview and update of compds. that have been recently reported as modulators of ERs, with a particular focus on their potential clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrROACfUL51e7Vg90H21EOLACvtfcHk0lhOS7Z4WvmMXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFenu7vI&md5=ac6863afe52e6a18ffd89d3ba6770023</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.steroids.2014.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.steroids.2014.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DPaterni%26aufirst%3DI.%26aulast%3DGranchi%26aufirst%3DC.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMinutolo%26aufirst%3DF.%26atitle%3DEstrogen%2520receptors%2520alpha%2520%2528ERalpha%2529%2520and%2520beta%2520%2528ERbeta%2529%253A%2520subtype-selective%2520ligands%2520and%2520clinical%2520potential%26jtitle%3DSteroids%26date%3D2014%26volume%3D90%26spage%3D13%26epage%3D29%26doi%3D10.1016%2Fj.steroids.2014.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span> <span> </span><span class="NLM_article-title">Oestrogen receptors in breast cancer: basic mechanisms and clinical implications</span>. <i>ecancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">370</span>, <span class="refDoi"> DOI: 10.3332/ecancer.2013.370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.3332%2Fecancer.2013.370" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=370&author=C.+Williamsauthor=C.+Y.+Lin&title=Oestrogen+receptors+in+breast+cancer%3A+basic+mechanisms+and+clinical+implications&doi=10.3332%2Fecancer.2013.370"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3332%2Fecancer.2013.370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3332%252Fecancer.2013.370%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DC.%2BY.%26atitle%3DOestrogen%2520receptors%2520in%2520breast%2520cancer%253A%2520basic%2520mechanisms%2520and%2520clinical%2520implications%26jtitle%3Decancer%26date%3D2013%26volume%3D7%26spage%3D370%26doi%3D10.3332%2Fecancer.2013.370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. J.</span></span> <span> </span><span class="NLM_article-title">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer: hormonal agents for treatment and prevention of breast cancer</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2007.01587.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1111%2Fj.1742-1241.2007.01587.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=17892469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=2051-2063&author=C.+J.+Fabian&title=The+what%2C+why+and+how+of+aromatase+inhibitors%3A+hormonal+agents+for+treatment+and+prevention+of+breast+cancer%3A+hormonal+agents+for+treatment+and+prevention+of+breast+cancer&doi=10.1111%2Fj.1742-1241.2007.01587.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer</span></div><div class="casAuthors">Fabian, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2051-2063</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - pos. breast cancer in postmenopausal women.  Approx. 185,000 new cases of invasive breast cancer are diagnosed yearly, and at least half of these women are both postmenopausal and eligible for adjuvant therapy with AIs.  In addn., AIs are currently being tested as primary prevention therapy in large randomized trials involving tens of thousands of women at increased risk for breast cancer.  Given the vol. of use, internists will increasingly see postmenopausal women who are taking or considering treatment with AIs.  Physicians need to be able to: (i) briefly discuss the pros and cons of using a selective estrogen receptor modulator such as tamoxifen or raloxifene vs. an AI for risk redn. and (ii) recognize and manage AI-assocd. adverse events.  The primary purpose of this review is to help internists with these two tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopE3D6sucnebVg90H21EOLACvtfcHk0lhOS7Z4WvmMXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D&md5=38f2869d30e8e2696ec9623bf32a8d1b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2007.01587.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2007.01587.x%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520what%252C%2520why%2520and%2520how%2520of%2520aromatase%2520inhibitors%253A%2520hormonal%2520agents%2520for%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%253A%2520hormonal%2520agents%2520for%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2007%26volume%3D61%26spage%3D2051%26epage%3D2063%26doi%3D10.1111%2Fj.1742-1241.2007.01587.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, K. C.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulators</span>. <i>Asian Spine J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4184/asj.2016.10.4.787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.4184%2Fasj.2016.10.4.787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=27559463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A280%3ADC%252BC2szktFyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=787-791&author=K.+C.+An&title=Selective+estrogen+receptor+modulators&doi=10.4184%2Fasj.2016.10.4.787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulators</span></div><div class="casAuthors">An Ki-Chan</div><div class="citationInfo"><span class="NLM_cas:title">Asian spine journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">787-91</span>
        ISSN:<span class="NLM_cas:issn">1976-1902</span>.
    </div><div class="casAbstract">Selective estrogen receptor modulators (SERMs) are now being used as a treatment for breast cancer, osteoporosis and postmenopausal symptoms, as these drugs have features that can act as an estrogen agonist and an antagonist, depending on the target tissue.  After tamoxifen, raloxifene, lasofoxifene and bazedoxifene SERMs have been developed and used for treatment.  The clinically decisive difference among these drugs (i.e., the key difference) is their endometrial safety.  Compared to bisphosphonate drug formulations for osteoporosis, SERMs are to be used primarily in postmenopausal women of younger age and are particularly recommended if there is a family history of invasive breast cancer, as their use greatly reduces the incidence of this type of cancer in women.  Among the above mentioned SERMs, raloxifene has been widely used in prevention and treatment of postmenopausal osteoporosis and vertebral compression fractures, and clinical studies are now underway to test the comparative advantages of raloxifene with those of bazedoxifene, a more recently developed SERM.  Research on a number of adverse side effects of SERM agents is being performed to determine the long-term safety of this class of compouds for treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfiFc2kej-uhFwe7cAcrfPfW6udTcc2eZ9gf2baqEiSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szktFyntw%253D%253D&md5=96fc6c0262831c93c7ed82e84ebf3a24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4184%2Fasj.2016.10.4.787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4184%252Fasj.2016.10.4.787%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DK.%2BC.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%26jtitle%3DAsian%2520Spine%2520J.%26date%3D2016%26volume%3D10%26spage%3D787%26epage%3D791%26doi%3D10.4184%2Fasj.2016.10.4.787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. A.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptors: therapies targeted to receptor subtypes</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/clpt.2010.226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1038%2Fclpt.2010.226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=21124311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=44-55&author=S.+Nilssonauthor=J.+A.+Gustafsson&title=Estrogen+receptors%3A+therapies+targeted+to+receptor+subtypes&doi=10.1038%2Fclpt.2010.226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen Receptors: Therapies Targeted to Receptor Subtypes</span></div><div class="casAuthors">Nilsson, S.; Gustafsson, J.-Aa.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-55</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past two decades, we have learned that estrogens play important physiol. roles not only in women but also in men and that the biol. effects of estrogen are mediated by not one but two distinct estrogen receptors (ERs), ERα and ERβ.  Our appreciation of the physiol. importance of estrogen and the mechanisms by which it acts has significantly increased over the years; however, we are only now beginning to decipher the roles of ERα and ERβ in different organs and to elucidate how selective ligands, acting through either of the two ERs, can prevent or treat various age- or sex-specific diseases.  The specific roles of ERα and ERβ and the therapeutic potential of ER subtype-selective agonists in bone and metabolic homeostasis, depression, vasomotor symptoms, neurodegenerative diseases, and cancer are reviewed herein.  It must be stated, however, that appropriate clin. studies are necessary to validate these compds. as agents for the prevention and treatment of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0tQWjd5LTLVg90H21EOLACvtfcHk0lhn81rqyRexag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zN&md5=30f4fac2dcdfb20035b54783a7684a8c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.226%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DS.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26atitle%3DEstrogen%2520receptors%253A%2520therapies%2520targeted%2520to%2520receptor%2520subtypes%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D44%26epage%3D55%26doi%3D10.1038%2Fclpt.2010.226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2010.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.coph.2010.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=20926342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=620-628&author=D.+P.+McDonnellauthor=S.+E.+Wardell&title=The+molecular+mechanisms+underlying+the+pharmacological+actions+of+ER+modulators%3A+Implications+for+new+drug+discovery+in+breast+cancer&doi=10.1016%2Fj.coph.2010.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">620-628</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the mol. mechanisms underlying the pharmacol. actions of estrogen receptor (ER) ligands has evolved considerably in recent years.  Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, so called for their ability to function as ER agonists or antagonists depending on the tissue in which they operate.  These mechanistic insights have had a significant impact on the discovery of second generation SERMs, some of which are in late stage clin. development for the treatment/prevention of breast cancer as well as other estrogenopathies.  In addn. to the SERMs, however, have emerged the Selective Estrogen Degraders (SERDs), which as their name suggests, interact with and facilitate ER turnover in cells.  One drug of this class, fulvestrant, has been approved as a third line treatment for ER-pos. metastatic breast cancer.  Whereas the first generation SERMs/SERDs were discovered in a serendipitous manner, this review will highlight how our understanding of the mol. pharmacol. of ER ligands has been utilized in the development of the next generation of SERMs/SERDs, some of which are likely to have a major impact on the pharmacotherapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8b2l5p-n0bbVg90H21EOLACvtfcHk0lhn81rqyRexag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P&md5=24d1490ca0b0570c21e9768c9de134d6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2010.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2010.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26atitle%3DThe%2520molecular%2520mechanisms%2520underlying%2520the%2520pharmacological%2520actions%2520of%2520ER%2520modulators%253A%2520Implications%2520for%2520new%2520drug%2520discovery%2520in%2520breast%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2010%26volume%3D10%26spage%3D620%26epage%3D628%26doi%3D10.1016%2Fj.coph.2010.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrecengost, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, A. H.</span></span> <span> </span><span class="NLM_article-title">Pathways to tamoxifen resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>256</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2007.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.canlet.2007.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=17475399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=2007&pages=1-24&author=R.+B.+Rigginsauthor=R.+S.+Schrecengostauthor=M.+S.+Guerreroauthor=A.+H.+Bouton&title=Pathways+to+tamoxifen+resistance&doi=10.1016%2Fj.canlet.2007.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways to tamoxifen resistance</span></div><div class="casAuthors">Riggins, Rebecca B.; Schrecengost, Randy S.; Guerrero, Michael S.; Bouton, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer.  While these approaches have proven to be beneficial to a large no. of patients, both de novo and acquired resistance to these drugs is a significant problem.  Recent advances in our understanding of the mol. mechanisms that contribute to resistance have provided a means to begin to predict patient responses to these drugs and develop rational approaches for combining therapeutic agents to circumvent or desensitize the resistant phenotype.  Here, we review common mechanisms of antiestrogen resistance and discuss the implications for prediction of response and design of effective combinatorial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreh_AisSEW9LVg90H21EOLACvtfcHk0lgYFXKex0VPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D&md5=25203d3e50ade6508421835d29bf048c</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2007.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2007.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DRiggins%26aufirst%3DR.%2BB.%26aulast%3DSchrecengost%26aufirst%3DR.%2BS.%26aulast%3DGuerrero%26aufirst%3DM.%2BS.%26aulast%3DBouton%26aufirst%3DA.%2BH.%26atitle%3DPathways%2520to%2520tamoxifen%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2007%26volume%3D256%26spage%3D1%26epage%3D24%26doi%3D10.1016%2Fj.canlet.2007.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkovsky, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.coph.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=29719270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=59-65&author=J.+N.+Millsauthor=A.+C.+Rutkovskyauthor=A.+Giordano&title=Mechanisms+of+resistance+in+estrogen+receptor+positive+breast+cancer%3A+overcoming+resistance+to+tamoxifen%2Faromatase+inhibitors&doi=10.1016%2Fj.coph.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors</span></div><div class="casAuthors">Mills, Jamie N.; Rutkovsky, Alex C.; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Several mechanisms of resistance have been identified, underscoring the complex nature of estrogen receptor (ER) signaling and the many connections between this pathway and other essential signaling pathways in breast cancer cells.  Many therapeutic targets of cell signaling and cell cycle pathways have met success with endocrine therapy and remain an ongoing area of investigation.  This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways.  Addnl., we highlight individual and combination strategies in current clin. trials that target these pathways and others under investigation for the treatment of ER pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVYQkU5BQS2LVg90H21EOLACvtfcHk0lgYFXKex0VPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D&md5=7eb380dd5c8e441b8dd2602b40aa94b5</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DJ.%2BN.%26aulast%3DRutkovsky%26aufirst%3DA.%2BC.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520resistance%2520in%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%253A%2520overcoming%2520resistance%2520to%2520tamoxifen%252Faromatase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D41%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.coph.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0001-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1038%2Fs41568-018-0001-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=29662238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=377-388&author=J.+A.+Katzenellenbogenauthor=C.+G.+Mayneauthor=B.+S.+Katzenellenbogenauthor=G.+L.+Greeneauthor=S.+Chandarlapaty&title=Structural+underpinnings+of+oestrogen+receptor+mutations+in+endocrine+therapy+resistance&doi=10.1038%2Fs41568-018-0001-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance</span></div><div class="casAuthors">Katzenellenbogen, John A.; Mayne, Christopher G.; Katzenellenbogen, Benita S.; Greene, Geoffrey L.; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">377-388</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Estrogen receptor-α (ERα), a key driver of breast cancer, normally requires estrogen for activation.  Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are assocd. with poor patient outcomes.  The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone.  Such mutations provide opportunities to probe fundamental issues underlying ligand-mediated control of ERα activity.  Instructive contrasts between these ERα mutations and those that arise in the androgen receptor (AR) during anti-androgen treatment of prostate cancer highlight differences in how activation functions in ERs and AR control receptor activity, how hormonal pressures (deprivation vs. antagonism) drive the selection of phenotypically different mutants, how altered protein conformations can reduce antagonist potency and how altered ligand-receptor contacts can invert the response that a receptor has to an agonist ligand vs. an antagonist ligand.  A deeper understanding of how ligand regulation of receptor conformation is linked to receptor function offers a conceptual framework for developing new anti-estrogens that might be more effective in preventing and treating breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp89VSk_QiS7Vg90H21EOLACvtfcHk0lgYFXKex0VPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7s%253D&md5=c891ccc27bb2cd117c4705006e78f619</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0001-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0001-z%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DStructural%2520underpinnings%2520of%2520oestrogen%2520receptor%2520mutations%2520in%2520endocrine%2520therapy%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D377%26epage%3D388%26doi%3D10.1038%2Fs41568-018-0001-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span> <span> </span><span class="NLM_article-title">Biological determinants of endocrine resistance in breast cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1038/nrc2713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1038%2Fnrc2713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=19701242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=631-643&author=E.+A.+Musgroveauthor=R.+L.+Sutherland&title=Biological+determinants+of+endocrine+resistance+in+breast+cancer&doi=10.1038%2Fnrc2713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Biological determinants of endocrine resistance in breast cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endocrine therapies targeting estrogen action (anti-estrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance.  Candidate mol. biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation and survival signaling in endocrine resistance.  However, definition of the specific genetic lesions and mol. processes that det. clin. endocrine resistance is incomplete.  The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbi_1MVsJjz7Vg90H21EOLACvtfcHk0lgYFXKex0VPpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL&md5=e57a6a082e0f41d26422350657201de5</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2713%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DBiological%2520determinants%2520of%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D631%26epage%3D643%26doi%3D10.1038%2Fnrc2713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goeppert, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uddin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">Activating ESR1 mutations differentially affect the efficacy of ER antagonists</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1158%2F2159-8290.CD-15-1523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=27986707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=277-287&author=W.+Toyauthor=H.+Weirauthor=P.+Razaviauthor=M.+Lawsonauthor=A.+U.+Goeppertauthor=A.+M.+Mazzolaauthor=A.+Smithauthor=J.+Wilsonauthor=C.+Morrowauthor=W.+L.+Wongauthor=E.+De+Stanchinaauthor=K.+E.+Carlsonauthor=T.+S.+Martinauthor=S.+Uddinauthor=Z.+Liauthor=S.+Fanningauthor=J.+A.+Katzenellenbogenauthor=G.+Greeneauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=Activating+ESR1+mutations+differentially+affect+the+efficacy+of+ER+antagonists&doi=10.1158%2F2159-8290.CD-15-1523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists</span></div><div class="casAuthors">Toy, Weiyi; Weir, Hazel; Razavi, Pedram; Lawson, Mandy; Goeppert, Anne U.; Mazzola, Anne Marie; Smith, Aaron; Wilson, Joanne; Morrow, Christopher; Wong, Wai Lin; De Stanchina, Elisa; Carlson, Kathryn E.; Martin, Teresa S.; Uddin, Sharmeen; Li, Zhiqiang; Fanning, Sean; Katzenellenbogen, John A.; Greene, Geoffrey; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor.  The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER antagonists like fulvestrant is not established.  In this report, we characterize the spectrum of ESR1 mutations from more than 900 patients.  ESR1 mutations were detected in 10%, with D538G being the most frequent (36%), followed by Y537S (14%).  Several novel, activating mutations were also detected (e.g., L469V, V422del, and Y537D).  Although many mutations lead to constitutive activity and reduced sensitivity to ER antagonists, only select mutants such as Y537S caused a magnitude of change assocd. with fulvestrant resistance in vivo.  Correspondingly, tumors driven by Y537S, but not D5358G, E380Q, or S463P, were less effectively inhibited by fulvestrant than more potent and bioavailable antagonists, including AZD9496.  These data point to a need for antagonists with optimal pharmacokinetic properties to realize clin. efficacy against certain ESR1 mutants.  Significance: A diversity of activating ESR1 mutations exist, only some of which confer resistance to existing ER antagonists that might be overcome by next-generation inhibitors such as AZD9496.  Cancer Discov; 7(3); 277-87. ©2016 AACR.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZyS-eS6T9ZLVg90H21EOLACvtfcHk0lj3ZmQ1ISsttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbo%253D&md5=398dd5202db358ba8facab67055895c9</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1523%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DWeir%26aufirst%3DH.%26aulast%3DRazavi%26aufirst%3DP.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DGoeppert%26aufirst%3DA.%2BU.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DMorrow%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DDe%2BStanchina%26aufirst%3DE.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DUddin%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DActivating%2520ESR1%2520mutations%2520differentially%2520affect%2520the%2520efficacy%2520of%2520ER%2520antagonists%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D277%26epage%3D287%26doi%3D10.1158%2F2159-8290.CD-15-1523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Künzer, H.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of C(7)-Substituted Estra-1,3,5(10)-triene and New Starting Products by this Process</span>. Ger. Offen. <span class="NLM_patent">DE4218743C2</span>, <span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=H.+K%C3%BCnzer&title=Process+for+the+Preparation+of+C%287%29-Substituted+Estra-1%2C3%2C5%2810%29-triene+and+New+Starting+Products+by+this+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCnzer%26aufirst%3DH.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520C%25287%2529-Substituted%2520Estra-1%252C3%252C5%252810%2529-triene%2520and%2520New%2520Starting%2520Products%2520by%2520this%2520Process%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart-Cussac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macpherson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4535</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1200%2FJCO.2008.21.1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=19704066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4530-4535&author=J.+F.+R.+Robertsonauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=E.+Macphersonauthor=J.+Lindemannauthor=M.+J.+Ellis&title=Activity+of+fulvestrant+500+mg+versus+anastrozole+1+mg+as+first-line+treatment+for+advanced+breast+cancer%3A+results+from+the+FIRST+study&doi=10.1200%2FJCO.2008.21.1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span></div><div class="casAuthors">Robertson, John F. R.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; MacPherson, Euan; Lindemann, Justin; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4530-4535</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the clin. activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-pos. breast cancer in postmenopausal women.  Patients and Methods: FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) is a phase II, randomized, open-label, multicenter study of a fulvestrant high-dose (HD) regimen (500 mg/mo plus 500 mg on day 14 of month 1) vs. anastrozole (1 mg/d).  The primary efficacy end point was clin. benefit rate (CBR), defined as the proportion of patients experiencing an objective response (OR) or stable disease for ≥ 24 wk.  The primary anal. was performed 6 mo after the last patient was randomly assigned.  Results: CBR was similar for fulvestrant HD (n = 102) and anastrozole (n = 103), 72.5% v 67.0%, resp. (odds ratio, 1.30; 95% CI, 0.72 to 2.38; P = .386).  Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%.  Time to progression (TTP) was significantly longer for fulvestrant vs. anastrozole (median TTP not reached for fulvestrant HD v 12.5 mo for anastrozole; hazard ratio, 0.63; 95% CI, 0.39 to 1.00; P = .0496).  Duration of OR and CB also numerically favored fulvestrant HD.  Both treatments were well tolerated, with no significant differences in the incidence of prespecified adverse events.  Conclusion: First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was assocd. with significantly longer TTP.  Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-OU2SQaTsabVg90H21EOLACvtfcHk0lj3ZmQ1ISsttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J&md5=a7a6f5cd7fcdbc8cb6839a2800cd5cb8</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.1136%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivity%2520of%2520fulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520the%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4530%26epage%3D4535%26doi%3D10.1200%2FJCO.2008.21.1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (“Faslodex”) – a new treatment option for patients progressing on prior endocrine therapy</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0090267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1677%2Ferc.0.0090267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=12542403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1GmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=267-276&author=C.+Morrisauthor=A.+E.+Wakeling&title=Fulvestrant+%28%E2%80%9CFaslodex%E2%80%9D%29+%E2%80%93+a+new+treatment+option+for+patients+progressing+on+prior+endocrine+therapy&doi=10.1677%2Ferc.0.0090267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant ("Faslodex") - a new treatment option for patients progressing on prior endocrine therapy</span></div><div class="casAuthors">Morris, C.; Wakeling, A.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  Since its introduction more than 30 yr ago, tamoxifen has been the most widely used endocrine therapy for the treatment of women with advanced breast cancer.  More recently, a no. of alternative endocrine treatments have been developed, including several selective estrogen receptor modulators (SERMs), aromatase inhibitors (Als) and, most recently, fulvestrant ("Faslodex").  Fulvestrant is an estrogen receptor (ER) antagonist, which, unlike the SERMs, has no known agonist (estrogenic) effect and downregulates the ER protein.  Tamoxifen is effective and well tolerated, although the non-steroidal Als, anastrozole and letrozole, are more effective treatments for advanced disease than tamoxifen.  Fulvestrant has recently gained US Food and Drug Administration approval for the treatment of hormone receptor-pos. metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.  In two global phase III clin. trials fulvestrant was at least as effective and as equally well tolerated as anastrozole for the treatment of postmenopausal women with advanced and metastatic breast cancer.  In a retrospective anal. of the combined data from these trials, mean duration of response was significantly greater for fulvestrant compared with anastrozole.  These new hormonal treatments expand the choice of endocrine therapy for women with advanced breast cancer and offer new options for sequencing and combining treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUEBpo3hJZ27Vg90H21EOLACvtfcHk0lj3ZmQ1ISsttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1GmsLk%253D&md5=666742ffe67d7d7ea4aaec2ea814a018</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0090267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0090267%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26atitle%3DFulvestrant%2520%2528%25E2%2580%259CFaslodex%25E2%2580%259D%2529%2520%25E2%2580%2593%2520a%2520new%2520treatment%2520option%2520for%2520patients%2520progressing%2520on%2520prior%2520endocrine%2520therapy%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2002%26spage%3D267%26epage%3D276%26doi%3D10.1677%2Ferc.0.0090267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (Faslodex) - how to make a good drug better</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=17673609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&author=J.+F.+Robertson&title=Fulvestrant+%28Faslodex%29+-+how+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant (Faslodex)-how to make a good drug better</span></div><div class="casAuthors">Robertson, John F. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">774-784</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Fulvestrant (Faslodex; AstraZeneca Pharmaceuticals, Wilmington, DE) is an estrogen receptor (ER) antagonist with a novel mode of action; it binds, blocks, and increases degrdn. of ER.  Fulvestrant (at the approved dose [250 mg/mo]) is at least as effective as anastrozole (1 mg/day) in the treatment of postmenopausal women with hormone receptor-pos. advanced breast cancer (HR+ ABC) progressing or recurring on antiestrogen therapy, and is also an active first-line treatment.  Although fulvestrant (250 mg/mo) is clearly effective, it takes 3-6 mo to achieve steady-state plasma levels.  Steady-state concns. are approx. twofold higher than those achieved with a single dose; reaching this earlier, for example, via a loading-dose (LD) regimen (250 mg/mo plus 500 mg on day 0 and 250 mg on day 14 of month 1), may allow responses to be achieved more quickly and limit the possibility of early relapse.  Fulvestrant high-dose (HD) regimens (500 mg/mo) offer the possibility of greater antitumor activity, because (a) ER downregulation is a dose-dependent process (an approx. 70% redn. is obsd. with a single 250 mg dose of fulvestrant) and (b) evidence correlates greater ER downregulation with superior efficacy.  A fulvestrant HD regimen offers the potential of achieving near 100% ER downregulation.  There is also potential to increase fulvestrant-ER binding by reducing plasma estrogen levels, for example, with concomitant aromatase inhibitor treatment.  Several ongoing trials use LD, HD, and combination regimens; results from these studies are awaited with interest.  Meanwhile, fulvestrant (250 mg/mo) remains a valuable addnl. endocrine treatment for postmenopausal women with HR+ ABC recurring or progressing on antiestrogen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxuzoAnKMBfLVg90H21EOLACvtfcHk0lhOnPrW3NeJ9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D&md5=25f69688f5819c7883f408ad74642058</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26atitle%3DFulvestrant%2520%2528Faslodex%2529%2520-%2520how%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzelka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khasanov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrini, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergrass, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J. P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapunar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Results of the confirm phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">4594</span>– <span class="NLM_lpage">4600</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.28.8415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1200%2FJCO.2010.28.8415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=20855825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4594-4600&author=A.+Di%0ALeoauthor=G.+Jerusalemauthor=L.+Petruzelkaauthor=R.+Torresauthor=I.+N.+Bondarenkoauthor=R.+Khasanovauthor=D.+Verhoevenauthor=J.+L.+Pedriniauthor=I.+Smirnovaauthor=M.+R.+Lichinitserauthor=K.+Pendergrassauthor=S.+Garnettauthor=J.+P.+O.+Lindemannauthor=F.+Sapunarauthor=M.+Martin&title=Results+of+the+confirm+phase+III+trial+comparing+fulvestrant+250+mg+with+fulvestrant+500+mg+in+postmenopausal+women+with+estrogen+receptor%E2%80%93positive+advanced+breast+cancer&doi=10.1200%2FJCO.2010.28.8415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer</span></div><div class="casAuthors">di Leo, Angelo; Jerusalem, Guy; Petruzelka, Lubos; Torres, Roberto; Bondarenko, Igor N.; Khasanov, Rustem; Verhoeven, Didier; Pedrini, Jose L.; Smirnova, Iya; Lichinitser, Mikhail R.; Pendergrass, Kelly; Garnett, Sally; Lindemann, Justin P. O.; Sapunar, Francisco; Martin, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4594-4600</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per mo for treatment of postmenopausal women with estrogen receptor-pos. advanced breast cancer who experienced progression after prior endocrine therapy.  Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) is a double-blind, parallel-group, multicenter, phase III study.  Patients were randomly assigned to fulvestrant 500 mg (500 mg i.m. on day 0, then 500 mg i.m. on days 14 and 28 and every 28 days thereafter) or 250 mg every 28 days.  Primary end point was progression-free survival (PFS).  Secondary end points included objective response rate, clin. benefit rate (CBR), duration of clin. benefit (DoCB), overall survival (OS), and quality of life (QOL).  PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% redn. in risk of progression.  Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, resp.).  CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.  DoCB and OS were 16.6 and 25.1 mo, resp., for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 mo, resp., in the 250-mg group.  Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.  QOL was similar for both arms.  Fulvestrant 500 mg was assocd. with a statistically significant increase in PFS and not assocd. with increased toxicity, corresponding to a clin. meaningful improvement in benefit vs. risk compared with fulvestrant 250 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5x_viRvCGrVg90H21EOLACvtfcHk0lhOnPrW3NeJ9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO&md5=9b82ff995b029df754e4295d3153867e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.28.8415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.28.8415%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DPetruzelka%26aufirst%3DL.%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DBondarenko%26aufirst%3DI.%2BN.%26aulast%3DKhasanov%26aufirst%3DR.%26aulast%3DVerhoeven%26aufirst%3DD.%26aulast%3DPedrini%26aufirst%3DJ.%2BL.%26aulast%3DSmirnova%26aufirst%3DI.%26aulast%3DLichinitser%26aufirst%3DM.%2BR.%26aulast%3DPendergrass%26aufirst%3DK.%26aulast%3DGarnett%26aufirst%3DS.%26aulast%3DLindemann%26aufirst%3DJ.%2BP.%2BO.%26aulast%3DSapunar%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DResults%2520of%2520the%2520confirm%2520phase%2520III%2520trial%2520comparing%2520fulvestrant%2520250%2520mg%2520with%2520fulvestrant%2520500%2520mg%2520in%2520postmenopausal%2520women%2520with%2520estrogen%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4594%26epage%3D4600%26doi%3D10.1200%2FJCO.2010.28.8415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in Tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+j.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+Tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lgrpZ2EwCaJfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2Bj.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520Tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5163</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=26463130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+tumor+regression+in+a+tamoxifen-resistant+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Nagasawa, Johnny Y.; Douglas, Karensa L.; Lai, Andiliy G.; Kahraman, Mehmet; Bonnefous, Celine; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5163-5167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective estrogen receptor degraders (SERDs) have shown promise for the treatment of ER+ breast cancer.  Disclosed herein is the continued optimization of the authors' indazole series of SERDs.  Exploration of ER degrdn. and antagonism in vitro followed by in vivo antagonism and oral exposure culminated in the discovery of indazoles (I) and (II), which induce tumor regression in a tamoxifen-resistant breast cancer xenograft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6i7tfU3k5frVg90H21EOLACvtfcHk0lgrpZ2EwCaJfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI&md5=fc890bcabc5f84fce015d50bae14c2b6</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520tumor%2520regression%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&author=C.+De%0ASaviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0ljYUCaSktEx0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.+L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+potent%2C+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen+receptor+positive+breast+cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0ljYUCaSktEx0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.%2BL.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520potent%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=C.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+degradation+maximizes+activity+in+a+tamoxifen-resistant+breast+cancer+model%3A+identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0lg2-Da3xqkHOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DC.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520degradation%2520maximizes%2520activity%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520model%253A%2520identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an orally bioavailable chromene-based selective estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+orally+bioavailable+chromene-based+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+a+model+of+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0lg2-Da3xqkHOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%2520chromene-based%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520a%2520model%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dijcks, F. A.</span>; <span class="NLM_string-name">Lusher, S. J.</span>; <span class="NLM_string-name">Stock, H. T.</span>; <span class="NLM_string-name">Veeneman, G. H.</span></span> <span> </span><span class="NLM_article-title">N-Substituted Azetidine Derivatives</span>. PCT Int. Appl. <span class="NLM_patent">WO2012084711</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=F.+A.+Dijcks&author=S.+J.+Lusher&author=H.+T.+Stock&author=G.+H.+Veeneman&title=N-Substituted+Azetidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDijcks%26aufirst%3DF.%2BA.%26atitle%3DN-Substituted%2520Azetidine%2520Derivatives%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M. P.</span></span> <span> </span><span class="NLM_article-title">Generation of a set of simple, interpretable ADMET rules of thumb</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1021/jm701122q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701122q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=817-834&author=M.+P.+Gleeson&title=Generation+of+a+set+of+simple%2C+interpretable+ADMET+rules+of+thumb&doi=10.1021%2Fjm701122q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Set of Simple, Interpretable ADMET Rules of Thumb</span></div><div class="casAuthors">Gleeson, M. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">817-834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A set of simple, consistent structure-property guides have been detd. from an anal. of a no. of key ADMET assays run within GSK: soly., permeability, bioavailability, vol. of distribution, plasma protein binding, CNS penetration, brain tissue binding, P-gp efflux, hERG inhibition, and cytochrome P 450 1A2/2C9/2C19/2D6/3A4 inhibition.  The rules have been formulated using mol. properties that chemists intuitively know how to alter in a mol., namely, mol. wt., logP, and ionization state.  The rules supplement the more predictive black-box models available to us by clearly illustrating the key underlying trends, which are in line with reports in the literature.  It is clear from the analyses reported herein that almost all ADMET parameters deteriorate with either increasing mol. wt., logP, or both, with ionization state playing either a beneficial or detrimental affect depending on the parameter in question.  This study reemphasizes the need to focus on a lower mol. wt. and logP area of physicochem. property space to obtain improved ADMET parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PTdPHoD-c7Vg90H21EOLACvtfcHk0lg2-Da3xqkHOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D&md5=42db5918ad8e9ea3ecf3a13846b3a434</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm701122q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701122q%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26atitle%3DGeneration%2520of%2520a%2520set%2520of%2520simple%252C%2520interpretable%2520ADMET%2520rules%2520of%2520thumb%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D817%26epage%3D834%26doi%3D10.1021%2Fjm701122q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span>; <span class="NLM_string-name">Cheng, J.</span>; <span class="NLM_string-name">Wang, M.</span>; <span class="NLM_string-name">Sun, F.</span>; <span class="NLM_string-name">Koundinya, M.</span>; <span class="NLM_string-name">Guo, Z.</span>; <span class="NLM_string-name">Hebert, A.</span>; <span class="NLM_string-name">McManus, J.</span>; <span class="NLM_string-name">Levit, M.</span>; <span class="NLM_string-name">Hoffman, D.</span>; <span class="NLM_string-name">Courjaud, A.</span>; <span class="NLM_string-name">Arrebola, R.</span>; <span class="NLM_string-name">Cao, H.</span>; <span class="NLM_string-name">Pollard, J.</span>; <span class="NLM_string-name">Besret, L.</span>; <span class="NLM_string-name">Abecassis, P. Y.</span>; <span class="NLM_string-name">Schio, L.</span>; <span class="NLM_string-name">El-Ahmad, Y.</span>; <span class="NLM_string-name">Halley, F.</span>; <span class="NLM_string-name">Tabart, M.</span>; <span class="NLM_string-name">Certal, V.</span>; <span class="NLM_string-name">Thompson, F.</span>; <span class="NLM_string-name">McCort, G.</span>; <span class="NLM_string-name">Filoche-Rommé, B.</span>; <span class="NLM_string-name">Debussche, L.</span>; <span class="NLM_string-name">Cheng, H.</span>; <span class="NLM_string-name">Garcia-Echeverria, C.</span>; <span class="NLM_string-name">Bouaboula, M.</span></span> <span> </span><span class="NLM_article-title">Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong anti-tumor activity in wild-type and mutant ER+ breast cancer models</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Shomali%2C+M.%3B+Cheng%2C+J.%3B+Wang%2C+M.%3B+Sun%2C+F.%3B+Koundinya%2C+M.%3B+Guo%2C+Z.%3B+Hebert%2C+A.%3B+McManus%2C+J.%3B+Levit%2C+M.%3B+Hoffman%2C+D.%3B+Courjaud%2C+A.%3B+Arrebola%2C+R.%3B+Cao%2C+H.%3B+Pollard%2C+J.%3B+Besret%2C+L.%3B+Abecassis%2C+P.+Y.%3B+Schio%2C+L.%3B+El-Ahmad%2C+Y.%3B+Halley%2C+F.%3B+Tabart%2C+M.%3B+Certal%2C+V.%3B+Thompson%2C+F.%3B+McCort%2C+G.%3B+Filoche-Romm%C3%A9%2C+B.%3B+Debussche%2C+L.%3B+Cheng%2C+H.%3B+Garcia-Echeverria%2C+C.%3B+Bouaboula%2C+M.+Identification+of+SAR439859%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+has+strong+anti-tumor+activity+in+wild-type+and+mutant+ER%2B+breast+cancer+models.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DShomali%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520SAR439859%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520has%2520strong%2520anti-tumor%2520activity%2520in%2520wild-type%2520and%2520mutant%2520ER%252B%2520breast%2520cancer%2520models" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbano, A.</span></span> <span> </span><span class="NLM_article-title">General synthesis of 8-aryl-2-tetralones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4956</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/jo060688j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo060688j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=4956-4964&author=M.+C.+Carrenoauthor=M.+Gonzalez-Lopezauthor=A.+Latorreauthor=A.+Urbano&title=General+synthesis+of+8-aryl-2-tetralones&doi=10.1021%2Fjo060688j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">General Synthesis of 8-Aryl-2-tetralones</span></div><div class="casAuthors">Carreno, M. Carmen; Gonzalez-Lopez, Marcos; Latorre, Alfonso; Urbano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4956-4964</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two alternative routes are described for the synthesis of 8-aryl-2-tetralones, e.g. I.  The first route starts from α-tetralone II and involves 3 or 4 steps, with the selective Na-EtOH redn. of 1-aryl-7-methoxynaphthalenes, e.g. III, being the key step.  The exclusive redn. of the A ring of naphthalenes, e.g. III, occurs when the aryl group at C-1 has no substituent at the ortho positions, affording tetrahydronaphthalenes, e.g. IV..  Redn. of the B ring of naphthalenes, e.g. V, becomes the major process when the aryl fragment has two substituents at the ortho positions, affording 8-aryl-2-tetralones, e.g. I, as the major component.  The second route involves 5 steps starting from 2-tetralone VI, with the key step being the Suzuki coupling with triflate VII.  This approach allows the synthesis of 8-aryl-2-tetralones, e.g. VIII, with no substituent at the ortho positions of the aryl fragment and with naphthalene and anthracene rings at C-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7ZkPi7aC1prVg90H21EOLACvtfcHk0ljQeUvo6KQEog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFGktr0%253D&md5=8abc27a6f86aafb7773c554e66cfdbda</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo060688j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo060688j%26sid%3Dliteratum%253Aachs%26aulast%3DCarreno%26aufirst%3DM.%2BC.%26aulast%3DGonzalez-Lopez%26aufirst%3DM.%26aulast%3DLatorre%26aufirst%3DA.%26aulast%3DUrbano%26aufirst%3DA.%26atitle%3DGeneral%2520synthesis%2520of%25208-aryl-2-tetralones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26spage%3D4956%26epage%3D4964%26doi%3D10.1021%2Fjo060688j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. C.</span></span> <span> </span><span class="NLM_article-title">Halogenation of 1,1-diaryl alkenes</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">829</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.tetlet.2010.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1amsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=826-829&author=M.+Y.+Changauthor=M.+F.+Leeauthor=C.+H.+Linauthor=N.+C.+Lee&title=Halogenation+of+1%2C1-diaryl+alkenes&doi=10.1016%2Fj.tetlet.2010.12.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Halogenation of 1,1-diaryl alkenes</span></div><div class="casAuthors">Chang, Meng-Yang; Lee, Ming-Fang; Lin, Chung-Han; Lee, Nein-Chia</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">826-829</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A variety of vinyl halides were prepd. from reaction of 1,1-diarylalkenes with different halogenating agents (e.g., Selectfluor and N-halosuccinimide) with good yields under mild and base-free conditions.  Synthesis of these mols. has been reported in the literature for being not easy to conduct.  Among all the existing prepns. of vinyl halide procedures, this protocol has the most facile and practical process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49gPmjcExSLVg90H21EOLACvtfcHk0ljQeUvo6KQEog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1amsg%253D%253D&md5=0e59293f9d442ebe9d2488632c742d32</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DM.%2BF.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DN.%2BC.%26atitle%3DHalogenation%2520of%25201%252C1-diaryl%2520alkenes%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D826%26epage%3D829%26doi%3D10.1016%2Fj.tetlet.2010.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span>; <span class="NLM_string-name">Brollo, M.</span>; <span class="NLM_string-name">Certal, V.</span>; <span class="NLM_string-name">El-Ahmad, Y.</span>; <span class="NLM_string-name">Filoche-Romme, B.</span>; <span class="NLM_string-name">Halley, F.</span>; <span class="NLM_string-name">Mccort, G.</span>; <span class="NLM_string-name">Schio, L.</span>; <span class="NLM_string-name">Tabart, M.</span>; <span class="NLM_string-name">Terrier, C.</span>; <span class="NLM_string-name">Thompson, F.</span></span> <span> </span><span class="NLM_article-title">Novel Substituted <i>N</i>-(3-Fluoropropyl)-pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO2018091153</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Bouaboula&author=M.+Brollo&author=V.+Certal&author=Y.+El-Ahmad&author=B.+Filoche-Romme&author=F.+Halley&author=G.+Mccort&author=L.+Schio&author=M.+Tabart&author=C.+Terrier&author=F.+Thompson&title=Novel+Substituted+N-%283-Fluoropropyl%29-pyrrolidine+Compounds%2C+Processes+for+their+Preparation+and+Therapeutic+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBouaboula%26aufirst%3DM.%26atitle%3DNovel%2520Substituted%2520N-%25283-Fluoropropyl%2529-pyrrolidine%2520Compounds%252C%2520Processes%2520for%2520their%2520Preparation%2520and%2520Therapeutic%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsunoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span> <span> </span><span class="NLM_article-title">Mitsunobu acylation of sterically congested secondary alcohols by N,N,N′,N′-tetramethylazodicarboxamide-tributyiphosphine reagents</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2530</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(95)00299-R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2F0040-4039%2895%2900299-R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADyaK2MXltVamt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=2529-2530&author=T.+Tsunodaauthor=Y.+Yamamiyaauthor=Y.+Kawamuraauthor=S.+Ito&title=Mitsunobu+acylation+of+sterically+congested+secondary+alcohols+by+N%2CN%2CN%E2%80%B2%2CN%E2%80%B2-tetramethylazodicarboxamide-tributyiphosphine+reagents&doi=10.1016%2F0040-4039%2895%2900299-R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mitsunobu acylation of sterically congested secondary alcohols by N,N,N',N'-tetramethylazodicarboxamide-tributylphosphine reagents</span></div><div class="casAuthors">Tsunoda, Tetsuto; Yamamiya, Yoshiko; Kawamura, Yumi; Ito, Sho</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2529-30</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four secondary alcs. of different steric environment (5α-cholestan-3β-ol, -3α-ol, (-)-menthol, (-)-8-phenylmenthol) reacted with five carboxylic acids (4-MeC6H4CO2H, PhCO2H, 4-O2NC6H4CO2H, ClCH2CO2H, Cl2CHCO2H) of different acidity in the presence of N,N,N',N'-tetramethylazodicarboxamide and tributylphosphine to give the corresponding epi-esters in better yield than with di-Et azodicarboxylate-triphenylphosphine in most cases.  Of special merit is the combination of the new reagent system with p-methoxybenzoic acid to achieve complete inversion of sterically congested secondary alcs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PgtvUY_ZarVg90H21EOLACvtfcHk0ljQeUvo6KQEog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltVamt7c%253D&md5=25a78b4ea154e0bf5b28c473dce80601</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2900299-R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252900299-R%26sid%3Dliteratum%253Aachs%26aulast%3DTsunoda%26aufirst%3DT.%26aulast%3DYamamiya%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DS.%26atitle%3DMitsunobu%2520acylation%2520of%2520sterically%2520congested%2520secondary%2520alcohols%2520by%2520N%252CN%252CN%25E2%2580%25B2%252CN%25E2%2580%25B2-tetramethylazodicarboxamide-tributyiphosphine%2520reagents%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D2529%26epage%3D2530%26doi%3D10.1016%2F0040-4039%2895%2900299-R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span>; <span class="NLM_string-name">Brollo, M.</span>; <span class="NLM_string-name">Certal, V.</span>; <span class="NLM_string-name">El-Ahmad, Y.</span>; <span class="NLM_string-name">Filoche-Romme, B.</span>; <span class="NLM_string-name">Halley, F.</span>; <span class="NLM_string-name">McCort, G.</span>; <span class="NLM_string-name">Schio, L.</span>; <span class="NLM_string-name">Tabart, M.</span>; <span class="NLM_string-name">Terrier, C.</span>; <span class="NLM_string-name">Thompson, F.</span></span> <span> </span><span class="NLM_article-title">Novel Substituted 6,7-Dihydro-5<i>H</i>-benzo[7]annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO2017140669</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Bouaboula&author=M.+Brollo&author=V.+Certal&author=Y.+El-Ahmad&author=B.+Filoche-Romme&author=F.+Halley&author=G.+McCort&author=L.+Schio&author=M.+Tabart&author=C.+Terrier&author=F.+Thompson&title=Novel+Substituted+6%2C7-Dihydro-5H-benzo%5B7%5Dannulene+Compounds%2C+Processes+for+their+Preparation+and+Therapeutic+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBouaboula%26aufirst%3DM.%26atitle%3DNovel%2520Substituted%25206%252C7-Dihydro-5H-benzo%255B7%255Dannulene%2520Compounds%252C%2520Processes%2520for%2520their%2520Preparation%2520and%2520Therapeutic%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D.</span>; <span class="NLM_string-name">DeCorte, B.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">McDonnell, M.</span>; <span class="NLM_string-name">McNally, J.</span></span> <span> </span><span class="NLM_article-title">Tricyclic δ-Opioid Modulators</span>. <span class="NLM_patent">US2006/30585</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+Scott&author=B.+DeCorte&author=L.+Liu&author=M.+McDonnell&author=J.+McNally&title=Tricyclic+%CE%B4-Opioid+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%26atitle%3DTricyclic%2520%25CE%25B4-Opioid%2520Modulators%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>D67</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0liYyZZLY8ZeMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3DD67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tickle, I. J.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Sharff, A.</span>; <span class="NLM_string-name">Vonrhein, C.</span>; <span class="NLM_string-name">Bricogne, G.</span></span> <i>STARANISO</i>; <span class="NLM_publisher-name">Global Phasing, Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=I.+J.+Tickle&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=A.+Sharff&author=C.+Vonrhein&author=G.+Bricogne&title=STARANISO"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26jtitle%3DSTARANISO%26pub%3DGlobal%2520Phasing%252C%2520Ltd%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0liYyZZLY8ZeMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljclDrqoO4wMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/S0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2FS0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0ljclDrqoO4wMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2FS0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindyalov, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">The protein data bank</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1093/nar/28.1.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+protein+data+bank&doi=10.1093%2Fnar%2F28.1.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0ljclDrqoO4wMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520protein%2520data%2520bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242%26doi%3D10.1093%2Fnar%2F28.1.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yunlong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Wukun Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15094-15114. <a href="https://doi.org/10.1021/acs.jmedchem.0c00913" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00913%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%25253A%252BA%252BPromising%252BStrategy%252Bfor%252BEstrogen%252BReceptor%252BPositive%252BEndocrine-Resistant%252BBreast%252BCancer%26aulast%3DLu%26aufirst%3DYunlong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D02112020%26volume%3D63%26issue%3D24%26spage%3D15094%26epage%3D15114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Thomas A. Moss, Amber Balazs, Bernard Barlaam, Jason Breed, Rodrigo J. Carbajo, Elisabetta Chiarparin, Paul R. J. Davey, Oona Delpuech, Stephen Fawell, David I. Fisher, Sladjana Gagrica, Eric T. Gangl, Tyler Grebe, Ryan D. Greenwood, Sudhir Hande, Holia Hatoum-Mokdad, Kara Herlihy, Samantha Hughes, Thomas A. Hunt, Hoan Huynh, Sophie L. M. Janbon, Tony Johnson, Stefan Kavanagh, Teresa Klinowska, Mandy Lawson, Andrew S. Lister, Stacey Marden, Dermot F. McGinnity, Christopher J. Morrow, J. Willem M. Nissink, Daniel H. O’Donovan, Bo Peng, Radoslaw Polanski, Darren S. Stead, Stephen Stokes, Kumar Thakur, Scott R. Throner, Michael J. Tucker, Jeffrey Varnes, Haixia Wang, David M. Wilson, Dedong Wu, Ye Wu, Bin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Wenzhan Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14530-14559. <a href="https://doi.org/10.1021/acs.jmedchem.0c01163" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01163%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BAZD9833%25252C%252Ba%252BPotent%252Band%252BOrally%252BBioavailable%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252Band%252BAntagonist%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07072020%26date%3D29092020%26date%3D10092020%26volume%3D63%26issue%3D23%26spage%3D14530%26epage%3D14559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jun Liang, Robert Blake, Jae Chang, Lori S. Friedman, Simon Goodacre, Steven Hartman, Ellen Rei Ingalla, James R. Kiefer, Tracy Kleinheinz, Sharada Labadie, Jun Li, Kwong Wah Lai, Jiangpeng Liao, Vidhi Mody, Neville McLean, Ciara Metcalfe, Michelle Nannini, Daniel Otwine, Yingqing Ran, Nick Ray, Fabien Roussel, Amy Sambrone, Deepak Sampath, Maia Vinogradova, John Wai, Tao Wang, Kuen Yeap, Amy Young, Jason Zbieg, Birong Zhang, Xiaoping Zheng, Yu Zhong, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojing Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1342-1347. <a href="https://doi.org/10.1021/acsmedchemlett.0c00224" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BGNE-149%252Bas%252Ba%252BFull%252BAntagonist%252Band%252BEfficient%252BDegrader%252Bof%252BEstrogen%252BReceptor%252Balpha%252Bfor%252BER%25252B%252BBreast%252BCancer%26aulast%3DLiang%26aufirst%3DJun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28042020%26date%3D26052020%26date%3D29052020%26date%3D26052020%26volume%3D11%26issue%3D6%26spage%3D1342%26epage%3D1347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kotyada  Suryanarayana</span>, <span class="hlFld-ContribAuthor ">Alice Rinky  Robert</span>, <span class="hlFld-ContribAuthor ">Nagaraju  Kerru</span>, <span class="hlFld-ContribAuthor ">Thangaiyan  Pooventhiran</span>, <span class="hlFld-ContribAuthor ">Renjith  Thomas</span>, <span class="hlFld-ContribAuthor ">Suresh  Maddila</span>, <span class="hlFld-ContribAuthor ">Sreekantha B.  Jonnalagadda</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, anticancer activity and molecular docking analysis of novel dinitrophenylpyrazole bearing 1,2,3-triazoles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1243 </em>, 130865. <a href="https://doi.org/10.1016/j.molstruc.2021.130865" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130865</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130865%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Banticancer%252Bactivity%252Band%252Bmolecular%252Bdocking%252Banalysis%252Bof%252Bnovel%252Bdinitrophenylpyrazole%252Bbearing%252B1%25252C2%25252C3-triazoles%26aulast%3DSuryanarayana%26aufirst%3DKotyada%26date%3D2021%26volume%3D1243%26spage%3D130865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Hernando</span>, <span class="hlFld-ContribAuthor ">Belén  Ortega-Morillo</span>, <span class="hlFld-ContribAuthor ">Marta  Tapia</span>, <span class="hlFld-ContribAuthor ">Santiago  Moragón</span>, <span class="hlFld-ContribAuthor ">María Teresa  Martínez</span>, <span class="hlFld-ContribAuthor ">Pilar  Eroles</span>, <span class="hlFld-ContribAuthor ">Iris  Garrido-Cano</span>, <span class="hlFld-ContribAuthor ">Anna  Adam-Artigues</span>, <span class="hlFld-ContribAuthor ">Ana  Lluch</span>, <span class="hlFld-ContribAuthor ">Begoña  Bermejo</span>, <span class="hlFld-ContribAuthor ">Juan Miguel  Cejalvo</span>. </span><span class="cited-content_cbyCitation_article-title">Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (15)
                                     , 7812. <a href="https://doi.org/10.3390/ijms22157812" title="DOI URL">https://doi.org/10.3390/ijms22157812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22157812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22157812%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOral%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%252Bas%252Ba%252BNovel%252BBreast%252BCancer%252BTherapy%25253A%252BPresent%252Band%252BFuture%252Bfrom%252Ba%252BClinical%252BPerspective%26aulast%3DHernando%26aufirst%3DCristina%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D15%26spage%3D7812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xi  Liu</span>, <span class="hlFld-ContribAuthor ">Qian  Hu</span>, <span class="hlFld-ContribAuthor ">Wanyan  Wang</span>, <span class="hlFld-ContribAuthor ">Hui  Ma</span>, <span class="hlFld-ContribAuthor ">Jiaqian  Pu</span>, <span class="hlFld-ContribAuthor ">Jiayan  Cui</span>, <span class="hlFld-ContribAuthor ">Ting  Gong</span>, <span class="hlFld-ContribAuthor ">Yu  Wu</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Lu</span>, <span class="hlFld-ContribAuthor ">Jin  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>188 </em>, 114583. <a href="https://doi.org/10.1016/j.bcp.2021.114583" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114583%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DA%252Bprotein-fragment%252Bcomplementation%252Bassay%252Breveals%252Bthat%252Bcelastrol%252Band%252Bgambogic%252Bacid%252Bsuppress%252BER%2525CE%2525B1%252Bmutants%252Bin%252Bbreast%252Bcancer%26aulast%3DLiu%26aufirst%3DXi%26date%3D2021%26volume%3D188%26spage%3D114583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zunyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhen  Ma</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Selective degradation of the estrogen receptor in the treatment of cancers. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Steroid Biochemistry and Molecular Biology</span><span> <strong>2021,</strong> <em>209 </em>, 105848. <a href="https://doi.org/10.1016/j.jsbmb.2021.105848" title="DOI URL">https://doi.org/10.1016/j.jsbmb.2021.105848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsbmb.2021.105848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsbmb.2021.105848%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Steroid%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DSelective%252Bdegradation%252Bof%252Bthe%252Bestrogen%252Breceptor%252Bin%252Bthe%252Btreatment%252Bof%252Bcancers%26aulast%3DWang%26aufirst%3DZunyuan%26date%3D2021%26volume%3D209%26spage%3D105848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maysoun  Shomali</span>, <span class="hlFld-ContribAuthor ">Jane  Cheng</span>, <span class="hlFld-ContribAuthor ">Fangxian  Sun</span>, <span class="hlFld-ContribAuthor ">Malvika  Koundinya</span>, <span class="hlFld-ContribAuthor ">Zhuyan  Guo</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Hebert</span>, <span class="hlFld-ContribAuthor ">Jessica  McManus</span>, <span class="hlFld-ContribAuthor ">Mikhail N.  Levit</span>, <span class="hlFld-ContribAuthor ">Dietmar  Hoffmann</span>, <span class="hlFld-ContribAuthor ">Albane  Courjaud</span>, <span class="hlFld-ContribAuthor ">Rosalia  Arrebola</span>, <span class="hlFld-ContribAuthor ">Hui  Cao</span>, <span class="hlFld-ContribAuthor ">Jack  Pollard</span>, <span class="hlFld-ContribAuthor ">Joon Sang  Lee</span>, <span class="hlFld-ContribAuthor ">Laurent  Besret</span>, <span class="hlFld-ContribAuthor ">Anne  Caron</span>, <span class="hlFld-ContribAuthor ">Dinesh S.  Bangari</span>, <span class="hlFld-ContribAuthor ">Pierre-Yves  Abecassis</span>, <span class="hlFld-ContribAuthor ">Laurent  Schio</span>, <span class="hlFld-ContribAuthor ">Youssef  El-Ahmad</span>, <span class="hlFld-ContribAuthor ">Frank  Halley</span>, <span class="hlFld-ContribAuthor ">Michel  Tabart</span>, <span class="hlFld-ContribAuthor ">Victor  Certal</span>, <span class="hlFld-ContribAuthor ">Fabienne  Thompson</span>, <span class="hlFld-ContribAuthor ">Gary  McCort</span>, <span class="hlFld-ContribAuthor ">Bruno  Filoche-Rommé</span>, <span class="hlFld-ContribAuthor ">Hong  Cheng</span>, <span class="hlFld-ContribAuthor ">Carlos  Garcia-Echeverria</span>, <span class="hlFld-ContribAuthor ">Laurent  Debussche</span>, <span class="hlFld-ContribAuthor ">Monsif  Bouaboula</span>. </span><span class="cited-content_cbyCitation_article-title">SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 250-262. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0390" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0390%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DSAR439859%25252C%252Ba%252BNovel%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252B%252528SERD%252529%25252C%252BDemonstrates%252BEffective%252Band%252BBroad%252BAntitumor%252BActivity%252Bin%252BWild-Type%252Band%252BMutant%252BER-Positive%252BBreast%252BCancer%252BModels%26aulast%3DShomali%26aufirst%3DMaysoun%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D250%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurent  Besret</span>, <span class="hlFld-ContribAuthor ">Sébastien  d’Heilly</span>, <span class="hlFld-ContribAuthor ">Cathy  Aubert</span>, <span class="hlFld-ContribAuthor ">Guillaume  Bluet</span>, <span class="hlFld-ContribAuthor ">Florence  Gruss-Leleu</span>, <span class="hlFld-ContribAuthor ">Françoise  Le-Gall</span>, <span class="hlFld-ContribAuthor ">Anne  Caron</span>, <span class="hlFld-ContribAuthor ">Laurent  Andrieu</span>, <span class="hlFld-ContribAuthor ">Sylvie  Vincent</span>, <span class="hlFld-ContribAuthor ">Maysoun  Shomali</span>, <span class="hlFld-ContribAuthor ">Monsif  Bouaboula</span>, <span class="hlFld-ContribAuthor ">Carole  Voland</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Ming</span>, <span class="hlFld-ContribAuthor ">Sébastien  Roy</span>, <span class="hlFld-ContribAuthor ">Srinivas  Rao</span>, <span class="hlFld-ContribAuthor ">Chantal  Carrez</span>, <span class="hlFld-ContribAuthor ">Erwan  Jouannot</span>. </span><span class="cited-content_cbyCitation_article-title">Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader. </span><span class="cited-content_cbyCitation_journal-name">EJNMMI Research</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13550-020-00646-w" title="DOI URL">https://doi.org/10.1186/s13550-020-00646-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13550-020-00646-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13550-020-00646-w%26sid%3Dliteratum%253Aachs%26jtitle%3DEJNMMI%2520Research%26atitle%3DTranslational%252Bstrategy%252Busing%252Bmultiple%252Bnuclear%252Bimaging%252Bbiomarkers%252Bto%252Bevaluate%252Btarget%252Bengagement%252Band%252Bearly%252Btherapeutic%252Befficacy%252Bof%252BSAR439859%25252C%252Ba%252Bnovel%252Bselective%252Bestrogen%252Breceptor%252Bdegrader%26aulast%3DBesret%26aufirst%3DLaurent%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Wang</span>, <span class="hlFld-ContribAuthor ">Abhishek  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (22)
                                     , 2072-2097. <a href="https://doi.org/10.1002/cmdc.202000473" title="DOI URL">https://doi.org/10.1002/cmdc.202000473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000473%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252BQuest%252Bfor%252BOrally%252BAvailable%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%26aulast%3DWang%26aufirst%3DLucia%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D22%26spage%3D2072%26epage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ariella B.  Hanker</span>, <span class="hlFld-ContribAuthor ">Dhivya R.  Sudhan</span>, <span class="hlFld-ContribAuthor ">Carlos L.  Arteaga</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Endocrine Resistance in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2020,</strong> <em>37 </em>
                                    (4)
                                     , 496-513. <a href="https://doi.org/10.1016/j.ccell.2020.03.009" title="DOI URL">https://doi.org/10.1016/j.ccell.2020.03.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2020.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2020.03.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DOvercoming%252BEndocrine%252BResistance%252Bin%252BBreast%252BCancer%26aulast%3DHanker%26aufirst%3DAriella%2BB.%26date%3D2020%26volume%3D37%26issue%3D4%26spage%3D496%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0019.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Role of aromatase and approved inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. SERM and SERD inhibitors on the market and in development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Hit compound <b>10a</b> and optimization strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystallography of (<b>43d</b>) bounds to the ERα ligand binding domain construct [298–554]-L536S (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SBO">6SBO</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo efficacy of compound <b>43d</b> in MCF-7 tamoxifen-sensitive xenograft at indicated doses po BID (MCF-7 tamoxifen-sensitive xenograft in mice supplemented subcutaneously with 0.72 mg estradiol pellets). MCF-7 cells were subcutaneously inoculated 2 to 3 days post-estradiol-pellet-implantation. <i>n</i> = 9 to 10 animals per group. Tumor volume (length × width<sup>2</sup>/2) was monitored weekly. Animals were treated with the vehicle or with compound <b>43d</b> twice daily.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10a</b>–<b>h</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KHMDS, PhN(SO<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>, THF, −50 °C to rt, 96%. (b) (4-Hydroxyphenyl)boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, rt, 70%. (c) Pyridinium tribromide, THF, rt, 79%. (d) (4-Methoxyphenyl)boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 70 °C, 55%. (e) For <b>16a</b>: 1,2-dibromoethane, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 73%. For <b>16b</b>: 1,3-dibromopropane, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 71%. (f) For <b>17a</b>: BF<sub>3</sub>, Me<sub>2</sub>S, DCM, rt, 86%. For <b>10d</b>: BF<sub>3</sub>·Me<sub>2</sub>S, DCM, rt, 28%. (g) For <b>10a</b>–<b>c</b> and <b>10e</b>–<b>h</b>: K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 15–73%. For <b>18d</b>: K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 93%.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>10i</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 80%. (b) 4 N HCl, dioxane, MeOH, rt, 81%. (c) BF<sub>3</sub>, Me<sub>2</sub>S, DCM, rt, 64%. (d) Propanal, NaBH<sub>3</sub>CN, AcOH, MeOH, 0 °C to rt, 50%. (e) (4-Hydroxyphenyl)boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, rt, 57%.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>10j</b>–<b>p</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<b>24a</b><b>,b</b>): Mitsunobu: (<i>E</i>)-<i>N</i>1,<i>N</i>1,<i>N</i>2,<i>N</i>2-tetramethyldiazene-1,2-dicarboxamide, PPh<sub>3</sub>, THF, rt, 37–75%. (b) (<b>25a</b><b>,b</b>): 4 N HCl, dioxane, MeOH, rt, 33–93%. (c) (<b>26a</b><b>,b</b>): BF<sub>3</sub>,Me<sub>2</sub>S, DCM, rt, 51–95%. (d) (<b>10j</b>–<b>l</b>): aldehyde, NaBH<sub>3</sub>CN, AcOH, MeOH, 0 °C to rt, 40–64%. (e) (<b>10m</b>–<b>p</b>): iodoalkyl, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 40–64%.</p></p></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>33a</b>–<b>p</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pivaloyl chloride, K<sub>2</sub>CO<sub>3</sub>, acetone, rt, 69–73%. (b) Trifluoromethanesulfonic anhydride, pyridine, DCM, rt, 93–97%. (c) PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, rt, 98–100%. (d) Pyridinium tribromide, THF, rt, 75–82%. (e) 5 N NaOH, MeOH, rt, 72–78%. (f) Ar-boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 70 °C, 8–92%.</p></p></figure><figure data-id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>37</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Mitsunobu: (<i>E</i>)-<i>N</i>1<i>,N</i>1,<i>N</i>2,<i>N</i>2-tetramethyldiazene-1,2-dicarboxamide, PPh<sub>3</sub>, THF, rt, 100%. (b) 4 N HCl, dioxane, MeOH, rt, 95%. (c) K<sub>2</sub>CO<sub>3</sub>, MeCN, 40 °C, 100%.</p></p></figure><figure data-id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/medium/jm9b01293_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds (<b>43a–f</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-2/acs.jmedchem.9b01293/20200115/images/large/jm9b01293_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01293&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5 N NaOH, MeOH, rt, 93%. (b) Trifluoromethanesulfonic anhydride, pyridine, DCM, 5 °C to rt, 89%. (c) PdCl<sub>2</sub>dppf, MeOH, DMF, CO (5 bar), 70 °C, 86%. (d) Pyridinium tribromide, THF, rt, 85%. (e) Ar-boronic acid, PdCl<sub>2</sub>dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, 70 °C, 45–75%. (f) 2 N NaOH, MeOH, rt, 28–96%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i109">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>New Global Cancer Data: GLOBOCAN 2018</i>; <span class="NLM_publisher-name">World
Health Organization</span>, 2018. <a href="https://www.uicc.org/new-global-cancer-data-globocan-2018" class="extLink">https://www.uicc.org/new-global-cancer-data-globocan-2018</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+New+Global+Cancer+Data%3A+GLOBOCAN+2018%3B+World%0AHealth+Organization%2C+2018.+https%3A%2F%2Fwww.uicc.org%2Fnew-global-cancer-data-globocan-2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Global%2520Cancer%2520Data%253A%2520GLOBOCAN%25202018%26pub%3DWorld%250AHealth%2520Organization" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yersal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barutca, S.</span></span> <span> </span><span class="NLM_article-title">Biological subtypes of breast cancer: prognostic and therapeutic implications</span>. <i>World J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.5306/wjco.v5.i3.412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.5306%2Fwjco.v5.i3.412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=25114856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhtVGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=412-424&author=O.+Yersalauthor=S.+Barutca&title=Biological+subtypes+of+breast+cancer%3A+prognostic+and+therapeutic+implications&doi=10.5306%2Fwjco.v5.i3.412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Biological subtypes of breast cancer: Prognostic and therapeutic implications</span></div><div class="casAuthors">Yersal Ozlem; Barutca Sabri</div><div class="citationInfo"><span class="NLM_cas:title">World journal of clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-24</span>
        ISSN:<span class="NLM_cas:issn">2218-4333</span>.
    </div><div class="casAbstract">Breast cancer is a heterogeneous complex of diseases, a spectrum of many subtypes with distinct biological features that lead to differences in response patterns to various treatment modalities and clinical outcomes.  Traditional classification systems regarding biological characteristics may have limitations for patient-tailored treatment strategies.  Tumors with similar clinical and pathological presentations may have different behaviors.  Analyses of breast cancer with new molecular techniques now hold promise for the development of more accurate tests for the prediction of recurrence.  Gene signatures have been developed as predictors of response to therapy and protein gene products that have direct roles in driving the biology and clinical behavior of cancer cells are potential targets for the development of novel therapeutics.  The present review summarizes current knowledge in breast cancer molecular biology, focusing on novel prognostic and predictive factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjCFvwnmL6j5NiNltV31zlfW6udTcc2ebnnxLVx9PoCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhtVGmtg%253D%253D&md5=2c6cc4bc4f0926c142f7e2e6af3c6e71</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.5306%2Fwjco.v5.i3.412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5306%252Fwjco.v5.i3.412%26sid%3Dliteratum%253Aachs%26aulast%3DYersal%26aufirst%3DO.%26aulast%3DBarutca%26aufirst%3DS.%26atitle%3DBiological%2520subtypes%2520of%2520breast%2520cancer%253A%2520prognostic%2520and%2520therapeutic%2520implications%26jtitle%3DWorld%2520J.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D5%26spage%3D412%26epage%3D424%26doi%3D10.5306%2Fwjco.v5.i3.412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paterni, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minutolo, F.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptors alpha (ERalpha) and beta (ERbeta): subtype-selective ligands and clinical potential</span>. <i>Steroids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.steroids.2014.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.steroids.2014.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=24971815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFenu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2014&pages=13-29&author=I.+Paterniauthor=C.+Granchiauthor=J.+A.+Katzenellenbogenauthor=F.+Minutolo&title=Estrogen+receptors+alpha+%28ERalpha%29+and+beta+%28ERbeta%29%3A+subtype-selective+ligands+and+clinical+potential&doi=10.1016%2Fj.steroids.2014.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential</span></div><div class="casAuthors">Paterni, Ilaria; Granchi, Carlotta; Katzenellenbogen, John A.; Minutolo, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Steroids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-29</span>CODEN:
                <span class="NLM_cas:coden">STEDAM</span>;
        ISSN:<span class="NLM_cas:issn">0039-128X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Estrogen receptors alpha (ERα) and beta (ERβ) are nuclear transcription factors that are involved in the regulation of many complex physiol. processes in humans.  Modulation of these receptors by prospective therapeutic agents is currently being considered for prevention and treatment of a wide variety of pathol. conditions, such as, cancer, metabolic and cardiovascular diseases, neurodegeneration, inflammation, and osteoporosis.  This review provides an overview and update of compds. that have been recently reported as modulators of ERs, with a particular focus on their potential clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrROACfUL51e7Vg90H21EOLACvtfcHk0ljAIYrnERikXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFenu7vI&md5=ac6863afe52e6a18ffd89d3ba6770023</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.steroids.2014.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.steroids.2014.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DPaterni%26aufirst%3DI.%26aulast%3DGranchi%26aufirst%3DC.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMinutolo%26aufirst%3DF.%26atitle%3DEstrogen%2520receptors%2520alpha%2520%2528ERalpha%2529%2520and%2520beta%2520%2528ERbeta%2529%253A%2520subtype-selective%2520ligands%2520and%2520clinical%2520potential%26jtitle%3DSteroids%26date%3D2014%26volume%3D90%26spage%3D13%26epage%3D29%26doi%3D10.1016%2Fj.steroids.2014.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span> <span> </span><span class="NLM_article-title">Oestrogen receptors in breast cancer: basic mechanisms and clinical implications</span>. <i>ecancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">370</span>, <span class="refDoi"> DOI: 10.3332/ecancer.2013.370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.3332%2Fecancer.2013.370" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=370&author=C.+Williamsauthor=C.+Y.+Lin&title=Oestrogen+receptors+in+breast+cancer%3A+basic+mechanisms+and+clinical+implications&doi=10.3332%2Fecancer.2013.370"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3332%2Fecancer.2013.370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3332%252Fecancer.2013.370%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DC.%2BY.%26atitle%3DOestrogen%2520receptors%2520in%2520breast%2520cancer%253A%2520basic%2520mechanisms%2520and%2520clinical%2520implications%26jtitle%3Decancer%26date%3D2013%26volume%3D7%26spage%3D370%26doi%3D10.3332%2Fecancer.2013.370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, C. J.</span></span> <span> </span><span class="NLM_article-title">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer: hormonal agents for treatment and prevention of breast cancer</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2007.01587.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1111%2Fj.1742-1241.2007.01587.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=17892469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=2051-2063&author=C.+J.+Fabian&title=The+what%2C+why+and+how+of+aromatase+inhibitors%3A+hormonal+agents+for+treatment+and+prevention+of+breast+cancer%3A+hormonal+agents+for+treatment+and+prevention+of+breast+cancer&doi=10.1111%2Fj.1742-1241.2007.01587.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer</span></div><div class="casAuthors">Fabian, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2051-2063</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - pos. breast cancer in postmenopausal women.  Approx. 185,000 new cases of invasive breast cancer are diagnosed yearly, and at least half of these women are both postmenopausal and eligible for adjuvant therapy with AIs.  In addn., AIs are currently being tested as primary prevention therapy in large randomized trials involving tens of thousands of women at increased risk for breast cancer.  Given the vol. of use, internists will increasingly see postmenopausal women who are taking or considering treatment with AIs.  Physicians need to be able to: (i) briefly discuss the pros and cons of using a selective estrogen receptor modulator such as tamoxifen or raloxifene vs. an AI for risk redn. and (ii) recognize and manage AI-assocd. adverse events.  The primary purpose of this review is to help internists with these two tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopE3D6sucnebVg90H21EOLACvtfcHk0ljAIYrnERikXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFGns7c%253D&md5=38f2869d30e8e2696ec9623bf32a8d1b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2007.01587.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2007.01587.x%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520what%252C%2520why%2520and%2520how%2520of%2520aromatase%2520inhibitors%253A%2520hormonal%2520agents%2520for%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%253A%2520hormonal%2520agents%2520for%2520treatment%2520and%2520prevention%2520of%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2007%26volume%3D61%26spage%3D2051%26epage%3D2063%26doi%3D10.1111%2Fj.1742-1241.2007.01587.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, K. C.</span></span> <span> </span><span class="NLM_article-title">Selective estrogen receptor modulators</span>. <i>Asian Spine J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">791</span>, <span class="refDoi"> DOI: 10.4184/asj.2016.10.4.787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.4184%2Fasj.2016.10.4.787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=27559463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A280%3ADC%252BC2szktFyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=787-791&author=K.+C.+An&title=Selective+estrogen+receptor+modulators&doi=10.4184%2Fasj.2016.10.4.787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Estrogen Receptor Modulators</span></div><div class="casAuthors">An Ki-Chan</div><div class="citationInfo"><span class="NLM_cas:title">Asian spine journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">787-91</span>
        ISSN:<span class="NLM_cas:issn">1976-1902</span>.
    </div><div class="casAbstract">Selective estrogen receptor modulators (SERMs) are now being used as a treatment for breast cancer, osteoporosis and postmenopausal symptoms, as these drugs have features that can act as an estrogen agonist and an antagonist, depending on the target tissue.  After tamoxifen, raloxifene, lasofoxifene and bazedoxifene SERMs have been developed and used for treatment.  The clinically decisive difference among these drugs (i.e., the key difference) is their endometrial safety.  Compared to bisphosphonate drug formulations for osteoporosis, SERMs are to be used primarily in postmenopausal women of younger age and are particularly recommended if there is a family history of invasive breast cancer, as their use greatly reduces the incidence of this type of cancer in women.  Among the above mentioned SERMs, raloxifene has been widely used in prevention and treatment of postmenopausal osteoporosis and vertebral compression fractures, and clinical studies are now underway to test the comparative advantages of raloxifene with those of bazedoxifene, a more recently developed SERM.  Research on a number of adverse side effects of SERM agents is being performed to determine the long-term safety of this class of compouds for treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfiFc2kej-uhFwe7cAcrfPfW6udTcc2ebonVljVru9N7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szktFyntw%253D%253D&md5=96fc6c0262831c93c7ed82e84ebf3a24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4184%2Fasj.2016.10.4.787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4184%252Fasj.2016.10.4.787%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DK.%2BC.%26atitle%3DSelective%2520estrogen%2520receptor%2520modulators%26jtitle%3DAsian%2520Spine%2520J.%26date%3D2016%26volume%3D10%26spage%3D787%26epage%3D791%26doi%3D10.4184%2Fasj.2016.10.4.787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. A.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptors: therapies targeted to receptor subtypes</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1038/clpt.2010.226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1038%2Fclpt.2010.226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=21124311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=44-55&author=S.+Nilssonauthor=J.+A.+Gustafsson&title=Estrogen+receptors%3A+therapies+targeted+to+receptor+subtypes&doi=10.1038%2Fclpt.2010.226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen Receptors: Therapies Targeted to Receptor Subtypes</span></div><div class="casAuthors">Nilsson, S.; Gustafsson, J.-Aa.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-55</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past two decades, we have learned that estrogens play important physiol. roles not only in women but also in men and that the biol. effects of estrogen are mediated by not one but two distinct estrogen receptors (ERs), ERα and ERβ.  Our appreciation of the physiol. importance of estrogen and the mechanisms by which it acts has significantly increased over the years; however, we are only now beginning to decipher the roles of ERα and ERβ in different organs and to elucidate how selective ligands, acting through either of the two ERs, can prevent or treat various age- or sex-specific diseases.  The specific roles of ERα and ERβ and the therapeutic potential of ER subtype-selective agonists in bone and metabolic homeostasis, depression, vasomotor symptoms, neurodegenerative diseases, and cancer are reviewed herein.  It must be stated, however, that appropriate clin. studies are necessary to validate these compds. as agents for the prevention and treatment of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0tQWjd5LTLVg90H21EOLACvtfcHk0lhWjF2G5-t4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFylt7zN&md5=30f4fac2dcdfb20035b54783a7684a8c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.226%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DS.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26atitle%3DEstrogen%2520receptors%253A%2520therapies%2520targeted%2520to%2520receptor%2520subtypes%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D89%26spage%3D44%26epage%3D55%26doi%3D10.1038%2Fclpt.2010.226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2010.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.coph.2010.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=20926342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=620-628&author=D.+P.+McDonnellauthor=S.+E.+Wardell&title=The+molecular+mechanisms+underlying+the+pharmacological+actions+of+ER+modulators%3A+Implications+for+new+drug+discovery+in+breast+cancer&doi=10.1016%2Fj.coph.2010.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer</span></div><div class="casAuthors">McDonnell, Donald P.; Wardell, Suzanne E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">620-628</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the mol. mechanisms underlying the pharmacol. actions of estrogen receptor (ER) ligands has evolved considerably in recent years.  Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, so called for their ability to function as ER agonists or antagonists depending on the tissue in which they operate.  These mechanistic insights have had a significant impact on the discovery of second generation SERMs, some of which are in late stage clin. development for the treatment/prevention of breast cancer as well as other estrogenopathies.  In addn. to the SERMs, however, have emerged the Selective Estrogen Degraders (SERDs), which as their name suggests, interact with and facilitate ER turnover in cells.  One drug of this class, fulvestrant, has been approved as a third line treatment for ER-pos. metastatic breast cancer.  Whereas the first generation SERMs/SERDs were discovered in a serendipitous manner, this review will highlight how our understanding of the mol. pharmacol. of ER ligands has been utilized in the development of the next generation of SERMs/SERDs, some of which are likely to have a major impact on the pharmacotherapy of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8b2l5p-n0bbVg90H21EOLACvtfcHk0lhWjF2G5-t4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVals73P&md5=24d1490ca0b0570c21e9768c9de134d6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2010.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2010.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DWardell%26aufirst%3DS.%2BE.%26atitle%3DThe%2520molecular%2520mechanisms%2520underlying%2520the%2520pharmacological%2520actions%2520of%2520ER%2520modulators%253A%2520Implications%2520for%2520new%2520drug%2520discovery%2520in%2520breast%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2010%26volume%3D10%26spage%3D620%26epage%3D628%26doi%3D10.1016%2Fj.coph.2010.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrecengost, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, A. H.</span></span> <span> </span><span class="NLM_article-title">Pathways to tamoxifen resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>256</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2007.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.canlet.2007.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=17475399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=2007&pages=1-24&author=R.+B.+Rigginsauthor=R.+S.+Schrecengostauthor=M.+S.+Guerreroauthor=A.+H.+Bouton&title=Pathways+to+tamoxifen+resistance&doi=10.1016%2Fj.canlet.2007.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways to tamoxifen resistance</span></div><div class="casAuthors">Riggins, Rebecca B.; Schrecengost, Randy S.; Guerrero, Michael S.; Bouton, Amy H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-24</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer.  While these approaches have proven to be beneficial to a large no. of patients, both de novo and acquired resistance to these drugs is a significant problem.  Recent advances in our understanding of the mol. mechanisms that contribute to resistance have provided a means to begin to predict patient responses to these drugs and develop rational approaches for combining therapeutic agents to circumvent or desensitize the resistant phenotype.  Here, we review common mechanisms of antiestrogen resistance and discuss the implications for prediction of response and design of effective combinatorial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreh_AisSEW9LVg90H21EOLACvtfcHk0lhWjF2G5-t4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFGrtLo%253D&md5=25203d3e50ade6508421835d29bf048c</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2007.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2007.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DRiggins%26aufirst%3DR.%2BB.%26aulast%3DSchrecengost%26aufirst%3DR.%2BS.%26aulast%3DGuerrero%26aufirst%3DM.%2BS.%26aulast%3DBouton%26aufirst%3DA.%2BH.%26atitle%3DPathways%2520to%2520tamoxifen%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2007%26volume%3D256%26spage%3D1%26epage%3D24%26doi%3D10.1016%2Fj.canlet.2007.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkovsky, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.coph.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=29719270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=59-65&author=J.+N.+Millsauthor=A.+C.+Rutkovskyauthor=A.+Giordano&title=Mechanisms+of+resistance+in+estrogen+receptor+positive+breast+cancer%3A+overcoming+resistance+to+tamoxifen%2Faromatase+inhibitors&doi=10.1016%2Fj.coph.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors</span></div><div class="casAuthors">Mills, Jamie N.; Rutkovsky, Alex C.; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Several mechanisms of resistance have been identified, underscoring the complex nature of estrogen receptor (ER) signaling and the many connections between this pathway and other essential signaling pathways in breast cancer cells.  Many therapeutic targets of cell signaling and cell cycle pathways have met success with endocrine therapy and remain an ongoing area of investigation.  This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways.  Addnl., we highlight individual and combination strategies in current clin. trials that target these pathways and others under investigation for the treatment of ER pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVYQkU5BQS2LVg90H21EOLACvtfcHk0lihw8dBTX3f6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D&md5=7eb380dd5c8e441b8dd2602b40aa94b5</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DJ.%2BN.%26aulast%3DRutkovsky%26aufirst%3DA.%2BC.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520resistance%2520in%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%253A%2520overcoming%2520resistance%2520to%2520tamoxifen%252Faromatase%2520inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D41%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.coph.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0001-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1038%2Fs41568-018-0001-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=29662238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=377-388&author=J.+A.+Katzenellenbogenauthor=C.+G.+Mayneauthor=B.+S.+Katzenellenbogenauthor=G.+L.+Greeneauthor=S.+Chandarlapaty&title=Structural+underpinnings+of+oestrogen+receptor+mutations+in+endocrine+therapy+resistance&doi=10.1038%2Fs41568-018-0001-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance</span></div><div class="casAuthors">Katzenellenbogen, John A.; Mayne, Christopher G.; Katzenellenbogen, Benita S.; Greene, Geoffrey L.; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">377-388</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Estrogen receptor-α (ERα), a key driver of breast cancer, normally requires estrogen for activation.  Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are assocd. with poor patient outcomes.  The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone.  Such mutations provide opportunities to probe fundamental issues underlying ligand-mediated control of ERα activity.  Instructive contrasts between these ERα mutations and those that arise in the androgen receptor (AR) during anti-androgen treatment of prostate cancer highlight differences in how activation functions in ERs and AR control receptor activity, how hormonal pressures (deprivation vs. antagonism) drive the selection of phenotypically different mutants, how altered protein conformations can reduce antagonist potency and how altered ligand-receptor contacts can invert the response that a receptor has to an agonist ligand vs. an antagonist ligand.  A deeper understanding of how ligand regulation of receptor conformation is linked to receptor function offers a conceptual framework for developing new anti-estrogens that might be more effective in preventing and treating breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp89VSk_QiS7Vg90H21EOLACvtfcHk0lihw8dBTX3f6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7s%253D&md5=c891ccc27bb2cd117c4705006e78f619</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0001-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0001-z%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DStructural%2520underpinnings%2520of%2520oestrogen%2520receptor%2520mutations%2520in%2520endocrine%2520therapy%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D377%26epage%3D388%26doi%3D10.1038%2Fs41568-018-0001-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Musgrove, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, R. L.</span></span> <span> </span><span class="NLM_article-title">Biological determinants of endocrine resistance in breast cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1038/nrc2713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1038%2Fnrc2713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=19701242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=631-643&author=E.+A.+Musgroveauthor=R.+L.+Sutherland&title=Biological+determinants+of+endocrine+resistance+in+breast+cancer&doi=10.1038%2Fnrc2713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Biological determinants of endocrine resistance in breast cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">631-643</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endocrine therapies targeting estrogen action (anti-estrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance.  Candidate mol. biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation and survival signaling in endocrine resistance.  However, definition of the specific genetic lesions and mol. processes that det. clin. endocrine resistance is incomplete.  The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbi_1MVsJjz7Vg90H21EOLACvtfcHk0lihw8dBTX3f6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVegtrzL&md5=e57a6a082e0f41d26422350657201de5</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2713%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DBiological%2520determinants%2520of%2520endocrine%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D631%26epage%3D643%26doi%3D10.1038%2Fnrc2713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Toy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goeppert, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzola, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uddin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span> <span> </span><span class="NLM_article-title">Activating ESR1 mutations differentially affect the efficacy of ER antagonists</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1158%2F2159-8290.CD-15-1523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=27986707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=277-287&author=W.+Toyauthor=H.+Weirauthor=P.+Razaviauthor=M.+Lawsonauthor=A.+U.+Goeppertauthor=A.+M.+Mazzolaauthor=A.+Smithauthor=J.+Wilsonauthor=C.+Morrowauthor=W.+L.+Wongauthor=E.+De+Stanchinaauthor=K.+E.+Carlsonauthor=T.+S.+Martinauthor=S.+Uddinauthor=Z.+Liauthor=S.+Fanningauthor=J.+A.+Katzenellenbogenauthor=G.+Greeneauthor=J.+Baselgaauthor=S.+Chandarlapaty&title=Activating+ESR1+mutations+differentially+affect+the+efficacy+of+ER+antagonists&doi=10.1158%2F2159-8290.CD-15-1523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists</span></div><div class="casAuthors">Toy, Weiyi; Weir, Hazel; Razavi, Pedram; Lawson, Mandy; Goeppert, Anne U.; Mazzola, Anne Marie; Smith, Aaron; Wilson, Joanne; Morrow, Christopher; Wong, Wai Lin; De Stanchina, Elisa; Carlson, Kathryn E.; Martin, Teresa S.; Uddin, Sharmeen; Li, Zhiqiang; Fanning, Sean; Katzenellenbogen, John A.; Greene, Geoffrey; Baselga, Jose; Chandarlapaty, Sarat</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor.  The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER antagonists like fulvestrant is not established.  In this report, we characterize the spectrum of ESR1 mutations from more than 900 patients.  ESR1 mutations were detected in 10%, with D538G being the most frequent (36%), followed by Y537S (14%).  Several novel, activating mutations were also detected (e.g., L469V, V422del, and Y537D).  Although many mutations lead to constitutive activity and reduced sensitivity to ER antagonists, only select mutants such as Y537S caused a magnitude of change assocd. with fulvestrant resistance in vivo.  Correspondingly, tumors driven by Y537S, but not D5358G, E380Q, or S463P, were less effectively inhibited by fulvestrant than more potent and bioavailable antagonists, including AZD9496.  These data point to a need for antagonists with optimal pharmacokinetic properties to realize clin. efficacy against certain ESR1 mutants.  Significance: A diversity of activating ESR1 mutations exist, only some of which confer resistance to existing ER antagonists that might be overcome by next-generation inhibitors such as AZD9496.  Cancer Discov; 7(3); 277-87. ©2016 AACR.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZyS-eS6T9ZLVg90H21EOLACvtfcHk0ljD4Do3a8_s7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Klsbo%253D&md5=398dd5202db358ba8facab67055895c9</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1523%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DW.%26aulast%3DWeir%26aufirst%3DH.%26aulast%3DRazavi%26aufirst%3DP.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DGoeppert%26aufirst%3DA.%2BU.%26aulast%3DMazzola%26aufirst%3DA.%2BM.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DMorrow%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DDe%2BStanchina%26aufirst%3DE.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DUddin%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DGreene%26aufirst%3DG.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DChandarlapaty%26aufirst%3DS.%26atitle%3DActivating%2520ESR1%2520mutations%2520differentially%2520affect%2520the%2520efficacy%2520of%2520ER%2520antagonists%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D277%26epage%3D287%26doi%3D10.1158%2F2159-8290.CD-15-1523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Künzer, H.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of C(7)-Substituted Estra-1,3,5(10)-triene and New Starting Products by this Process</span>. Ger. Offen. <span class="NLM_patent">DE4218743C2</span>, <span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=H.+K%C3%BCnzer&title=Process+for+the+Preparation+of+C%287%29-Substituted+Estra-1%2C3%2C5%2810%29-triene+and+New+Starting+Products+by+this+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCnzer%26aufirst%3DH.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520C%25287%2529-Substituted%2520Estra-1%252C3%252C5%252810%2529-triene%2520and%2520New%2520Starting%2520Products%2520by%2520this%2520Process%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart-Cussac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macpherson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4535</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1200%2FJCO.2008.21.1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=19704066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4530-4535&author=J.+F.+R.+Robertsonauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=E.+Macphersonauthor=J.+Lindemannauthor=M.+J.+Ellis&title=Activity+of+fulvestrant+500+mg+versus+anastrozole+1+mg+as+first-line+treatment+for+advanced+breast+cancer%3A+results+from+the+FIRST+study&doi=10.1200%2FJCO.2008.21.1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span></div><div class="casAuthors">Robertson, John F. R.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; MacPherson, Euan; Lindemann, Justin; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4530-4535</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the clin. activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-pos. breast cancer in postmenopausal women.  Patients and Methods: FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) is a phase II, randomized, open-label, multicenter study of a fulvestrant high-dose (HD) regimen (500 mg/mo plus 500 mg on day 14 of month 1) vs. anastrozole (1 mg/d).  The primary efficacy end point was clin. benefit rate (CBR), defined as the proportion of patients experiencing an objective response (OR) or stable disease for ≥ 24 wk.  The primary anal. was performed 6 mo after the last patient was randomly assigned.  Results: CBR was similar for fulvestrant HD (n = 102) and anastrozole (n = 103), 72.5% v 67.0%, resp. (odds ratio, 1.30; 95% CI, 0.72 to 2.38; P = .386).  Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%.  Time to progression (TTP) was significantly longer for fulvestrant vs. anastrozole (median TTP not reached for fulvestrant HD v 12.5 mo for anastrozole; hazard ratio, 0.63; 95% CI, 0.39 to 1.00; P = .0496).  Duration of OR and CB also numerically favored fulvestrant HD.  Both treatments were well tolerated, with no significant differences in the incidence of prespecified adverse events.  Conclusion: First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was assocd. with significantly longer TTP.  Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-OU2SQaTsabVg90H21EOLACvtfcHk0ljD4Do3a8_s7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J&md5=a7a6f5cd7fcdbc8cb6839a2800cd5cb8</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.1136%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivity%2520of%2520fulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520the%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4530%26epage%3D4535%26doi%3D10.1200%2FJCO.2008.21.1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (“Faslodex”) – a new treatment option for patients progressing on prior endocrine therapy</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1677/erc.0.0090267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1677%2Ferc.0.0090267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=12542403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1GmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=267-276&author=C.+Morrisauthor=A.+E.+Wakeling&title=Fulvestrant+%28%E2%80%9CFaslodex%E2%80%9D%29+%E2%80%93+a+new+treatment+option+for+patients+progressing+on+prior+endocrine+therapy&doi=10.1677%2Ferc.0.0090267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant ("Faslodex") - a new treatment option for patients progressing on prior endocrine therapy</span></div><div class="casAuthors">Morris, C.; Wakeling, A.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-276</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  Since its introduction more than 30 yr ago, tamoxifen has been the most widely used endocrine therapy for the treatment of women with advanced breast cancer.  More recently, a no. of alternative endocrine treatments have been developed, including several selective estrogen receptor modulators (SERMs), aromatase inhibitors (Als) and, most recently, fulvestrant ("Faslodex").  Fulvestrant is an estrogen receptor (ER) antagonist, which, unlike the SERMs, has no known agonist (estrogenic) effect and downregulates the ER protein.  Tamoxifen is effective and well tolerated, although the non-steroidal Als, anastrozole and letrozole, are more effective treatments for advanced disease than tamoxifen.  Fulvestrant has recently gained US Food and Drug Administration approval for the treatment of hormone receptor-pos. metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.  In two global phase III clin. trials fulvestrant was at least as effective and as equally well tolerated as anastrozole for the treatment of postmenopausal women with advanced and metastatic breast cancer.  In a retrospective anal. of the combined data from these trials, mean duration of response was significantly greater for fulvestrant compared with anastrozole.  These new hormonal treatments expand the choice of endocrine therapy for women with advanced breast cancer and offer new options for sequencing and combining treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUEBpo3hJZ27Vg90H21EOLACvtfcHk0ljD4Do3a8_s7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1GmsLk%253D&md5=666742ffe67d7d7ea4aaec2ea814a018</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1677%2Ferc.0.0090267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Ferc.0.0090267%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26atitle%3DFulvestrant%2520%2528%25E2%2580%259CFaslodex%25E2%2580%259D%2529%2520%25E2%2580%2593%2520a%2520new%2520treatment%2520option%2520for%2520patients%2520progressing%2520on%2520prior%2520endocrine%2520therapy%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2002%26spage%3D267%26epage%3D276%26doi%3D10.1677%2Ferc.0.0090267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant (Faslodex) - how to make a good drug better</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-7-774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1634%2Ftheoncologist.12-7-774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=17673609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=774-784&author=J.+F.+Robertson&title=Fulvestrant+%28Faslodex%29+-+how+to+make+a+good+drug+better&doi=10.1634%2Ftheoncologist.12-7-774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant (Faslodex)-how to make a good drug better</span></div><div class="casAuthors">Robertson, John F. R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">774-784</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Fulvestrant (Faslodex; AstraZeneca Pharmaceuticals, Wilmington, DE) is an estrogen receptor (ER) antagonist with a novel mode of action; it binds, blocks, and increases degrdn. of ER.  Fulvestrant (at the approved dose [250 mg/mo]) is at least as effective as anastrozole (1 mg/day) in the treatment of postmenopausal women with hormone receptor-pos. advanced breast cancer (HR+ ABC) progressing or recurring on antiestrogen therapy, and is also an active first-line treatment.  Although fulvestrant (250 mg/mo) is clearly effective, it takes 3-6 mo to achieve steady-state plasma levels.  Steady-state concns. are approx. twofold higher than those achieved with a single dose; reaching this earlier, for example, via a loading-dose (LD) regimen (250 mg/mo plus 500 mg on day 0 and 250 mg on day 14 of month 1), may allow responses to be achieved more quickly and limit the possibility of early relapse.  Fulvestrant high-dose (HD) regimens (500 mg/mo) offer the possibility of greater antitumor activity, because (a) ER downregulation is a dose-dependent process (an approx. 70% redn. is obsd. with a single 250 mg dose of fulvestrant) and (b) evidence correlates greater ER downregulation with superior efficacy.  A fulvestrant HD regimen offers the potential of achieving near 100% ER downregulation.  There is also potential to increase fulvestrant-ER binding by reducing plasma estrogen levels, for example, with concomitant aromatase inhibitor treatment.  Several ongoing trials use LD, HD, and combination regimens; results from these studies are awaited with interest.  Meanwhile, fulvestrant (250 mg/mo) remains a valuable addnl. endocrine treatment for postmenopausal women with HR+ ABC recurring or progressing on antiestrogen therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxuzoAnKMBfLVg90H21EOLACvtfcHk0lgEputiJL5FrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslertbg%253D&md5=25f69688f5819c7883f408ad74642058</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-7-774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-7-774%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%26atitle%3DFulvestrant%2520%2528Faslodex%2529%2520-%2520how%2520to%2520make%2520a%2520good%2520drug%2520better%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D774%26epage%3D784%26doi%3D10.1634%2Ftheoncologist.12-7-774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzelka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khasanov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrini, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergrass, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J. P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapunar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Results of the confirm phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">4594</span>– <span class="NLM_lpage">4600</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.28.8415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1200%2FJCO.2010.28.8415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=20855825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4594-4600&author=A.+Di%0ALeoauthor=G.+Jerusalemauthor=L.+Petruzelkaauthor=R.+Torresauthor=I.+N.+Bondarenkoauthor=R.+Khasanovauthor=D.+Verhoevenauthor=J.+L.+Pedriniauthor=I.+Smirnovaauthor=M.+R.+Lichinitserauthor=K.+Pendergrassauthor=S.+Garnettauthor=J.+P.+O.+Lindemannauthor=F.+Sapunarauthor=M.+Martin&title=Results+of+the+confirm+phase+III+trial+comparing+fulvestrant+250+mg+with+fulvestrant+500+mg+in+postmenopausal+women+with+estrogen+receptor%E2%80%93positive+advanced+breast+cancer&doi=10.1200%2FJCO.2010.28.8415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer</span></div><div class="casAuthors">di Leo, Angelo; Jerusalem, Guy; Petruzelka, Lubos; Torres, Roberto; Bondarenko, Igor N.; Khasanov, Rustem; Verhoeven, Didier; Pedrini, Jose L.; Smirnova, Iya; Lichinitser, Mikhail R.; Pendergrass, Kelly; Garnett, Sally; Lindemann, Justin P. O.; Sapunar, Francisco; Martin, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4594-4600</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per mo for treatment of postmenopausal women with estrogen receptor-pos. advanced breast cancer who experienced progression after prior endocrine therapy.  Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) is a double-blind, parallel-group, multicenter, phase III study.  Patients were randomly assigned to fulvestrant 500 mg (500 mg i.m. on day 0, then 500 mg i.m. on days 14 and 28 and every 28 days thereafter) or 250 mg every 28 days.  Primary end point was progression-free survival (PFS).  Secondary end points included objective response rate, clin. benefit rate (CBR), duration of clin. benefit (DoCB), overall survival (OS), and quality of life (QOL).  PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% redn. in risk of progression.  Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, resp.).  CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.  DoCB and OS were 16.6 and 25.1 mo, resp., for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 mo, resp., in the 250-mg group.  Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.  QOL was similar for both arms.  Fulvestrant 500 mg was assocd. with a statistically significant increase in PFS and not assocd. with increased toxicity, corresponding to a clin. meaningful improvement in benefit vs. risk compared with fulvestrant 250 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5x_viRvCGrVg90H21EOLACvtfcHk0lgEputiJL5FrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO&md5=9b82ff995b029df754e4295d3153867e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.28.8415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.28.8415%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DPetruzelka%26aufirst%3DL.%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DBondarenko%26aufirst%3DI.%2BN.%26aulast%3DKhasanov%26aufirst%3DR.%26aulast%3DVerhoeven%26aufirst%3DD.%26aulast%3DPedrini%26aufirst%3DJ.%2BL.%26aulast%3DSmirnova%26aufirst%3DI.%26aulast%3DLichinitser%26aufirst%3DM.%2BR.%26aulast%3DPendergrass%26aufirst%3DK.%26aulast%3DGarnett%26aufirst%3DS.%26aulast%3DLindemann%26aufirst%3DJ.%2BP.%2BO.%26aulast%3DSapunar%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DResults%2520of%2520the%2520confirm%2520phase%2520III%2520trial%2520comparing%2520fulvestrant%2520250%2520mg%2520with%2520fulvestrant%2520500%2520mg%2520in%2520postmenopausal%2520women%2520with%2520estrogen%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4594%26epage%3D4600%26doi%3D10.1200%2FJCO.2010.28.8415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in Tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+j.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+Tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lgEputiJL5FrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2Bj.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520Tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xenograft</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5163</span>– <span class="NLM_lpage">5167</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.bmcl.2015.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=26463130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5163-5167&author=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=K.+L.+Douglasauthor=A.+G.+Laiauthor=M.+Kahramanauthor=C.+Bonnefousauthor=A.+M.+Aparicioauthor=B.+D.+Darimontauthor=K.+L.+Grillotauthor=J.+D.+Josephauthor=J.+A.+Kaufmanauthor=K.-J.+Leeauthor=N.+Luauthor=M.+J.+Moonauthor=R.+Y.+Prudenteauthor=J.+Sensintaffarauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Optimization+of+an+indazole+series+of+selective+estrogen+receptor+degraders%3A+tumor+regression+in+a+tamoxifen-resistant+breast+cancer+xenograft&doi=10.1016%2Fj.bmcl.2015.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft</span></div><div class="casAuthors">Govek, Steven P.; Nagasawa, Johnny Y.; Douglas, Karensa L.; Lai, Andiliy G.; Kahraman, Mehmet; Bonnefous, Celine; Aparicio, Anna M.; Darimont, Beatrice D.; Grillot, Katherine L.; Joseph, James D.; Kaufman, Joshua A.; Lee, Kyoung-Jin; Lu, Nhin; Moon, Michael J.; Prudente, Rene Y.; Sensintaffar, John; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5163-5167</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Selective estrogen receptor degraders (SERDs) have shown promise for the treatment of ER+ breast cancer.  Disclosed herein is the continued optimization of the authors' indazole series of SERDs.  Exploration of ER degrdn. and antagonism in vitro followed by in vivo antagonism and oral exposure culminated in the discovery of indazoles (I) and (II), which induce tumor regression in a tamoxifen-resistant breast cancer xenograft.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6i7tfU3k5frVg90H21EOLACvtfcHk0lh3BrykyDXg5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GksbrI&md5=fc890bcabc5f84fce015d50bae14c2b6</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DDouglas%26aufirst%3DK.%2BL.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DAparicio%26aufirst%3DA.%2BM.%26aulast%3DDarimont%26aufirst%3DB.%2BD.%26aulast%3DGrillot%26aufirst%3DK.%2BL.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DKaufman%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DK.-J.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DPrudente%26aufirst%3DR.%2BY.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DOptimization%2520of%2520an%2520indazole%2520series%2520of%2520selective%2520estrogen%2520receptor%2520degraders%253A%2520tumor%2520regression%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520xenograft%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5163%26epage%3D5167%26doi%3D10.1016%2Fj.bmcl.2015.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Savi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Almeida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curwen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayter, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span> <span> </span><span class="NLM_article-title">Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8128</span>– <span class="NLM_lpage">8140</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00984</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00984" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8128-8140&author=C.+De%0ASaviauthor=R.+H.+Bradburyauthor=A.+A.+Rabowauthor=R.+A.+Normanauthor=C.+de+Almeidaauthor=D.+M.+Andrewsauthor=P.+Ballardauthor=D.+Buttarauthor=R.+J.+Callisauthor=G.+S.+Currieauthor=J.+O.+Curwenauthor=C.+D.+Daviesauthor=C.+S.+Donaldauthor=L.+J.+Feronauthor=H.+Gingellauthor=S.+C.+Glossopauthor=B.+R.+Hayterauthor=S.+Hussainauthor=G.+Karoutchiauthor=S.+G.+Lamontauthor=P.+MacFaulauthor=T.+A.+Mossauthor=S.+E.+Pearsonauthor=M.+Tongeauthor=G.+E.+Walkerauthor=H.+M.+Weirauthor=Z.+Wilson&title=Optimization+of+a+novel+binding+motif+to+%28E%29-3-%283%2C5-difluoro-4-%28%281R%2C3R%29-2-%282-fluoro-2-methylpropyl%29-3-methyl-2%2C3%2C4%2C9-tetrahydro-1H-pyrido%5B3%2C4-b%5Dindol-1-yl%29phenyl%29acrylic+acid+%28AZD9496%29%2C+a+potent+and+orally+bioavailable+selective+estrogen+receptor+downregulator+and+antagonist&doi=10.1021%2Facs.jmedchem.5b00984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist</span></div><div class="casAuthors">De Savi, Chris; Bradbury, Robert H.; Rabow, Alfred A.; Norman, Richard A.; de Almeida, Camila; Andrews, David M.; Ballard, Peter; Buttar, David; Callis, Rowena J.; Currie, Gordon S.; Curwen, Jon O.; Davies, Chris D.; Donald, Craig S.; Feron, Lyman J. L.; Gingell, Helen; Glossop, Steven C.; Hayter, Barry R.; Hussain, Syeed; Karoutchi, Galith; Lamont, Scott G.; MacFaul, Philip; Moss, Thomas A.; Pearson, Stuart E.; Tonge, Michael; Walker, Graeme E.; Weir, Hazel M.; Wilson, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8128-8140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equiv. potency and preclin. pharmacol. to the i.m. SERD fulvestrant is described.  A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand.  Aided by crystal structures of novel ligands bound to an ER construct, medicinal chem. iterations led to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (30b, AZD9496), a clin. candidate with high oral bioavailability across preclin. species that is currently being evaluated in phase I clin. trials for the treatment of advanced estrogen receptor (ER) pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP-ZYYxmMtg7Vg90H21EOLACvtfcHk0lh3BrykyDXg5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKiu7fK&md5=df7eee70ca783a2933cd494b53f71488</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00984%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAlmeida%26aufirst%3DC.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCallis%26aufirst%3DR.%2BJ.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DCurwen%26aufirst%3DJ.%2BO.%26aulast%3DDavies%26aufirst%3DC.%2BD.%26aulast%3DDonald%26aufirst%3DC.%2BS.%26aulast%3DFeron%26aufirst%3DL.%2BJ.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DGlossop%26aufirst%3DS.%2BC.%26aulast%3DHayter%26aufirst%3DB.%2BR.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DG.%2BE.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26aulast%3DWilson%26aufirst%3DZ.%26atitle%3DOptimization%2520of%2520a%2520novel%2520binding%2520motif%2520to%2520%2528E%2529-3-%25283%252C5-difluoro-4-%2528%25281R%252C3R%2529-2-%25282-fluoro-2-methylpropyl%2529-3-methyl-2%252C3%252C4%252C9-tetrahydro-1H-pyrido%255B3%252C4-b%255Dindol-1-yl%2529phenyl%2529acrylic%2520acid%2520%2528AZD9496%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520downregulator%2520and%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8128%26epage%3D8140%26doi%3D10.1021%2Facs.jmedchem.5b00984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tria, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaither, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiong-Yip, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2837</span>– <span class="NLM_lpage">2864</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01682</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01682" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2837-2864&author=G.+S.+Triaauthor=T.+Abramsauthor=J.+Bairdauthor=H.+E.+Burksauthor=B.+Firestoneauthor=L.+A.+Gaitherauthor=L.+G.+Hamannauthor=G.+Heauthor=C.+A.+Kirbyauthor=S.+Kimauthor=F.+Lombardoauthor=K.+J.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Springerauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=B.+Yuauthor=C.+L.+Tiong-Yipauthor=S.+Peukert&title=Discovery+of+LSZ102%2C+a+potent%2C+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+for+the+treatment+of+estrogen+receptor+positive+breast+cancer&doi=10.1021%2Facs.jmedchem.7b01682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></div><div class="casAuthors">Tria, George S.; Abrams, Tinya; Baird, Jason; Burks, Heather E.; Firestone, Brant; Gaither, L. Alex; Hamann, Lawrence G.; He, Guo; Kirby, Christina A.; Kim, Sunkyu; Lombardo, Franco; Macchi, Kaitlin J.; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Springer, Clayton; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Yu, Bing; Tiong-Yip, Choi-Lai; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2837-2864</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In breast cancer, estrogen receptor alpha (ERα) pos. cancer accounts for approx. 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation.  Treatment of ERα pos. breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs).  The steroid-based anti-estrogen fulvestrant, the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies.  Its efficacy, however, may be limited due to its poor physicochem. properties.  THe authors describe the design and synthesis of a series of potent benzothiophene-contg. compds. that exhibit oral bioavailability and preclin. activity as SERDs.  This article culminates in the identification of LSZ102 (I), a compd. in clin. development for the treatment of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcHgOrWwlRvrVg90H21EOLACvtfcHk0ljN5tZFRazcXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFynurc%253D&md5=dba954f9f11121fae1bb50979428a83b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26aulast%3DTria%26aufirst%3DG.%2BS.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DFirestone%26aufirst%3DB.%26aulast%3DGaither%26aufirst%3DL.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DMacchi%26aufirst%3DK.%2BJ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DTiong-Yip%26aufirst%3DC.%2BL.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520LSZ102%252C%2520a%2520potent%252C%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520for%2520the%2520treatment%2520of%2520estrogen%2520receptor%2520positive%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2837%26epage%3D2864%26doi%3D10.1021%2Facs.jmedchem.7b01682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α degradation maximizes activity in a tamoxifen-resistant breast cancer model: identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=C.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+J.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+degradation+maximizes+activity+in+a+tamoxifen-resistant+breast+cancer+model%3A+identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0ljN5tZFRazcXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DC.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520degradation%2520maximizes%2520activity%2520in%2520a%2520tamoxifen-resistant%2520breast%2520cancer%2520model%253A%2520identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an orally bioavailable chromene-based selective estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+orally+bioavailable+chromene-based+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+a+model+of+tamoxifen-resistant+breast+cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0ljN5tZFRazcXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520orally%2520bioavailable%2520chromene-based%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520a%2520model%2520of%2520tamoxifen-resistant%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dijcks, F. A.</span>; <span class="NLM_string-name">Lusher, S. J.</span>; <span class="NLM_string-name">Stock, H. T.</span>; <span class="NLM_string-name">Veeneman, G. H.</span></span> <span> </span><span class="NLM_article-title">N-Substituted Azetidine Derivatives</span>. PCT Int. Appl. <span class="NLM_patent">WO2012084711</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=F.+A.+Dijcks&author=S.+J.+Lusher&author=H.+T.+Stock&author=G.+H.+Veeneman&title=N-Substituted+Azetidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDijcks%26aufirst%3DF.%2BA.%26atitle%3DN-Substituted%2520Azetidine%2520Derivatives%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, M. P.</span></span> <span> </span><span class="NLM_article-title">Generation of a set of simple, interpretable ADMET rules of thumb</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1021/jm701122q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701122q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=817-834&author=M.+P.+Gleeson&title=Generation+of+a+set+of+simple%2C+interpretable+ADMET+rules+of+thumb&doi=10.1021%2Fjm701122q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Set of Simple, Interpretable ADMET Rules of Thumb</span></div><div class="casAuthors">Gleeson, M. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">817-834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A set of simple, consistent structure-property guides have been detd. from an anal. of a no. of key ADMET assays run within GSK: soly., permeability, bioavailability, vol. of distribution, plasma protein binding, CNS penetration, brain tissue binding, P-gp efflux, hERG inhibition, and cytochrome P 450 1A2/2C9/2C19/2D6/3A4 inhibition.  The rules have been formulated using mol. properties that chemists intuitively know how to alter in a mol., namely, mol. wt., logP, and ionization state.  The rules supplement the more predictive black-box models available to us by clearly illustrating the key underlying trends, which are in line with reports in the literature.  It is clear from the analyses reported herein that almost all ADMET parameters deteriorate with either increasing mol. wt., logP, or both, with ionization state playing either a beneficial or detrimental affect depending on the parameter in question.  This study reemphasizes the need to focus on a lower mol. wt. and logP area of physicochem. property space to obtain improved ADMET parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PTdPHoD-c7Vg90H21EOLACvtfcHk0li1rDCw59Qzcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D&md5=42db5918ad8e9ea3ecf3a13846b3a434</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm701122q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701122q%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26atitle%3DGeneration%2520of%2520a%2520set%2520of%2520simple%252C%2520interpretable%2520ADMET%2520rules%2520of%2520thumb%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D817%26epage%3D834%26doi%3D10.1021%2Fjm701122q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span>; <span class="NLM_string-name">Cheng, J.</span>; <span class="NLM_string-name">Wang, M.</span>; <span class="NLM_string-name">Sun, F.</span>; <span class="NLM_string-name">Koundinya, M.</span>; <span class="NLM_string-name">Guo, Z.</span>; <span class="NLM_string-name">Hebert, A.</span>; <span class="NLM_string-name">McManus, J.</span>; <span class="NLM_string-name">Levit, M.</span>; <span class="NLM_string-name">Hoffman, D.</span>; <span class="NLM_string-name">Courjaud, A.</span>; <span class="NLM_string-name">Arrebola, R.</span>; <span class="NLM_string-name">Cao, H.</span>; <span class="NLM_string-name">Pollard, J.</span>; <span class="NLM_string-name">Besret, L.</span>; <span class="NLM_string-name">Abecassis, P. Y.</span>; <span class="NLM_string-name">Schio, L.</span>; <span class="NLM_string-name">El-Ahmad, Y.</span>; <span class="NLM_string-name">Halley, F.</span>; <span class="NLM_string-name">Tabart, M.</span>; <span class="NLM_string-name">Certal, V.</span>; <span class="NLM_string-name">Thompson, F.</span>; <span class="NLM_string-name">McCort, G.</span>; <span class="NLM_string-name">Filoche-Rommé, B.</span>; <span class="NLM_string-name">Debussche, L.</span>; <span class="NLM_string-name">Cheng, H.</span>; <span class="NLM_string-name">Garcia-Echeverria, C.</span>; <span class="NLM_string-name">Bouaboula, M.</span></span> <span> </span><span class="NLM_article-title">Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong anti-tumor activity in wild-type and mutant ER+ breast cancer models</span>. Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Shomali%2C+M.%3B+Cheng%2C+J.%3B+Wang%2C+M.%3B+Sun%2C+F.%3B+Koundinya%2C+M.%3B+Guo%2C+Z.%3B+Hebert%2C+A.%3B+McManus%2C+J.%3B+Levit%2C+M.%3B+Hoffman%2C+D.%3B+Courjaud%2C+A.%3B+Arrebola%2C+R.%3B+Cao%2C+H.%3B+Pollard%2C+J.%3B+Besret%2C+L.%3B+Abecassis%2C+P.+Y.%3B+Schio%2C+L.%3B+El-Ahmad%2C+Y.%3B+Halley%2C+F.%3B+Tabart%2C+M.%3B+Certal%2C+V.%3B+Thompson%2C+F.%3B+McCort%2C+G.%3B+Filoche-Romm%C3%A9%2C+B.%3B+Debussche%2C+L.%3B+Cheng%2C+H.%3B+Garcia-Echeverria%2C+C.%3B+Bouaboula%2C+M.+Identification+of+SAR439859%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+has+strong+anti-tumor+activity+in+wild-type+and+mutant+ER%2B+breast+cancer+models.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DShomali%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520SAR439859%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520has%2520strong%2520anti-tumor%2520activity%2520in%2520wild-type%2520and%2520mutant%2520ER%252B%2520breast%2520cancer%2520models" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbano, A.</span></span> <span> </span><span class="NLM_article-title">General synthesis of 8-aryl-2-tetralones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4956</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/jo060688j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo060688j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=4956-4964&author=M.+C.+Carrenoauthor=M.+Gonzalez-Lopezauthor=A.+Latorreauthor=A.+Urbano&title=General+synthesis+of+8-aryl-2-tetralones&doi=10.1021%2Fjo060688j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">General Synthesis of 8-Aryl-2-tetralones</span></div><div class="casAuthors">Carreno, M. Carmen; Gonzalez-Lopez, Marcos; Latorre, Alfonso; Urbano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4956-4964</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two alternative routes are described for the synthesis of 8-aryl-2-tetralones, e.g. I.  The first route starts from α-tetralone II and involves 3 or 4 steps, with the selective Na-EtOH redn. of 1-aryl-7-methoxynaphthalenes, e.g. III, being the key step.  The exclusive redn. of the A ring of naphthalenes, e.g. III, occurs when the aryl group at C-1 has no substituent at the ortho positions, affording tetrahydronaphthalenes, e.g. IV..  Redn. of the B ring of naphthalenes, e.g. V, becomes the major process when the aryl fragment has two substituents at the ortho positions, affording 8-aryl-2-tetralones, e.g. I, as the major component.  The second route involves 5 steps starting from 2-tetralone VI, with the key step being the Suzuki coupling with triflate VII.  This approach allows the synthesis of 8-aryl-2-tetralones, e.g. VIII, with no substituent at the ortho positions of the aryl fragment and with naphthalene and anthracene rings at C-8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7ZkPi7aC1prVg90H21EOLACvtfcHk0ljW9OJmP0raKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFGktr0%253D&md5=8abc27a6f86aafb7773c554e66cfdbda</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo060688j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo060688j%26sid%3Dliteratum%253Aachs%26aulast%3DCarreno%26aufirst%3DM.%2BC.%26aulast%3DGonzalez-Lopez%26aufirst%3DM.%26aulast%3DLatorre%26aufirst%3DA.%26aulast%3DUrbano%26aufirst%3DA.%26atitle%3DGeneral%2520synthesis%2520of%25208-aryl-2-tetralones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26spage%3D4956%26epage%3D4964%26doi%3D10.1021%2Fjo060688j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. C.</span></span> <span> </span><span class="NLM_article-title">Halogenation of 1,1-diaryl alkenes</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">829</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2Fj.tetlet.2010.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1amsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=826-829&author=M.+Y.+Changauthor=M.+F.+Leeauthor=C.+H.+Linauthor=N.+C.+Lee&title=Halogenation+of+1%2C1-diaryl+alkenes&doi=10.1016%2Fj.tetlet.2010.12.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Halogenation of 1,1-diaryl alkenes</span></div><div class="casAuthors">Chang, Meng-Yang; Lee, Ming-Fang; Lin, Chung-Han; Lee, Nein-Chia</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">826-829</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A variety of vinyl halides were prepd. from reaction of 1,1-diarylalkenes with different halogenating agents (e.g., Selectfluor and N-halosuccinimide) with good yields under mild and base-free conditions.  Synthesis of these mols. has been reported in the literature for being not easy to conduct.  Among all the existing prepns. of vinyl halide procedures, this protocol has the most facile and practical process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49gPmjcExSLVg90H21EOLACvtfcHk0ljW9OJmP0raKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1amsg%253D%253D&md5=0e59293f9d442ebe9d2488632c742d32</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DM.%2BF.%26aulast%3DLin%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DN.%2BC.%26atitle%3DHalogenation%2520of%25201%252C1-diaryl%2520alkenes%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D826%26epage%3D829%26doi%3D10.1016%2Fj.tetlet.2010.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span>; <span class="NLM_string-name">Brollo, M.</span>; <span class="NLM_string-name">Certal, V.</span>; <span class="NLM_string-name">El-Ahmad, Y.</span>; <span class="NLM_string-name">Filoche-Romme, B.</span>; <span class="NLM_string-name">Halley, F.</span>; <span class="NLM_string-name">Mccort, G.</span>; <span class="NLM_string-name">Schio, L.</span>; <span class="NLM_string-name">Tabart, M.</span>; <span class="NLM_string-name">Terrier, C.</span>; <span class="NLM_string-name">Thompson, F.</span></span> <span> </span><span class="NLM_article-title">Novel Substituted <i>N</i>-(3-Fluoropropyl)-pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO2018091153</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Bouaboula&author=M.+Brollo&author=V.+Certal&author=Y.+El-Ahmad&author=B.+Filoche-Romme&author=F.+Halley&author=G.+Mccort&author=L.+Schio&author=M.+Tabart&author=C.+Terrier&author=F.+Thompson&title=Novel+Substituted+N-%283-Fluoropropyl%29-pyrrolidine+Compounds%2C+Processes+for+their+Preparation+and+Therapeutic+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBouaboula%26aufirst%3DM.%26atitle%3DNovel%2520Substituted%2520N-%25283-Fluoropropyl%2529-pyrrolidine%2520Compounds%252C%2520Processes%2520for%2520their%2520Preparation%2520and%2520Therapeutic%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsunoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span> <span> </span><span class="NLM_article-title">Mitsunobu acylation of sterically congested secondary alcohols by N,N,N′,N′-tetramethylazodicarboxamide-tributyiphosphine reagents</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2529</span>– <span class="NLM_lpage">2530</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(95)00299-R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1016%2F0040-4039%2895%2900299-R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADyaK2MXltVamt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=2529-2530&author=T.+Tsunodaauthor=Y.+Yamamiyaauthor=Y.+Kawamuraauthor=S.+Ito&title=Mitsunobu+acylation+of+sterically+congested+secondary+alcohols+by+N%2CN%2CN%E2%80%B2%2CN%E2%80%B2-tetramethylazodicarboxamide-tributyiphosphine+reagents&doi=10.1016%2F0040-4039%2895%2900299-R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mitsunobu acylation of sterically congested secondary alcohols by N,N,N',N'-tetramethylazodicarboxamide-tributylphosphine reagents</span></div><div class="casAuthors">Tsunoda, Tetsuto; Yamamiya, Yoshiko; Kawamura, Yumi; Ito, Sho</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2529-30</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four secondary alcs. of different steric environment (5α-cholestan-3β-ol, -3α-ol, (-)-menthol, (-)-8-phenylmenthol) reacted with five carboxylic acids (4-MeC6H4CO2H, PhCO2H, 4-O2NC6H4CO2H, ClCH2CO2H, Cl2CHCO2H) of different acidity in the presence of N,N,N',N'-tetramethylazodicarboxamide and tributylphosphine to give the corresponding epi-esters in better yield than with di-Et azodicarboxylate-triphenylphosphine in most cases.  Of special merit is the combination of the new reagent system with p-methoxybenzoic acid to achieve complete inversion of sterically congested secondary alcs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PgtvUY_ZarVg90H21EOLACvtfcHk0ljW9OJmP0raKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltVamt7c%253D&md5=25a78b4ea154e0bf5b28c473dce80601</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2900299-R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252900299-R%26sid%3Dliteratum%253Aachs%26aulast%3DTsunoda%26aufirst%3DT.%26aulast%3DYamamiya%26aufirst%3DY.%26aulast%3DKawamura%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DS.%26atitle%3DMitsunobu%2520acylation%2520of%2520sterically%2520congested%2520secondary%2520alcohols%2520by%2520N%252CN%252CN%25E2%2580%25B2%252CN%25E2%2580%25B2-tetramethylazodicarboxamide-tributyiphosphine%2520reagents%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D2529%26epage%3D2530%26doi%3D10.1016%2F0040-4039%2895%2900299-R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouaboula, M.</span>; <span class="NLM_string-name">Brollo, M.</span>; <span class="NLM_string-name">Certal, V.</span>; <span class="NLM_string-name">El-Ahmad, Y.</span>; <span class="NLM_string-name">Filoche-Romme, B.</span>; <span class="NLM_string-name">Halley, F.</span>; <span class="NLM_string-name">McCort, G.</span>; <span class="NLM_string-name">Schio, L.</span>; <span class="NLM_string-name">Tabart, M.</span>; <span class="NLM_string-name">Terrier, C.</span>; <span class="NLM_string-name">Thompson, F.</span></span> <span> </span><span class="NLM_article-title">Novel Substituted 6,7-Dihydro-5<i>H</i>-benzo[7]annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof</span>. PCT Int. Appl. <span class="NLM_patent">WO2017140669</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Bouaboula&author=M.+Brollo&author=V.+Certal&author=Y.+El-Ahmad&author=B.+Filoche-Romme&author=F.+Halley&author=G.+McCort&author=L.+Schio&author=M.+Tabart&author=C.+Terrier&author=F.+Thompson&title=Novel+Substituted+6%2C7-Dihydro-5H-benzo%5B7%5Dannulene+Compounds%2C+Processes+for+their+Preparation+and+Therapeutic+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBouaboula%26aufirst%3DM.%26atitle%3DNovel%2520Substituted%25206%252C7-Dihydro-5H-benzo%255B7%255Dannulene%2520Compounds%252C%2520Processes%2520for%2520their%2520Preparation%2520and%2520Therapeutic%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D.</span>; <span class="NLM_string-name">DeCorte, B.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">McDonnell, M.</span>; <span class="NLM_string-name">McNally, J.</span></span> <span> </span><span class="NLM_article-title">Tricyclic δ-Opioid Modulators</span>. <span class="NLM_patent">US2006/30585</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+Scott&author=B.+DeCorte&author=L.+Liu&author=M.+McDonnell&author=J.+McNally&title=Tricyclic+%CE%B4-Opioid+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%26atitle%3DTricyclic%2520%25CE%25B4-Opioid%2520Modulators%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonrhein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flensburg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paciorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Womack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricogne, G.</span></span> <span> </span><span class="NLM_article-title">Data processing and analysis with the autoPROC toolbox</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>D67</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1107/S0907444911007773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444911007773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D67&publication_year=2011&pages=293-302&author=C.+Vonrheinauthor=C.+Flensburgauthor=P.+Kellerauthor=A.+Sharffauthor=O.+Smartauthor=W.+Paciorekauthor=T.+Womackauthor=G.+Bricogne&title=Data+processing+and+analysis+with+the+autoPROC+toolbox&doi=10.1107%2FS0907444911007773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Data processing and analysis with the autoPROC toolbox</span></div><div class="casAuthors">Vonrhein, Clemens; Flensburg, Claus; Keller, Peter; Sharff, Andrew; Smart, Oliver; Paciorek, Wlodek; Womack, Thomas; Bricogne, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-302</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A typical diffraction expt. will generate many images and data sets from different crystals in a very short time.  This creates a challenge for the high-throughput operation of modern synchrotron beamlines as well as for the subsequent data processing.  Novice users in particular may feel overwhelmed by the tables, plots and nos. that the different data-processing programs and software packages present to them.  Here, some of the more common problems that a user has to deal with when processing a set of images that will finally make up a processed data set are shown, concg. on difficulties that may often show up during the first steps along the path of turning the expt. (i.e. data collection) into a model (i.e. interpreted electron d.).  Difficulties such as unexpected crystal forms, issues in crystal handling and suboptimal choices of data-collection strategies can often be dealt with, or at least diagnosed, by analyzing specific data characteristics during processing.  In the end, one wants to distinguish problems over which one has no immediate control once the expt. is finished from problems that can be remedied a posteriori.  A new software package, autoPROC, is also presented that combines third-party processing programs with new tools and an automated workflow script that is intended to provide users with both guidance and insight into the offline processing of data affected by the difficulties mentioned above, with particular emphasis on the automated treatment of multi-sweep data sets collected on multi-axis goniostats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmah7iUrMLXLVg90H21EOLACvtfcHk0liRoqEkQmc2qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqtLs%253D&md5=a0a3579f6b371b6312819883864aa80d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1107%2FS0907444911007773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444911007773%26sid%3Dliteratum%253Aachs%26aulast%3DVonrhein%26aufirst%3DC.%26aulast%3DFlensburg%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DP.%26aulast%3DSharff%26aufirst%3DA.%26aulast%3DSmart%26aufirst%3DO.%26aulast%3DPaciorek%26aufirst%3DW.%26aulast%3DWomack%26aufirst%3DT.%26aulast%3DBricogne%26aufirst%3DG.%26atitle%3DData%2520processing%2520and%2520analysis%2520with%2520the%2520autoPROC%2520toolbox%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3DD67%26spage%3D293%26epage%3D302%26doi%3D10.1107%2FS0907444911007773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tickle, I. J.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Keller, P.</span>; <span class="NLM_string-name">Paciorek, W.</span>; <span class="NLM_string-name">Sharff, A.</span>; <span class="NLM_string-name">Vonrhein, C.</span>; <span class="NLM_string-name">Bricogne, G.</span></span> <i>STARANISO</i>; <span class="NLM_publisher-name">Global Phasing, Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=I.+J.+Tickle&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=A.+Sharff&author=C.+Vonrhein&author=G.+Bricogne&title=STARANISO"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26jtitle%3DSTARANISO%26pub%3DGlobal%2520Phasing%252C%2520Ltd%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0liRoqEkQmc2qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0liRoqEkQmc2qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/S0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2FS0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0lgBdLJNB-VuHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2FS0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindyalov, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, P. E.</span></span> <span> </span><span class="NLM_article-title">The protein data bank</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1093/nar/28.1.235</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+protein+data+bank&doi=10.1093%2Fnar%2F28.1.235"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0lgBdLJNB-VuHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520protein%2520data%2520bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242%26doi%3D10.1093%2Fnar%2F28.1.235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SBO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SBO','PDB','6SBO'); return false;">PDB: 6SBO</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i106"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01293">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_55173"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01293?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01293</a>. <ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings as well as IC<sub>50</sub> and percent ER degradation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01293/suppl_file/jm9b01293_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01293/suppl_file/jm9b01293_si_001.csv">jm9b01293_si_001.csv (3.11 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01293&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01293%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01293" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994dd0097e2495","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
